{"docstore/data": {"3c34daa5-c03c-47a0-a9b3-155c75c619b2": {"__data__": {"id_": "3c34daa5-c03c-47a0-a9b3-155c75c619b2", "embedding": null, "metadata": {"page_label": "1", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "Exhibit\u00a010.11\n\u00a0\n***Certain\u00a0portions\u00a0of\u00a0this\u00a0exhibit\u00a0have\u00a0been\u00a0omitted\u00a0based\u00a0on\u00a0a\u00a0request\u00a0for\u00a0confidential\u00a0treatment\u00a0pursuant\u00a0to\u00a0Rule\u00a024b-2\u00a0under\u00a0the\u00a0Securities\nExchange\u00a0Act\u00a0of\u00a01934,\u00a0as\u00a0amended.\u00a0The\u00a0omitted\u00a0portions\u00a0have\u00a0been\u00a0filed\u00a0separately\u00a0with\u00a0the\u00a0Securities\u00a0and\u00a0Exchange\u00a0Commission.\n\u00a0\nSTRATEGIC\u00a0ALLIANCE\u00a0AGREEMENT\n\u00a0\n\u00a0\nThis\u00a0Strategic\u00a0Collaboration\u00a0Agreement\u00a0(\u201c Agreement \u201d),\u00a0effective\u00a0as\u00a0of\u00a0the\u00a023rd\u00a0day\u00a0of\u00a0 September,\u00a02016\u00a0(\u201c Effective\u00a0Date \u201d),\u00a0is\nentered\u00a0into\u00a0by\u00a0and\u00a0between\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0M.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center,\u00a0with\u00a0a\u00a0place\u00a0of\u00a0business\u00a0located\u00a0at\u00a01515\nHolcombe\u00a0Blvd.,\u00a0Houston,\u00a0TX\u00a077030,\u00a0USA\u00a0(\u201c MD\u00a0Anderson \u201d),\u00a0a\u00a0member\u00a0institution\u00a0of\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0System\u00a0(\u201c System\u201d)\nand\u00a0Adaptimmune\u00a0LLC,\u00a0with\u00a0a\u00a0place\u00a0of\u00a0business\u00a0located\u00a0at\u00a02001\u00a0Market\u00a0Street,\u00a0Philadelphia,\u00a0PA\u00a01903,\u00a0USA\u00a0(\u201c Adaptimmune \u201d)\u037e\u00a0and\nAdaptimmune\u00a0Limited,\u00a0with\u00a0a\u00a0place\u00a0of\u00a0business\u00a0at\u00a0101\u00a0Milton\u00a0Park,\u00a0Abingdon,\u00a0Oxfordshire,\u00a0OX14\u00a04RY\u00a0(\u201cAdaptimmune\u00a0Limited\u201d)\n(MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0each\u00a0a\u00a0\u201c Party\u201d\u00a0and\u00a0collectively\u00a0the\u00a0\u201c Parties\u201d).\n\u00a0\nWITNESSETH\n\u00a0\nWhereas \u00a0Adaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited\u00a0are\u00a0biotechnology\u00a0companies\u00a0involved\u00a0in\u00a0the\u00a0field\u00a0of\u00a0research,\u00a0development\u00a0and\nmarketing\u00a0of\u00a0pharmaceutical\u00a0products\u00a0and\u00a0therapies,\u00a0including\u00a0the\u00a0sponsorship\u00a0of\u00a0clinical\u00a0trials.\n\u00a0\nWhereas \u00a0MD\u00a0Anderson\u00a0is\u00a0a\u00a0comprehensive\u00a0cancer\u00a0research,\u00a0treatment,\u00a0and\u00a0prevention\u00a0center,\u00a0with\u00a0scientists\u00a0and\u00a0technicians\u00a0in\nsubstantive\u00a0fields\u00a0relating\u00a0to\u00a0cancer\u00a0research.\n\u00a0\nWhereas \u00a0the\u00a0Parties\u00a0hereby\u00a0wish\u00a0to\u00a0establish\u00a0a\u00a0strategic\u00a0alliance,\u00a0as\u00a0further\u00a0described\u00a0herein,\u00a0(\u201c Alliance\u201d)\u00a0whereby\u00a0Adaptimmune\nwill\u00a0provide\u00a0funding\u00a0and\u00a0in-kind\u00a0support\u00a0for:\u00a0(a)\u00a0one\u00a0or\u00a0more\u00a0preclinical\u00a0studies\u00a0(\u201c Pre-clinical\u00a0Studies \u201d)\u037e\u00a0and\u00a0(b)\u00a0one\u00a0or\u00a0more\u00a0clinical\nand\u00a0related\u00a0correlative\u00a0studies\u00a0(\u201c Clinical\u00a0Studies \u201d)\u00a0to\u00a0be\u00a0conducted\u00a0by\u00a0MD\u00a0Anderson\u00a0pursuant\u00a0to\u00a0this\u00a0Agreement\u00a0(each\u00a0such\u00a0Clinical\nStudy\u00a0or\u00a0Pre-clinical\u00a0Study,\u00a0a\u00a0\u201c Study,\u201d\u00a0and\u00a0all\u00a0such\u00a0Clinical\u00a0Studies\u00a0and\u00a0Pre-clinical\u00a0Studies,\u00a0the\u00a0\u201c Studies.\u201d).\n\u00a0\nNow\u00a0therefore ,\u00a0in\u00a0consideration\u00a0of\u00a0the\u00a0premises\u00a0and\u00a0the\u00a0mutual\u00a0covenants\u00a0and\u00a0conditions\u00a0hereinafter\u00a0recited,\u00a0the\u00a0Parties\u00a0do\u00a0hereby\nagree\u00a0as\u00a0follows:\n\u00a0\n1.\u00a0Subject\u00a0and\u00a0Scope\u00a0of\u00a0Agreement\n\u00a0\n1.1 \u00a0The\u00a0initial\u00a0scope\u00a0of\u00a0the\u00a0Alliance\u00a0will\u00a0consist\u00a0of\u00a0the\u00a0Studies\u00a0described\u00a0in\u00a0Exhibit\u00a0I,\u00a0the\u00a0details\u00a0of\u00a0which\u00a0are\u00a0to\u00a0be\u00a0mutually\u00a0agreed\nupon\u00a0by\u00a0the\u00a0JSC\u00a0from\u00a0time\u00a0to\u00a0time\u00a0in\u00a0accordance\u00a0with\u00a0Sections\u00a01.5\u00a0\u2013\u00a01.8\u00a0below).\u00a0The\u00a0Studies\u00a0and/or\u00a0the\u00a0scope\u00a0of\u00a0the\u00a0Alliance\u00a0may\u00a0be\nreplaced\u00a0and/or\u00a0changed\u00a0as\u00a0agreed\u00a0upon\u00a0by\u00a0the\u00a0JSC.\u00a0Adaptimmune\u00a0shall\u00a0have\u00a0responsibility\u00a0for\u00a0IND\u00a0filing\u00a0and\u00a0monitoring\u00a0unless\notherwise\u00a0agreed\u00a0by\u00a0JSC.\u00a0The\u00a0Alliance\u00a0Funding\u00a0(defined\u00a0in\u00a0Section\u00a01.3\u00a0below)\u00a0will\u00a0cover\u00a0enrollment\u00a0of\u00a0a\u00a0minimum\u00a0of\u00a0***\u00a0Clinical\nStudy\u00a0subjects\u00a0into\u00a0Clinical\u00a0Studies\u00a0(with\u00a0Clinical\u00a0Studies\u00a0in\u00a0this\u00a0context\u00a0excluding\u00a0any\u00a0screening\u00a0Study\u00a0or\u00a0long\u00a0term\u00a0follow-up\u00a0Study)\n(\u201cMinimum\u00a0Patient\u00a0Numbers\u201d).\u00a0MD\u00a0Anderson\u00a0represents\u00a0and\u00a0undertakes\u00a0that\u00a0(a)\u00a0***\u00a0 and\u00a0(b)\u00a0that\u00a0the\u00a0***\n\u00a0\n(together\u00a0(a)\u00a0and\u00a0(b)\u00a0being\u00a0the\u00a0***):\n\u00a0\n1.2 \u00a0Adaptimmune\u00a0shall\u00a0be\u00a0the\u00a0sponsor\u00a0of\u00a0any\u00a0Clinical\u00a0Study.\u00a0MDACC\u00a0shall\u00a0be\u00a0responsible\u00a0for\u00a0the\u00a0conduct\u00a0of\u00a0each\u00a0Study\u00a0in\naccordance\u00a0with\u00a0the\u00a0relevant\u00a0protocol\u00a0and/or\u00a0workscope.\u00a0The\u00a0Agreement\u00a0shall\u00a0govern\u00a0the\u00a0performance\u00a0of\u00a0Studies\u00a0by\u00a0MD\u00a0Anderson\nand\u00a0one\u00a0or\u00a0more\u00a0Principal\u00a0Investigator(s)\u00a0on\u00a0basis\u00a0of\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n1\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "f80b64e2-d6a1-4315-b037-2e79ed9010d0": {"__data__": {"id_": "f80b64e2-d6a1-4315-b037-2e79ed9010d0", "embedding": null, "metadata": {"page_label": "2", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nStudy\u00a0specific\u00a0documents\u00a0(\u201c Study\u00a0Orders \u201d)\u00a0as\u00a0agreed\u00a0upon\u00a0by\u00a0the\u00a0Parties.\u00a0This\u00a0Agreement\u00a0shall\u00a0apply\u00a0to\u00a0all\u00a0Studies\u00a0set\u00a0out\u00a0in\u00a0the\nStudy\u00a0Orders\u00a0performed\u00a0by\u00a0MD\u00a0Anderson\u00a0and\u00a0the\u00a0MD\u00a0Anderson\u00a0principal\u00a0investigator(s)\u00a0responsible\u00a0for\u00a0the\u00a0performance\u00a0of\u00a0such\nStudies\u00a0(\u201c Principal\u00a0Investigator(s) \u201d)\u00a0upon\u00a0execution\u00a0of\u00a0Study\u00a0Orders\u00a0during\u00a0the\u00a0term\u00a0of\u00a0this\u00a0Agreement.\u00a0Each\u00a0Study\u00a0Order\u00a0shall\u00a0be\nsubstantially\u00a0in\u00a0the\u00a0form\u00a0attached\u00a0as\u00a0Exhibit\u00a0III\u00a0to\u00a0this\u00a0Agreement\u00a0and\u00a0shall\u00a0detail\u00a0the\u00a0specifics\u00a0of\u00a0the\u00a0Study\u00a0to\u00a0be\u00a0performed\u00a0under\nsuch\u00a0Study\u00a0Order\u00a0including,\u00a0without\u00a0limitation,\u00a0(i)\u00a0the\u00a0detailed\u00a0Protocol\u00a0or\u00a0workscope,\u00a0(ii)\u00a0the\u00a0Principal\u00a0Investigator\u00a0and\u00a0(iii)\u00a0identify\nany\u00a0project-specific\u00a0resources\u00a0or\u00a0support\u00a0provided\u00a0by\u00a0Adaptimmune.\u00a0In\u00a0the\u00a0event\u00a0of\u00a0any\u00a0conflict\u00a0of\u00a0terms\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0the\nterms\u00a0of\u00a0a\u00a0Study\u00a0Order,\u00a0the\u00a0terms\u00a0of\u00a0this\u00a0Agreement\u00a0shall\u00a0govern,\u00a0unless\u00a0the\u00a0Study\u00a0Order\u00a0specifically\u00a0and\u00a0expressly\u00a0supersedes\u00a0this\nAgreement\u00a0with\u00a0respect\u00a0to\u00a0a\u00a0specific\u00a0term,\u00a0 and\u00a0then\u00a0only\u00a0with\u00a0respect\u00a0to\u00a0the\u00a0particular\u00a0Study\u00a0Order\u00a0and\u00a0specific\u00a0term.\u00a0If\u00a0there\u00a0is\u00a0any\ndiscrepancy\u00a0or\u00a0conflict\u00a0between\u00a0the\u00a0terms\u00a0contained\u00a0in\u00a0a\u00a0Protocol\u00a0or\u00a0workscope\u00a0and\u00a0this\u00a0Agreement\u00a0and/or\u00a0the\u00a0relevant\u00a0Study\u00a0Order,\nthe\u00a0terms\u00a0of\u00a0the\u00a0Protocol\u00a0or\u00a0workscope\u00a0shall\u00a0govern\u00a0and\u00a0control\u00a0with\u00a0respect\u00a0to\u00a0clinical/scientific\u00a0matters\u00a0and\u00a0the\u00a0terms\u00a0of\u00a0the\nAgreement\u00a0and/or\u00a0the\u00a0relevant\u00a0Study\u00a0Order\u00a0in\u00a0that\u00a0order\u00a0shall\u00a0govern\u00a0and\u00a0control\u00a0with\u00a0respect\u00a0to\u00a0all\u00a0other\u00a0matters,\u00a0e.g.,\u00a0legal\u00a0and\nfinancial\u00a0matters.\n\u00a0\n1.3 \u00a0Adaptimmune\u00a0agrees\u00a0to\u00a0commit\u00a0funding\u00a0in\u00a0an\u00a0amount\u00a0of\u00a0at\u00a0least\u00a0nineteen\u00a0million\u00a0six\u00a0hundred\u00a0and\u00a0forty\u00a0four\u00a0thousand\u00a0Dollars\u00a0US\n($19,644,000)\u00a0for\u00a0the\u00a0performance\u00a0of\u00a0the\u00a0Studies\u00a0as\u00a0set\u00a0out\u00a0in\u00a0Exhibit\u00a0I\u00a0during\u00a0the\u00a0term\u00a0(\u201c Alliance\u00a0Funding \u201d).\u00a0The\u00a0JSC\u00a0may\u00a0allocate\nand/or\u00a0re-allocate\u00a0funds\u00a0to\u00a0Studies\u00a0as\u00a0necessary\u00a0and\u00a0agreed\u00a0by\u00a0JSC.\u00a0The\u00a0basic\u00a0per\u00a0patient\u00a0estimate\u00a0for\u00a0Clinical\u00a0Studies\u00a0is\u00a0as\u00a0follows:\nfor\u00a0screening\u00a0Clinical\u00a0Studies:\u00a0$***,\u00a0for\u00a0long\u00a0term\u00a0follow-up\u00a0Clinical\u00a0Studies:\u00a0$***\u00a0and\u00a0for\u00a0other\u00a0Clinical\u00a0Studies:\u00a0$***.\u00a0If\u00a0the\u00a0Parties\nextend\u00a0the\u00a0term\u00a0by\u00a0mutual\u00a0agreement\u00a0as\u00a0set\u00a0forth\u00a0herein,\u00a0the\u00a0Parties\u00a0shall\u00a0negotiate\u00a0in\u00a0good\u00a0faith\u00a0the\u00a0amount\u00a0of\u00a0future\u00a0Study\u00a0funding\ncommitments\u00a0by\u00a0Adaptimmune\u00a0applicable\u00a0to\u00a0such\u00a0extended\u00a0term.\u00a0In\u00a0the\u00a0event\u00a0a\u00a0Study\u00a0is\u00a0terminated\u00a0early,\u00a0then\u00a0in\u00a0relation\u00a0to\u00a0any\u00a0funds\nallocated\u00a0to\u00a0such\u00a0Study,\u00a0the\u00a0Parties\u00a0shall\u00a0promptly\u00a0discuss\u00a0and\u00a0agree\u00a0upon\u00a0a\u00a0replacement\u00a0of\u00a0that\u00a0Study\u00a0with\u00a0a\u00a0new\u00a0study\u00a0of\u00a0similar\nscope\u00a0that\u00a0is\u00a0of\u00a0mutual\u00a0scientific\u00a0interest\u00a0to\u00a0the\u00a0Parties\u00a0and\u00a0that\u00a0is\u00a0approved\u00a0by\u00a0the\u00a0JSC,\u00a0and\u00a0that\u00a0will\u00a0be\u00a0funded\u00a0by\u00a0the\u00a0Alliance\nFunding.\u00a0If\u00a0there\u00a0is\u00a0any\u00a0Alliance\u00a0Funding\u00a0at\u00a0the\u00a0expiration\u00a0or\u00a0termination\u00a0of\u00a0this\u00a0Agreement,\u00a0it\u00a0will\u00a0be\u00a0allocated\u00a0to\u00a0studies,\u00a0research\u00a0or\ntests\u00a0agreed\u00a0by\u00a0the\u00a0JSC,\u00a0and\u00a0such\u00a0Alliance\u00a0Funding\u00a0will\u00a0be\u00a0payable\u00a0in\u00a0accordance\u00a0with\u00a0agreed\u00a0milestones\u00a0relevant\u00a0to\u00a0such\u00a0agreed\nstudies,\u00a0research\u00a0or\u00a0tests.\n\u00a0\nThe\u00a0Parties\u00a0understand\u00a0that\u00a0the\u00a0compensation\u00a0being\u00a0paid\u00a0to\u00a0MD\u00a0Anderson\u00a0under\u00a0this\u00a0Agreement\u00a0constitutes\u00a0the\u00a0fair\u00a0market\u00a0value\u00a0of\nthe\u00a0services\u00a0to\u00a0be\u00a0provided\u00a0hereunder.\u00a0Neither\u00a0MD\u00a0Anderson\u00a0nor\u00a0Principal\u00a0Investigator\u00a0shall\u00a0seek\u00a0or\u00a0accept\u00a0reimbursement\u00a0from\u00a0any\nthird-party\u00a0payor\u00a0for\u00a0any\u00a0Study\u00a0items\u00a0or\u00a0procedures\u00a0supplied\u00a0by\u00a0or\u00a0paid\u00a0for\u00a0by\u00a0Adaptimmune\u00a0under\u00a0this\u00a0Agreement.\u00a0 MD\u00a0Anderson\nacknowledges\u00a0that\u00a0Adaptimmune\u00a0may\u00a0be\u00a0obligated\u00a0to\u00a0disclose\u00a0all\u00a0payments\u00a0made\u00a0hereunder,\u00a0including\u00a0the\u00a0provision\u00a0of\u00a0non-monetary\nitems\u00a0of\u00a0value,\u00a0as\u00a0may\u00a0be\u00a0required\u00a0under\u00a0Applicable\u00a0Law,\u00a0including\u00a0the\u00a0Physician\u00a0Payments\u00a0Sunshine\u00a0Act,\u00a0passed\u00a0as\u00a0Section\u00a06002\u00a0of\nthe\u00a02010\u00a0Patient\u00a0Protection\u00a0and\u00a0Affordable\u00a0Care\u00a0Act\u00a0and,\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0by\u00a0Applicable\u00a0Laws,\u00a0agrees\u00a0to\u00a0keep\u00a0and\u00a0maintain\nrelevant\u00a0records\u00a0of\u00a0such\u00a0and,\u00a0upon\u00a0Adaptimmune\u2019s\u00a0reasonable\u00a0request,\u00a0provide\u00a0such\u00a0records\u00a0to\u00a0Adaptimmune\u00a0to\u00a0the\u00a0extent\u00a0such\ninformation\u00a0is\u00a0not\u00a0already\u00a0in\u00a0Adaptimmune\u2019s\u00a0possession,\u00a0but\u00a0only\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0for\u00a0Adaptimmune\u00a0to\u00a0comply\u00a0with\u00a0its\u00a0legally\nrequired\u00a0reporting\u00a0obligations.\u00a0 MD\u00a0Anderson\u00a0consents\u00a0to\u00a0such\u00a0disclosure,\u00a0to\u00a0the\u00a0extent\u00a0such\u00a0disclosure\u00a0is\u00a0required\u00a0for\u00a0Adaptimmune\nto\u00a0comply\u00a0with\u00a0Applicable\u00a0Laws.\u00a0MD\u00a0Anderson\u00a0shall\u00a0ensure\u00a0that\u00a0the\u00a0Principal\u00a0Investigator\u00a0provides\u00a0in\u00a0a\u00a0timely\u00a0manner\u00a0all\u00a0such\nreasonable\u00a0information\u00a0to\u00a0Adaptimmune\u00a0necessary\u00a0for\u00a0Adaptimmune\u00a0to\u00a0comply\u00a0with\u00a0any\u00a0disclosure\u00a0requirements\u00a0to\u00a0the\u00a0extent\nrequired\u00a0by\u00a0and\u00a0in\u00a0accordance\u00a0with\u00a021\u00a0C.F.R.\u00a0Part\u00a054,\u00a0including\u00a0but\u00a0not\u00a0limited\u00a0to,\u00a0any\u00a0information\u00a0required\u00a0to\u00a0be\u00a0disclosed\u00a0in\nconnection\u00a0with\u00a0any\u00a0financial\u00a0relationship\u00a0between\u00a0Adaptimmune\u00a0and\u00a0the\u00a0Principal\u00a0Investigators\u00a0and\u00a0sub-investigators\u00a0involved\u00a0in\u00a0the\nStudy,\u00a0as\u00a0well\u00a0as\u00a0any\u00a0immediate\u00a0family\u00a0members\u00a0thereof.\u00a0MD\u00a0Anderson\u00a0will\u00a0ensure\u00a0that\u00a0Principal\u00a0Investigator\u00a0promptly\u00a0updates\u00a0any\nprovided\u00a0information\u00a0if\u00a0any\u00a0relevant\u00a0changes\u00a0occur\u00a0during\u00a0the\u00a0performance\u00a0of\u00a0any\u00a0Study\u00a0and\u00a0for\u00a0one\u00a0year\u00a0following\u00a0completion\u00a0of\u00a0any\nStudy.\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n2\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "3b7cbd0d-b700-43a9-ab09-6ee3a844d9f2": {"__data__": {"id_": "3b7cbd0d-b700-43a9-ab09-6ee3a844d9f2", "embedding": null, "metadata": {"page_label": "3", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nNo\u00a0amounts\u00a0paid\u00a0under\u00a0this\u00a0Agreement\u00a0are\u00a0intended\u00a0to\u00a0be\u00a0for,\u00a0nor\u00a0shall\u00a0they\u00a0be\u00a0construed\u00a0as,\u00a0an\u00a0offer\u00a0or\u00a0payment\u00a0made\u00a0in\u00a0exchange\nfor\u00a0any\u00a0explicit\u00a0or\u00a0implicit\u00a0agreement\u00a0to\u00a0purchase,\u00a0prescribe,\u00a0recommend,\u00a0or\u00a0provide\u00a0a\u00a0favorable\u00a0formulary\u00a0status,\u00a0for\u00a0any\nAdaptimmune\u00a0product\u00a0or\u00a0service.\u00a0Any\u00a0such\u00a0compensation\u00a0will\u00a0be\u00a0consistent\u00a0with\u00a0fair\u00a0market\u00a0value\u00a0in\u00a0arms-length\u00a0transactions\u00a0and\nwill\u00a0not\u00a0be\u00a0determined\u00a0in\u00a0a\u00a0manner\u00a0that\u00a0takes\u00a0into\u00a0account\u00a0the\u00a0volume\u00a0or\u00a0value\u00a0of\u00a0any\u00a0referrals\u00a0or\u00a0business\u00a0otherwise\u00a0generated\nbetween\u00a0the\u00a0Parties\u00a0for\u00a0which\u00a0payment\u00a0may\u00a0be\u00a0made\u00a0in\u00a0whole\u00a0or\u00a0in\u00a0part\u00a0under\u00a0Medicare,\u00a0Medicaid\u00a0or\u00a0other\u00a0Federal\u00a0health\u00a0care\nprograms.\u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0each\u00a0confirm\u00a0that\u00a0in\u00a0entering\u00a0into\u00a0this\u00a0Agreement\u00a0they\u00a0have\u00a0not\u00a0accepted\u00a0any\u00a0bribes\u00a0or\nillegal\u00a0inducements\u00a0to\u00a0enter\u00a0into\u00a0this\u00a0Agreement\u00a0or\u00a0to\u00a0perform\u00a0any\u00a0Study\u00a0and\u00a0will\u00a0not\u00a0accept\u00a0any\u00a0bribe\u00a0or\u00a0illegal\u00a0inducement\u00a0or\u00a0offer\nany\u00a0bribe\u00a0or\u00a0illegal\u00a0inducement\u00a0in\u00a0the\u00a0performance\u00a0of\u00a0or\u00a0for\u00a0the\u00a0performance\u00a0of\u00a0any\u00a0Study\u00a0whether\u00a0during\u00a0or\u00a0after\u00a0the\u00a0termination\u00a0or\nexpiry\u00a0of\u00a0this\u00a0Agreement.\n\u00a0\n\u00a0\n1.4 \u00a0The\u00a0nineteen\u00a0million\u00a0six\u00a0hundred\u00a0and\u00a0forty\u00a0four\u00a0thousand\u00a0Dollars\u00a0US\u00a0($19,644,000)\u00a0for\u00a0the\u00a0Studies\u00a0shall\u00a0be\u00a0due\u00a0and\u00a0payable\u00a0to\u00a0MD\nAnderson\u00a0according\u00a0to\u00a0the\u00a0schedule\u00a0outlined\u00a0in\u00a0Table\u00a02\u00a0in\u00a0Exhibit\u00a0II.\u00a0The\u00a0JSC\u00a0retains\u00a0the\u00a0right\u00a0to\u00a0prioritize\u00a0and\u00a0replace\u00a0Studies\u00a0as\nnecessary\u00a0subject\u00a0to\u00a0Section\u00a01.6.\n\u00a0\n1.5 \u00a0The\u00a0Parties\u00a0will\u00a0establish\u00a0a\u00a0Joint\u00a0Steering\u00a0Committee\u00a0(\u201c JSC\u201d)\u00a0of\u00a0equal\u00a0representation,\u00a0comprised\u00a0of\u00a0three\u00a0(3)\u00a0representatives\n(employees,\u00a0directors\u00a0or\u00a0consultants\u00a0who\u00a0are\u00a0subject\u00a0to\u00a0appropriate\u00a0confidentiality\u00a0obligations)\u00a0from\u00a0each\u00a0Party,\u00a0with\u00a0the\nrepresentatives\u00a0of\u00a0each\u00a0Party\u00a0collectively\u00a0having\u00a0one\u00a0vote\u00a0on\u00a0all\u00a0matters\u00a0to\u00a0be\u00a0decided\u00a0upon\u00a0by\u00a0the\u00a0JSC.\u00a0 Each\u00a0Party\u00a0can\u00a0appoint\u00a0and\nreplace\u00a0its\u00a0representatives\u00a0in\u00a0the\u00a0JSC\u00a0at\u00a0its\u00a0own\u00a0discretion\u00a0through\u00a0timely\u00a0written\u00a0notice\u00a0to\u00a0the\u00a0other\u00a0Party.\n\u00a0\n1.6 \u00a0The\u00a0JSC\u00a0will\u00a0have\u00a0meetings\u00a0(either\u00a0in\u00a0person,\u00a0by\u00a0teleconference\u00a0or\u00a0via\u00a0electronic\u00a0means)\u00a0at\u00a0least\u00a0quarterly.\u00a0 At\u00a0least\u00a0one\u00a0meeting\nper\u00a0year\u00a0will\u00a0be\u00a0conducted\u00a0in\u00a0person\u00a0or\u00a0by\u00a0videoconference\u00a0(including\u00a0the\u00a0kick-off\u00a0meeting).\u00a0The\u00a0JSC\u00a0will\u00a0decide\u00a0on\u00a0matters\u00a0by\nunanimous\u00a0vote\u00a0with\u00a0each\u00a0of\u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0exercising\u00a0one\u00a0vote\u00a0each\u00a0provided,\u00a0however,\u00a0that\u00a0no\u00a0action\u00a0may\nlawfully\u00a0be\u00a0taken\u00a0at\u00a0any\u00a0meeting\u00a0unless\u00a0at\u00a0least\u00a0two\u00a0representatives\u00a0of\u00a0each\u00a0Party\u00a0(including\u00a0for\u00a0this\u00a0purpose\u00a0any\u00a0proxy\u00a0representative\nappointed\u00a0as\u00a0provided\u00a0below)\u00a0are\u00a0present\u00a0at\u00a0the\u00a0meeting.\u00a0 If\u00a0a\u00a0member\u00a0of\u00a0the\u00a0JSC\u00a0is\u00a0unable\u00a0to\u00a0attend\u00a0a\u00a0meeting,\u00a0he\u00a0or\u00a0she\u00a0may\nappoint,\u00a0in\u00a0writing,\u00a0a\u00a0proxy\u00a0to\u00a0participate\u00a0and\u00a0vote\u00a0in\u00a0his\u00a0or\u00a0her\u00a0stead.\u00a0Decisions\u00a0may\u00a0also\u00a0be\u00a0made\u00a0by\u00a0electronic\u00a0mail,\u00a0provided\u00a0such\nelectronic\u00a0mail\u00a0is\u00a0provided\u00a0by\u00a0at\u00a0least\u00a0two\u00a0representatives\u00a0from\u00a0Adaptimmune\u00a0and\u00a0MD\u00a0Anderson\u00a0and\u00a0such\u00a0electronic\u00a0mail\u00a0is\nacknowledged\u00a0to\u00a0be\u00a0received\u00a0by\u00a0the\u00a0recipient.\u00a0Although\u00a0decision\u00a0will\u00a0be\u00a0made\u00a0by\u00a0mutual\u00a0agreement\u00a0of\u00a0the\u00a0JSC,\u00a0in\u00a0the\u00a0event\u00a0of\u00a0any\ndisagreement,\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n1.7 \u00a0The\u00a0main\u00a0task\u00a0of\u00a0the\u00a0JSC\u00a0will\u00a0be\u00a0to\u00a0oversee\u00a0the\u00a0Alliance.\u00a0 In\u00a0order\u00a0to\u00a0achieve\u00a0the\u00a0objectives\u00a0of\u00a0the\u00a0Alliance,\u00a0the\u00a0JSC\u00a0will\u00a0oversee\neach\u00a0Study\u00a0under\u00a0the\u00a0Alliance.\u00a0 The\u00a0JSC\u00a0will\u00a0provide\u00a0technical,\u00a0scientific,\u00a0clinical,\u00a0and\u00a0regulatory\u00a0guidance\u00a0to\u00a0the\u00a0Studies\u00a0and\u00a0will\u00a0be\nresponsible\u00a0for\u00a0monitoring\u00a0progress\u00a0of\u00a0these\u00a0Studies.\u00a0Additional\u00a0representatives\u00a0can\u00a0be\u00a0invited\u00a0by\u00a0the\u00a0JSC\u00a0on\u00a0a\u00a0case\u00a0by\u00a0case\u00a0basis\nshould\u00a0discussion\u00a0of\u00a0certain\u00a0topics\u00a0require\u00a0so,\u00a0provided\u00a0that\u00a0such\u00a0guests\u00a0will\u00a0be\u00a0subject\u00a0to\u00a0an\u00a0obligation\u00a0of\u00a0confidentiality\u00a0and\u00a0non-use\nat\u00a0least\u00a0as\u00a0strict\u00a0as\u00a0Section\u00a05\u00a0below.\u00a0In\u00a0the\u00a0event\u00a0a\u00a0Study\u00a0is\u00a0terminated\u00a0early\u00a0or\u00a0does\u00a0not\u00a0initiate,\u00a0the\u00a0Parties\u00a0shall\u00a0promptly\u00a0replace\u00a0that\nStudy\u00a0with\u00a0a\u00a0new\u00a0study\u00a0similar\u00a0in\u00a0scope\u00a0that\u00a0is\u00a0of\u00a0mutual\u00a0scientific\u00a0interest\u00a0to\u00a0the\u00a0Parties.\u00a0Once\u00a0agreed\u00a0by\u00a0the\u00a0JSC,\u00a0such\u00a0replacement\nstudy\u00a0will\u00a0be\u00a0funded\u00a0by\u00a0the\u00a0Alliance\u00a0Funding\u00a0and\u00a0payable\u00a0in\u00a0accordance\u00a0with\u00a0agreed\u00a0milestones\u00a0for\u00a0such\u00a0replacement\u00a0study.\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n3\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "ca173bb5-83b4-4a03-a2fe-33b195909863": {"__data__": {"id_": "ca173bb5-83b4-4a03-a2fe-33b195909863", "embedding": null, "metadata": {"page_label": "4", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n1.8 \u00a0In\u00a0addition,\u00a0the\u00a0JSC\u00a0will\u00a0be\u00a0responsible\u00a0for\u00a0coordinating\u00a0resolution\u00a0of\u00a0problems\u00a0arising\u00a0in\u00a0the\u00a0Studies\u00a0or\u00a0in\u00a0the\u00a0Alliance\u00a0as\u00a0a\u00a0whole.\nIn\u00a0the\u00a0event\u00a0of\u00a0any\u00a0matter\u00a0to\u00a0which\u00a0the\u00a0JSC\u00a0cannot\u00a0reach\u00a0resolution,\u00a0or\u00a0in\u00a0the\u00a0event\u00a0of\u00a0any\u00a0dispute\u00a0arising\u00a0as\u00a0to\u00a0any\u00a0matter\u00a0subject\u00a0to\nJSC\u00a0responsibility\u00a0and\u00a0save\u00a0where\u00a0Adaptimmune\u00a0has\u00a0the\u00a0deciding\u00a0vote\u00a0in\u00a0accordance\u00a0with\u00a0Section\u00a01.6\u00a0above,\u00a0such\u00a0matter\u00a0or\u00a0dispute\nwill\u00a0be\u00a0escalated\u00a0to\u00a0executive\u00a0management\u00a0of\u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0for\u00a0good\u00a0faith\u00a0resolution.\u00a0Both\u00a0Parties\u00a0shall\u00a0use\u00a0all\nreasonable\u00a0efforts\u00a0to\u00a0resolve\u00a0any\u00a0matter\u00a0or\u00a0dispute\u00a0on\u00a0a\u00a0timely\u00a0basis.\n\u00a0\n1.9 \u00a0MD\u00a0Anderson\u00a0represents\u00a0and\u00a0certifies\u00a0that\u00a0neither\u00a0MD\u00a0Anderson\u00a0nor\u00a0Principal\u00a0Investigator\u00a0will,\u00a0directly\u00a0or\u00a0indirectly,\u00a0offer\u00a0or\u00a0pay,\nor\u00a0authorize\u00a0an\u00a0offer\u00a0or\u00a0payment\u00a0of,\u00a0any\u00a0money\u00a0or\u00a0anything\u00a0of\u00a0value\u00a0to\u00a0any\u00a0Public\u00a0Official\u00a0(defined\u00a0below)\u00a0or\u00a0public\u00a0entity,\u00a0with\u00a0the\nknowledge\u00a0or\u00a0intent\u00a0that\u00a0the\u00a0payment,\u00a0promise\u00a0or\u00a0gift,\u00a0in\u00a0whole\u00a0or\u00a0in\u00a0part,\u00a0will\u00a0be\u00a0made\u00a0in\u00a0order\u00a0to\u00a0improperly\u00a0influence\u00a0an\u00a0official\u00a0act\nor\u00a0decision\u00a0that\u00a0will\u00a0assist\u00a0Adaptimmune\u00a0in\u00a0securing\u00a0an\u00a0improper\u00a0advantage\u00a0or\u00a0in\u00a0obtaining\u00a0or\u00a0retaining\u00a0business\u00a0or\u00a0in\u00a0directing\nbusiness\u00a0to\u00a0any\u00a0person\u00a0or\u00a0entity\u00a0in\u00a0relation\u00a0to\u00a0the\u00a0Study.\u00a0 In\u00a0addition\u00a0to\u00a0other\u00a0rights\u00a0or\u00a0remedies\u00a0under\u00a0this\u00a0Agreement\u00a0or\u00a0at\u00a0law,\nAdaptimmune\u00a0may\u00a0terminate\u00a0the\u00a0affected\u00a0Study\u00a0Order\u00a0if\u00a0MD\u00a0Anderson\u00a0breaches\u00a0any\u00a0of\u00a0the\u00a0representations\u00a0or\u00a0certifications\ncontained\u00a0in\u00a0this\u00a0Section\u00a0or\u00a0if\u00a0Adaptimmune\u00a0learns\u00a0that\u00a0improper\u00a0payments\u00a0are\u00a0being\u00a0or\u00a0have\u00a0been\u00a0made\u00a0to\u00a0any\u00a0Public\u00a0Official\u00a0by\u00a0MD\nAnderson\u00a0or\u00a0Investigator.\u00a0 For\u00a0the\u00a0purposes\u00a0of\u00a0this\u00a0Agreement,\u00a0\u201cPublic\u00a0Official\u201d\u00a0means\u00a0any\u00a0officer\u00a0or\u00a0employee\u00a0of\u00a0a\u00a0government,\u00a0a\npublic\u00a0international\u00a0organization\u00a0or\u00a0any\u00a0department\u00a0or\u00a0agency\u00a0thereof,\u00a0or\u00a0any\u00a0person\u00a0acting\u00a0in\u00a0an\u00a0official\u00a0capacity,\u00a0including,\u00a0for\u00a0a\npublic\u00a0agency\u00a0or\u00a0enterprise\u037e\u00a0and\u00a0any\u00a0political\u00a0party\u00a0or\u00a0party\u00a0official,\u00a0or\u00a0any\u00a0candidate\u00a0for\u00a0public\u00a0office.\u00a0Adaptimmune\u00a0acknowledges\nand\u00a0agrees\u00a0that\u00a0MD\u00a0Anderson\u00a0is\u00a0an\u00a0agency\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas,\u00a0and\u00a0its\u00a0investigator,\u00a0employees,\u00a0and\u00a0officers\u00a0do\u00a0constitute\u00a0a\u00a0Public\nOfficial,\u00a0as\u00a0used\u00a0in\u00a0this\u00a0paragraph,\u00a0for\u00a0purposes\u00a0of\u00a0this\u00a0Section.\u00a0Notwithstanding\u00a0anything\u00a0in\u00a0this\u00a0Section\u00a01.9,\u00a0nothing\u00a0in\u00a0this\u00a0Section\nshall\u00a0constitute\u00a0a\u00a0limitation\u00a0on\u00a0MD\u00a0Anderson\u2019s\u00a0ability\u00a0to\u00a0operate\u00a0within\u00a0its\u00a0legal\u00a0capacity\u00a0as\u00a0an\u00a0agency\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas,\u00a0nor\u00a0shall\nanything\u00a0in\u00a0this\u00a0Agreement\u00a0require\u00a0MD\u00a0Anderson\u00a0to\u00a0violate\u00a0any\u00a0law\u00a0or\u00a0to\u00a0refrain\u00a0from\u00a0complying\u00a0with\u00a0any\u00a0law\u00a0applicable\u00a0to\u00a0MD\nAnderson.\n\u00a0\n\u00a0\n2.\u00a0Responsibilities\u00a0and\u00a0Compliance\n\u00a0\n2.1 \u00a0Each\u00a0Clinical\u00a0Study\u00a0shall\u00a0be\u00a0subject\u00a0to\u00a0review\u00a0and\u00a0approval\u00a0of\u00a0the\u00a0Study\u00a0protocol\u00a0(\u201c Protocol\u201d)\u00a0as\u00a0required\u00a0by\u00a0MD\u00a0Anderson\u2019s\nInstitutional\u00a0Review\u00a0Board\u00a0(\u201c Institutional\u00a0Review\u00a0Board \u201d\u00a0or\u00a0\u201cIRB\u201d)\u00a0and/or\u00a0any\u00a0relevant\u00a0authorities\u00a0prior\u00a0to\u00a0commencement\u00a0of\u00a0the\nStudy\u00a0as\u00a0may\u00a0be\u00a0required\u00a0in\u00a0order\u00a0to\u00a0comply\u00a0with\u00a0Applicable\u00a0Laws.\n\u00a0\n2.2 \u00a0The\u00a0scope\u00a0of\u00a0the\u00a0Study\u00a0to\u00a0be\u00a0performed\u00a0shall\u00a0be\u00a0set\u00a0forth\u00a0in\u00a0the\u00a0Protocol(s)\u00a0or\u00a0workscope\u00a0referenced\u00a0in\u00a0the\u00a0Study\u00a0Order,\u00a0which\nshall\u00a0be\u00a0incorporated\u00a0by\u00a0reference\u00a0into\u00a0such\u00a0Study\u00a0Order.\u00a0 These\u00a0Protocol(s)/workscope\u00a0shall\u00a0be\u00a0considered\u00a0final\u00a0after\u00a0being\u00a0agreed\u00a0to\nby\u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0and,\u00a0for\u00a0Clinical\u00a0Studies,\u00a0including\u00a0approval\u00a0by\u00a0MD\u00a0Anderson\u2019s\u00a0IRB.\u00a0 The\u00a0Principal\u00a0Investigator\nfor\u00a0a\u00a0Clinical\u00a0Study\u00a0shall\u00a0submit\u00a0the\u00a0Protocol\u00a0and\u00a0reports\u00a0of\u00a0the\u00a0ongoing\u00a0conduct\u00a0of\u00a0the\u00a0Clinical\u00a0Study\u00a0to\u00a0the\u00a0IRB\u00a0as\u00a0required\u00a0by\u00a0the\nIRB,\u00a0obtain\u00a0written\u00a0approval\u00a0from\u00a0the\u00a0IRB,\u00a0and\u00a0inform\u00a0the\u00a0IRB\u00a0of\u00a0Study\u00a0closure.\n\u00a0\n2.3 \u00a0MD\u00a0Anderson\u00a0shall\u00a0and\u00a0will\u00a0ensure\u00a0that\u00a0each\u00a0Principal\u00a0Investigator\u00a0shall\u00a0conduct\u00a0a\u00a0Study\u00a0in\u00a0accordance\u00a0with\u00a0(a)\u00a0the\u00a0terms\u00a0and\nconditions\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0the\u00a0relevant\u00a0Study\u00a0Order,\u00a0(b)\u00a0the\u00a0provisions\u00a0of\u00a0the\u00a0Protocol\u00a0or\u00a0workscope,\u00a0as\u00a0applicable,\u00a0(c)\napplicable\u00a0Good\u00a0Clinical\u00a0Practice\u00a0requirements\u00a0as\u00a0incorporated\u00a0by\u00a0FDA\u00a0regulations\u00a0(\u201c GCP\u201d),\u00a0(d)\u00a0the\u00a0ethical\u00a0principles\u00a0of\u00a0the\nDeclaration\u00a0of\u00a0Helsinki,\u00a0as\u00a0applicable,\u00a0and\u00a0(e)\u00a0any\u00a0and\u00a0all\u00a0applicable\u00a0orders\u00a0and\u00a0mandates\u00a0of\u00a0relevant\u00a0authorities\u00a0(including\u00a0the\u00a0FDA)\nand\u00a0IRB,\u00a0and\u00a0applicable\u00a0MD\u00a0Anderson\u00a0policies.\u00a0MD\u00a0Anderson\u00a0shall\u00a0ensure\u00a0that\u00a0all\u00a0persons\u00a0participating\u00a0in\u00a0any\u00a0Study\u00a0are\u00a0either\nemployees\u00a0of\u00a0MD\u00a0Anderson\u00a0or\u00a0are\u00a0under\u00a0legally\u00a0binding\u00a0obligations\u00a0to\u00a0MD\u00a0Anderson\u00a0requiring\u00a0performance\u00a0in\u00a0accordance\u00a0with\u00a0the\nterms\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0that\u00a0all\u00a0persons\n\u00a0\n4\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "c389685b-6ecf-4e20-83a8-c8297388daae": {"__data__": {"id_": "c389685b-6ecf-4e20-83a8-c8297388daae", "embedding": null, "metadata": {"page_label": "5", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nconducting\u00a0any\u00a0Study\u00a0are\u00a0properly\u00a0trained\u00a0with\u00a0respect\u00a0to\u00a0their\u00a0tasks\u00a0performed\u00a0for\u00a0the\u00a0Study.\u00a0The\u00a0Study\u00a0shall\u00a0be\u00a0conducted\u00a0at\u00a0MD\nAnderson.\u00a0Only\u00a0Adaptimmune\u00a0shall\u00a0be\u00a0entitled\u00a0to\u00a0amend\u00a0or\u00a0modify\u00a0the\u00a0Protocol,\u00a0which\u00a0amendments\u00a0and\u00a0modification\u00a0must\u00a0be\napproved\u00a0by\u00a0the\u00a0IRB\u00a0prior\u00a0to\u00a0implementation.\u00a0Neither\u00a0MD\u00a0Anderson\u00a0or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0be\u00a0entitled\u00a0to\u00a0amend\u00a0any\u00a0Protocol\nfor\u00a0any\u00a0Study\u00a0except\u00a0as\u00a0necessary\u00a0to\u00a0eliminate\u00a0any\u00a0immediate\u00a0hazard\u00a0to\u00a0the\u00a0safety,\u00a0rights\u00a0or\u00a0welfare\u00a0of\u00a0the\u00a0Study\u00a0patient\u00a0or\u00a0unless\nrequired\u00a0by\u00a0the\u00a0IRB.\u00a0Any\u00a0deviation\u00a0from\u00a0the\u00a0Protocol\u00a0must\u00a0be\u00a0agreed\u00a0by\u00a0Adaptimmune\u00a0in\u00a0advance\u00a0unless\u00a0necessary\u00a0to\u00a0eliminate\u00a0an\napparent\u00a0immediate\u00a0hazard\u00a0to\u00a0the\u00a0safety,\u00a0rights\u00a0or\u00a0welfare\u00a0of\u00a0any\u00a0Study\u00a0patient\u00a0or\u00a0unless\u00a0required\u00a0by\u00a0the\u00a0IRB.\u00a0MD\u00a0Anderson\u00a0will\npromptly\u00a0report\u00a0any\u00a0known\u00a0deviation\u00a0to\u00a0Adaptimmune.\n\u00a0\n2.4 \u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0shall\u00a0comply\u00a0with\u00a0all\u00a0federal,\u00a0state,\u00a0and\u00a0local\u00a0laws\u00a0and\u00a0regulations\u00a0as\u00a0well\u00a0as\u00a0ethical\u00a0codes\napplicable\u00a0to\u00a0the\u00a0conduct\u00a0of\u00a0each\u00a0such\u00a0Study\u00a0(\u201cApplicable\u00a0Laws\u201d)\u00a0to\u00a0the\u00a0extent,\u00a0in\u00a0each\u00a0case,\u00a0applicable\u00a0to\u00a0the\u00a0relevant\u00a0performance\nof\u00a0a\u00a0Party\u2019s\u00a0obligations\u00a0under\u00a0this\u00a0Agreement\u00a0and\u00a0any\u00a0Study\u00a0Order.\n\u00a0\n2.5 \u00a0Prior\u00a0to\u00a0the\u00a0enrollment\u00a0of\u00a0any\u00a0patient\u00a0into\u00a0any\u00a0Clinical\u00a0Study,\u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0forward\u00a0to\nAdaptimmune\u00a0evidence\u00a0of\u00a0approval\u00a0of\u00a0each\u00a0Clinical\u00a0Study\u00a0by\u00a0MD\u00a0Anderson\u2019s\u00a0IRB,\u00a0and\u00a0with\u00a0respect\u00a0to\u00a0Studies\u00a0for\u00a0which\u00a0MD\nAnderson\u00a0serves\u00a0as\u00a0\u201csponsor\u201d\u00a0within\u00a0the\u00a0meaning\u00a0of\u00a0such\u00a0term\u00a0under\u00a0Applicable\u00a0Laws\u00a0and\u00a0regulations,\u00a0evidence\u00a0of\u00a0approval\u00a0of\u00a0the\nStudy\u00a0by\u00a0relevant\u00a0regulatory\u00a0authorities\u00a0(or\u00a0exemption\u00a0from\u00a0such\u00a0regulatory\u00a0authority/ies\u00a0review\u00a0and\u00a0approval).\u00a0MD\u00a0Anderson\u00a0shall,\nas\u00a0required\u00a0by\u00a0Applicable\u00a0Law,\u00a0obtain\u00a0from\u00a0the\u00a0IRB\u00a0written\u00a0evidence\u00a0of\u00a0continuing\u00a0review\u00a0and\u00a0approval\u00a0of\u00a0the\u00a0Study\u00a0and\u00a0shall\u00a0provide\nevidence\u00a0of\u00a0such\u00a0approval\u00a0to\u00a0Adaptimmune.\n\u00a0\n2.6 \u00a0If,\u00a0in\u00a0the\u00a0course\u00a0of\u00a0any\u00a0Clinical\u00a0Study\u00a0at\u00a0MD\u00a0Anderson,\u00a0a\u00a0Study\u00a0subject\u00a0is\u00a0injured\u00a0by\u00a0such\u00a0Study\u00a0subject\u2019s\u00a0participation\u00a0in\u00a0the\u00a0Study,\nMD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0inform\u00a0Adaptimmune\u00a0of\u00a0any\u00a0such\u00a0injury\u00a0by\u00a0fax\u00a0or\u00a0email\u00a0in\u00a0case\u00a0of\u00a0serious\u00a0and\nunexpected\u00a0 adverse\u00a0reactions\u00a0and/or\u00a0serious\u00a0and\u00a0unexpected\u00a0adverse\u00a0events\u00a0arising\u00a0from\u00a0the\u00a0use\u00a0of\u00a0Study\u00a0Drug\u00a0as\u00a0soon\u00a0as\nreasonably\u00a0possible\u00a0and\u00a0in\u00a0any\u00a0event\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0timescales\u00a0set\u00a0out\u00a0in\u00a0the\u00a0Protocol,\u00a0 and/or,\u00a0if\u00a0applicable,\u00a0pregnancies,\nwithin\u00a0the\u00a0timelines\u00a0stipulated\u00a0in\u00a0the\u00a0Protocol,\u00a0or\u00a0if\u00a0such\u00a0is\u00a0not\u00a0stipulated\u00a0in\u00a0the\u00a0Protocol,\u00a0within\u00a0***\u00a0(***)\u00a0business\u00a0days\u00a0following\u00a0MD\nAnderson\u00a0or\u00a0Principal\u00a0Investigator\u00a0becoming\u00a0aware\u00a0of\u00a0such\u00a0event.\n\u00a0\n2.7 \u00a0MD\u00a0Anderson\u00a0represents\u00a0that:\u00a0(a)\u00a0it\u00a0has\u00a0not\u00a0been\u00a0debarred\u00a0by\u00a0the\u00a0FDA\u00a0pursuant\u00a0to\u00a0its\u00a0authority\u00a0under\u00a0Sections\u00a0306(a)\u00a0and\u00a0(b)\u00a0of\nthe\u00a0U.S.\u00a0Food,\u00a0Drug,\u00a0and\u00a0Cosmetic\u00a0Act\u00a0(21\u00a0U.S.C..\u00a0\u00a7\u00a0335(a)\u00a0and\u00a0(b))\u00a0and\u00a0is\u00a0not\u00a0the\u00a0subject\u00a0of\u00a0any\u00a0investigation\u00a0or\u00a0proceeding\u00a0which\nmay\u00a0result\u00a0in\u00a0debarment\u00a0by\u00a0the\u00a0FDA,\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0applicable,\u00a0it\u00a0shall\u00a0not\u00a0use\u00a0any\u00a0Principal\u00a0Investigator\u00a0or\u00a0Study\u00a0team\u00a0member\u00a0in\nthe\u00a0performance\u00a0of\u00a0a\u00a0Study\u00a0that\u00a0has\u00a0been\u00a0so\u00a0debarred\u00a0or\u00a0subject\u00a0to\u00a0any\u00a0such\u00a0investigation\u00a0or\u00a0proceeding,\u00a0and\u037e\u00a0(b)\u00a0it\u00a0is\u00a0not\u00a0included\u00a0in\nthe\u00a0List\u00a0of\u00a0Excluded\u00a0Individuals/Entities\u00a0(maintained\u00a0by\u00a0the\u00a0U.S.\u00a0Department\u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services\u00a0Office\u00a0of\u00a0Inspector\nGeneral)\u00a0or\u00a0the\u00a0List\u00a0of\u00a0Parties\u00a0Excluded\u00a0from\u00a0Federal\u00a0Procurement\u00a0and\u00a0Non-procurement\u00a0maintained\u00a0by\u00a0the\u00a0U.S.\u00a0General\u00a0Services\nAdministration,\u00a0and\u00a0is\u00a0not\u00a0the\u00a0subject\u00a0of\u00a0any\u00a0investigation\u00a0or\u00a0proceeding\u00a0which\u00a0may\u00a0result\u00a0in\u00a0inclusion\u00a0in\u00a0any\u00a0such\u00a0list,\u00a0and\u00a0to\u00a0the\u00a0extent\napplicable,\u00a0it\u00a0shall\u00a0not\u00a0use\u00a0any\u00a0Principal\u00a0Investigator\u00a0or\u00a0Study\u00a0team\u00a0member\u00a0in\u00a0the\u00a0performance\u00a0of\u00a0a\u00a0Study\u00a0that\u00a0is\u00a0so\u00a0included\u00a0or\u00a0the\nsubject\u00a0of\u00a0any\u00a0such\u00a0investigation\u00a0or\u00a0proceeding. \u00a0MD\u00a0Anderson\u00a0agrees\u00a0to\u00a0promptly\u00a0notify\u00a0Adaptimmune\u00a0in\u00a0writing\u00a0if\u00a0it\u00a0becomes\u00a0aware\nof\u00a0any\u00a0such\u00a0debarment,\u00a0exclusion,\u00a0investigation\u00a0or\u00a0proceeding\u00a0of\u00a0MD\u00a0Anderson\u00a0or,\u00a0to\u00a0the\u00a0extent\u00a0applicable,\u00a0any\u00a0Principal\u00a0Investigator.\n\u00a0\n2.8 \u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0shall\u00a0comply\u00a0with\u00a0all\u00a0applicable\u00a0federal,\u00a0state\u00a0and\u00a0local\u00a0laws\u00a0pertaining\u00a0to\u00a0confidentiality,\u00a0consent\nand\u00a0disclosure\u00a0of\u00a0all\u00a0information\u00a0or\u00a0records\u00a0obtained\u00a0and\u00a0reviewed\u00a0in\u00a0the\u00a0course\u00a0of\u00a0the\u00a0Study,\u00a0and\u00a0shall\u00a0permit\u00a0access\u00a0to\u00a0such\ninformation\u00a0or\u00a0records\u00a0only\u00a0as\u00a0authorized\u00a0by\u00a0a\u00a0relevant\u00a0Study\u00a0subject,\u00a0the\u00a0IRB,\u00a0and\u00a0as\u00a0authorized\u00a0by\u00a0law.\u00a0 Each\u00a0Party\u00a0agrees\u00a0to\u00a0comply\nwith\u00a0all\u00a0provisions\u00a0of\u00a0the\u00a0Health\u00a0Insurance\u00a0Portability\u00a0and\u00a0Accountability\u00a0Act\u00a0(\u201c HIPAA\u201d)\u00a0regulations\u00a0(45\u00a0C.F.R.\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n5\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "7a831371-f5d0-43fd-83e5-5b43f4440ba5": {"__data__": {"id_": "7a831371-f5d0-43fd-83e5-5b43f4440ba5", "embedding": null, "metadata": {"page_label": "6", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nParts\u00a0160\u00a0and\u00a0164)\u00a0as\u00a0to\u00a0the\u00a0protection\u00a0and\u00a0security\u00a0of\u00a0Protected\u00a0Health\u00a0Information\u00a0(\u201c PHI\u201d)\u00a0to\u00a0the\u00a0extent\u00a0applicable\u00a0to\u00a0a\u00a0Party.\u00a0 Prior\nto\u00a0participation\u00a0of\u00a0each\u00a0subject\u00a0in\u00a0a\u00a0Clinical\u00a0Study,\u00a0MD\u00a0Anderson\u00a0 will\u00a0ensure\u00a0that\u00a0(a)\u00a0it\u00a0has\u00a0obtained\u00a0a\u00a0signed\u00a0written\u00a0informed\u00a0consent\ndocument\u00a0from\u00a0the\u00a0subject\u00a0(\u201c Consent\u201d)\u00a0and\u00a0(b)\u00a0it\u00a0has\u00a0obtained\u00a0a\u00a0signed,\u00a0written,\u00a0HIPAA\u00a0authorization\u00a0that\u00a0adequately\u00a0discloses\u00a0the\ncircumstances\u00a0under\u00a0which\u00a0the\u00a0subject\u2019s\u00a0personal\u00a0data\u00a0might\u00a0be\u00a0disclosed,\u00a0as\u00a0applicable,\u00a0and\u00a0documents\u00a0the\u00a0subject\u2019s\u00a0express\u00a0written\nauthorization\u00a0for\u00a0use\u00a0and\u00a0disclosure\u00a0of\u00a0the\u00a0subject\u2019s\u00a0PHI\u00a0for\u00a0Study\u00a0purposes,\u00a0as\u00a0applicable,\u00a0pursuant\u00a0to\u00a0the\u00a0HIPAA\u00a0regulations\n(\u201cAuthorization \u201d).\u00a0MD\u00a0Anderson\u00a0will\u00a0agree\u00a0to\u00a0the\u00a0contents\u00a0of\u00a0any\u00a0Consent\u00a0or\u00a0Authorization\u00a0provided\u00a0to\u00a0any\u00a0Study\u00a0patient\u00a0or\nprospective\u00a0Study\u00a0patient\u00a0with\u00a0Adaptimmune\u00a0prior\u00a0to\u00a0use\u00a0in\u00a0any\u00a0Clinical\u00a0Study.\u00a0Adaptimmune,\u00a0Adaptimmune\u00a0Limited\u00a0and\u00a0its\u00a0Joint\nResearch\u00a0Partners\u00a0will\u00a0only\u00a0obtain,\u00a0access,\u00a0use\u00a0and\u00a0disclose\u00a0the\u00a0individually\u00a0identifiable\u00a0health\u00a0information\u00a0of\u00a0each\u00a0Study\u00a0Subject\u00a0in\naccordance\u00a0with\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0the\u00a0IRB,\u00a0Consent\u00a0and\u00a0the\u00a0Authorization\u00a0document\u00a0and\u00a0in\u00a0accordance\u00a0with\u00a0this\nAgreement\u00a0and\u00a0Applicable\u00a0Laws.\u00a0\u201c Joint\u00a0Research\u00a0Partners, \u201d\u00a0for\u00a0the\u00a0purposes\u00a0of\u00a0this\u00a0Agreement,\u00a0means\u00a0Adaptimmune\u00a0Limited\u2019s\nstrategic\u00a0collaboration\u00a0partner,\u00a0GlaxoSmithKline\u00a0(including\u00a0all\u00a0companies\u00a0within\u00a0the\u00a0GlaxoSmithKline\u00a0group\u00a0of\u00a0companies)\u00a0but\u00a0only\u00a0to\nthe\u00a0extent\u00a0and\u00a0for\u00a0the\u00a0duration\u00a0that\u00a0GlaxoSmithKline\u00a0remains\u00a0a\u00a0collaboration\u00a0partner\u00a0of\u00a0Adaptimmune\u00a0or\u00a0otherwise\u00a0takes\u00a0over\u00a0control\nof\u00a0any\u00a0Study\u00a0Drug\u00a0which\u00a0is\u00a0the\u00a0subject\u00a0of\u00a0any\u00a0Study.\u00a0Adaptimmune\u00a0shall\u00a0have\u00a0in\u00a0place\u00a0with\u00a0its\u00a0Joint\u00a0Research\u00a0Partners\u00a0a\u00a0written\nagreement\u00a0with\u00a0terms\u00a0at\u00a0least\u00a0as\u00a0stringent\u00a0as\u00a0those\u00a0set\u00a0out\u00a0in\u00a0this\u00a0Agreement\u00a0in\u00a0relation\u00a0to\u00a0the\u00a0obtaining,\u00a0access,\u00a0use\u00a0and\u00a0disclosure\u00a0of\nindividually\u00a0identifiable\u00a0health\u00a0information\u00a0under\u00a0this\u00a0Section\u00a02.8\u00a0or\u00a0the\u00a0receipt,\u00a0access,\u00a0use\u00a0and\u00a0disclosure\u00a0of\u00a0MD\u00a0Anderson\nConfidential\u00a0Information\u00a0under\u00a0Section\u00a05.\n\u00a0\n2.9 \u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0will\u00a0promptly\u00a0notify\u00a0each\u00a0other\u00a0upon\u00a0identifying\u00a0any\u00a0aspect\u00a0of\u00a0a\u00a0Protocol,\u00a0including\u00a0information\ndiscovered\u00a0during\u00a0site\u00a0monitoring\u00a0visits,\u00a0or\u00a0Study\u00a0results\u00a0that\u00a0may\u00a0adversely\u00a0affect\u00a0the\u00a0safety,\u00a0well-being,\u00a0or\u00a0medical\u00a0care\u00a0of\u00a0the\u00a0Study\nsubjects,\u00a0or\u00a0that\u00a0may\u00a0affect\u00a0the\u00a0willingness\u00a0of\u00a0Study\u00a0subjects\u00a0to\u00a0continue\u00a0participation\u00a0in\u00a0a\u00a0Study,\u00a0influence\u00a0the\u00a0conduct\u00a0of\u00a0the\u00a0Study,\u00a0or\nthat\u00a0may\u00a0alter\u00a0the\u00a0IRB\u2019s\u00a0approval\u00a0to\u00a0continue\u00a0the\u00a0Study.\u00a0 MD\u00a0Anderson\u00a0will\u00a0promptly\u00a0notify\u00a0the\u00a0IRB\u00a0of\u00a0any\u00a0such\u00a0events.\u00a0 If\u00a0the\u00a0IRB\u00a0at\nany\u00a0time\u00a0suspends,\u00a0qualifies\u00a0or\u00a0withdraws\u00a0approval\u00a0of\u00a0the\u00a0Study,\u00a0MD\u00a0Anderson\u00a0shall\u00a0promptly\u00a0notify\u00a0Adaptimmune,\u00a0provide\u00a0a\nreasonable\u00a0written\u00a0explanation\u00a0of\u00a0the\u00a0circumstances\u00a0leading\u00a0to\u00a0such\u00a0suspension,\u00a0qualification\u00a0or\u00a0withdrawal,\u00a0and\u00a0cease\u00a0the\u00a0treatment\nof\u00a0all\u00a0Study\u00a0patients\u00a0as\u00a0medically\u00a0appropriate\u00a0and\u00a0if\u00a0required\u00a0by\u00a0the\u00a0IRB.\u00a0When\u00a0Study\u00a0subject\u00a0safety\u00a0or\u00a0medical\u00a0care\u00a0could\u00a0be\u00a0directly\naffected\u00a0by\u00a0Study\u00a0results,\u00a0then\u00a0notwithstanding\u00a0any\u00a0other\u00a0provision\u00a0of\u00a0this\u00a0Agreement,\u00a0MD\u00a0Anderson\u00a0will\u00a0send\u00a0Study\u00a0subjects\u00a0a\nwritten\u00a0communication\u00a0about\u00a0such\u00a0results.\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n2.10 \u00a0MD\u00a0Anderson\u00a0shall\u00a0not\u00a0subcontract\u00a0any\u00a0of\u00a0its\u00a0or\u00a0the\u00a0Principal\u00a0Investigator\u2019s\u00a0responsibilities\u00a0under\u00a0this\u00a0Agreement\u00a0without\u00a0the\nprior\u00a0written\u00a0consent\u00a0of\u00a0Adaptimmune.\u00a0Any\u00a0consent\u00a0provided\u00a0under\u00a0this\u00a0Section\u00a02.10\u00a0shall\u00a0not\u00a0enable\u00a0the\u00a0relevant\u00a0sub-contractor\u00a0to\nfurther\u00a0subcontract\u00a0its\u00a0responsibilities\u00a0to\u00a0any\u00a0other\u00a0third\u00a0party.\u00a0MD\u00a0Anderson\u00a0shall\u00a0ensure\u00a0that\u00a0any\u00a0subcontracting\u00a0is\u00a0governed\u00a0by\u00a0a\nbinding\u00a0agreement\u00a0which\u00a0imposes\u00a0on\u00a0the\u00a0subcontractor\u00a0obligations\u00a0and\u00a0responsibilities\u00a0substantially\u00a0equivalent\u00a0to\u00a0those\u00a0set\u00a0out\u00a0in\u00a0this\nAgreement,\u00a0to\u00a0the\u00a0extent\u00a0such\u00a0apply\u00a0to\u00a0the\u00a0subcontracted\u00a0activity\u00a0(including\u00a0obligations\u00a0of\u00a0confidentiality\u00a0and\u00a0ownership\u00a0of\nInventions).\u00a0Regardless\u00a0of\u00a0any\u00a0delegation\u00a0of\u00a0duties\u00a0to\u00a0any\u00a0subcontractor,\u00a0MD\u00a0Anderson\u00a0remains\u00a0obligated\u00a0to\u00a0fulfill\u00a0all\u00a0MD\u00a0Anderson\nobligations\u00a0to\u00a0Adaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited\u00a0hereunder.\n\u00a0\n3.\u00a0Personnel,\u00a0Materials\u00a0and\u00a0Equipment\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n6\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "91df6256-aa31-469c-9eeb-d0d32509bcd7": {"__data__": {"id_": "91df6256-aa31-469c-9eeb-d0d32509bcd7", "embedding": null, "metadata": {"page_label": "7", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n3.1 \u00a0Except\u00a0as\u00a0otherwise\u00a0set\u00a0forth\u00a0in\u00a0this\u00a0Agreement,\u00a0MD\u00a0Anderson\u00a0shall\u00a0provide\u00a0all\u00a0necessary\u00a0personnel,\u00a0facilities,\u00a0and\u00a0resources\u00a0to\naccomplish\u00a0their\u00a0responsibilities\u00a0under\u00a0this\u00a0Agreement\u00a0and\u00a0the\u00a0relevant\u00a0Study\u00a0Order.\n\u00a0\n3.2 \u00a0Adaptimmune\u00a0agrees\u00a0to\u00a0promptly\u00a0provide\u00a0MD\u00a0Anderson\u00a0with\u00a0the\u00a0required\u00a0quantities\u00a0of\u00a0the\u00a0drug\u00a0or\u00a0therapy\u00a0under\u00a0a\u00a0Study\u00a0Order\nthat\u00a0will\u00a0be\u00a0utilized\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0provisions\u00a0of\u00a0the\u00a0Protocol\u00a0or\u00a0workscope\u00a0applicable\u00a0to\u00a0the\u00a0Study\u00a0(\u201c Study\u00a0Drug \u201d),\u00a0Alliance\nFunding\u00a0applicable\u00a0to\u00a0the\u00a0Study,\u00a0and/or\u00a0support\u00a0services\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0for\u00a0the\u00a0conduct\u00a0of\u00a0a\u00a0Study\u00a0as\u00a0specified\u00a0in\u00a0the\u00a0Protocol\nor\u00a0workscope.\u00a0Any\u00a0Study\u00a0Drug\u00a0provided\u00a0by\u00a0Adaptimmune\u00a0will\u00a0be\u00a0used\u00a0solely\u00a0for\u00a0the\u00a0applicable\u00a0Study\u00a0and\u00a0solely\u00a0in\u00a0accordance\u00a0with\nthe\u00a0Protocol\u00a0or\u00a0workscope\u00a0for\u00a0the\u00a0relevant\u00a0Study.\u00a0 MD\u00a0Anderson\u00a0will\u00a0not\u00a0use\u00a0such\u00a0Study\u00a0Drug\u00a0outside\u00a0of\u00a0the\u00a0scope\u00a0of\u00a0the\u00a0Study.\u00a0 MD\nAnderson\u00a0will\u00a0not\u00a0transfer\u00a0or\u00a0provide\u00a0unsupervised\u00a0access\u00a0to\u00a0the\u00a0Study\u00a0Drug\u00a0to\u00a0any\u00a0third\u00a0party\u00a0for\u00a0any\u00a0purpose,\u00a0without\u00a0the\u00a0prior\nwritten\u00a0consent\u00a0of\u00a0Adaptimmune.\u00a0MD\u00a0Anderson\u00a0acknowledges\u00a0that\u00a0the\u00a0Study\u00a0Drug\u00a0is\u00a0experimental\u00a0in\u00a0nature,\u00a0and\u00a0shall\u00a0exercise\nprudence\u00a0and\u00a0reasonable\u00a0care\u00a0in\u00a0its\u00a0handling,\u00a0storage,\u00a0transportation,\u00a0disposition\u00a0and\u00a0containment\u00a0of\u00a0the\u00a0Study\u00a0Drug\u00a0and,\u00a0if\u00a0applicable,\nany\u00a0other\u00a0Proprietary\u00a0Materials\u00a0provided\u00a0by\u00a0Adaptimmune.\n\u00a0\n3.3. \u00a0Use\u00a0of\u00a0Proprietary\u00a0Materials.\u00a0 From\u00a0time\u00a0to\u00a0time\u00a0during\u00a0the\u00a0Term,\u00a0either\u00a0Party\u00a0(the\u00a0\u201c Transferring\u00a0Party \u201d)\u00a0may\u00a0supply\u00a0the\u00a0other\nParty\u00a0(the\u00a0\u201c Receiving\u00a0Party \u201d)\u00a0with\u00a0proprietary\u00a0materials\u00a0of\u00a0the\u00a0Transferring\u00a0Party\u00a0(other\u00a0than\u00a0Study\u00a0Drug)\u00a0(\u201c Proprietary\u00a0Materials \u201d)\nfor\u00a0use\u00a0in\u00a0the\u00a0Study\u00a0as\u00a0may\u00a0be\u00a0further\u00a0listed\u00a0in\u00a0the\u00a0Study\u00a0Order.\u00a0 In\u00a0connection\u00a0therewith,\u00a0each\u00a0Receiving\u00a0Party\u00a0hereby\u00a0agrees\u00a0that:\u00a0(a)\nthe\u00a0Receiving\u00a0Party\u00a0will\u00a0not\u00a0use\u00a0the\u00a0Proprietary\u00a0Materials\u00a0for\u00a0any\u00a0purpose\u00a0other\u00a0than\u00a0exercising\u00a0its\u00a0rights\u00a0or\u00a0performing\u00a0its\u00a0obligations\nhereunder\u037e\u00a0(b)\u00a0it\u00a0will\u00a0use\u00a0such\u00a0Proprietary\u00a0Materials\u00a0only\u00a0in\u00a0compliance\u00a0with\u00a0all\u00a0Applicable\u00a0Laws\u037e\u00a0(c)\u00a0it\u00a0will\u00a0not\u00a0transfer\u00a0any\u00a0such\nProprietary\u00a0Materials\u00a0to\u00a0any\u00a0third\u00a0party\u00a0without\u00a0the\u00a0prior\u00a0written\u00a0consent\u00a0of\u00a0the\u00a0Transferring\u00a0Party\u037e\u00a0(d)\u00a0it\u00a0will\u00a0not\u00a0acquire\u00a0any\u00a0rights\u00a0of\nownership,\u00a0or\u00a0title\u00a0in\u00a0or\u00a0to\u00a0such\u00a0Proprietary\u00a0Materials\u00a0as\u00a0a\u00a0result\u00a0of\u00a0such\u00a0supply\u00a0by\u00a0the\u00a0Transferring\u00a0Party\u037e\u00a0and\u00a0(e)\u00a0upon\u00a0the\u00a0expiration\nor\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0a\u00a0Study\u00a0Order,\u00a0if\u00a0requested\u00a0by\u00a0the\u00a0Transferring\u00a0Party,\u00a0it\u00a0will\u00a0destroy\u00a0or\u00a0return\u00a0any\u00a0such\nProprietary\u00a0Materials\n\u00a0\n3.4 \u00a0Nothing\u00a0in\u00a0this\u00a0Agreement\u00a0shall\u00a0be\u00a0construed\u00a0to\u00a0limit\u00a0the\u00a0freedom\u00a0of\u00a0MD\u00a0Anderson\u00a0or\u00a0of\u00a0any\u00a0Principal\u00a0Investigator\u00a0or\u00a0Study\u00a0team\nmember\u00a0or\u00a0Adaptimmune\u00a0to\u00a0engage\u00a0in\u00a0similar\u00a0clinical\u00a0trials\u00a0or\u00a0research\u00a0performed\u00a0independently\u00a0under\u00a0other\u00a0grants,\u00a0contracts,\u00a0or\nagreements\u00a0with\u00a0parties\u00a0other\u00a0than\u00a0Adaptimmune.\n\u00a0\n3.5 \u00a0MD\u00a0Anderson\u00a0will\u00a0obtain,\u00a0prepare,\u00a0store\u00a0and\u00a0ship\u00a0all\u00a0Study\u00a0patient\u00a0samples\u00a0required\u00a0to\u00a0be\u00a0collected\u00a0and\u00a0shipped\u00a0under\u00a0Protocol\u00a0for\nany\u00a0Clinical\u00a0Study\u00a0in\u00a0accordance\u00a0with\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0Applicable\u00a0Laws,\u00a0the\u00a0Consent,\u00a0Authorization,\u00a0the\u00a0IRB\u00a0and\u00a0any\napplicable\u00a0Study\u00a0reference\u00a0manuals\u00a0and\u00a0any\u00a0reasonable\u00a0written\u00a0instructions\u00a0provided\u00a0by\u00a0Adaptimmune.\u00a0Both\u00a0Parties\u00a0shall\u00a0retain\u00a0all\nsuch\u00a0samples\u00a0in\u00a0accordance\u00a0with\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0the\u00a0Consent,\u00a0Authorization,\u00a0the\u00a0IRB\u00a0and\u00a0Protocol\u00a0and\u00a0only\ndisseminate\u00a0such\u00a0samples\u00a0to\u00a0third\u00a0parties\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0the\u00a0Consent\u00a0and\u00a0HIPAA\u00a0Authorization\u00a0the\u00a0IRB,\u00a0Applicable\u00a0Laws,\nand\u00a0the\u00a0Protocol.\u00a0Adamptimmune,\u00a0and\u00a0service\u00a0providers\u00a0 for\u00a0the\u00a0Study\u00a0may\u00a0only\u00a0use\u00a0the\u00a0samples\u00a0only\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0the\nConsent\u00a0and\u00a0HIPAA\u00a0Authorization\u00a0documents,\u00a0the\u00a0IRB,\u00a0as\u00a0necessary\u00a0to\u00a0conduct\u00a0the\u00a0Study\u00a0and\u00a0as\u00a0permitted\u00a0by\u00a0Applicable\u00a0Laws.\n\u00a0\n4.\u00a0Payments\n\u00a0\n4.1 \u00a0Payments\u00a0of\u00a0Alliance\u00a0Funding\u00a0applicable\u00a0to\u00a0a\u00a0Study\u00a0will\u00a0be\u00a0made\u00a0according\u00a0to\u00a0the\u00a0terms\u00a0specified\u00a0in\u00a0Sections\u00a01.3\u00a0and\u00a01.4\u00a0above.\n\u00a0\n5.\u00a0Confidential\u00a0Information\n\u00a0\n7\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "b8dec37e-54ea-4f03-9ebf-1cbc64a1ab7a": {"__data__": {"id_": "b8dec37e-54ea-4f03-9ebf-1cbc64a1ab7a", "embedding": null, "metadata": {"page_label": "8", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n5.1 \u00a0In\u00a0conjunction\u00a0with\u00a0each\u00a0Study,\u00a0the\u00a0Parties\u00a0may\u00a0wish\u00a0to\u00a0disclose\u00a0confidential\u00a0information\u00a0to\u00a0each\u00a0other.\u00a0 For\u00a0purposes\u00a0of\u00a0this\nAgreement,\u00a0\u201cConfidential\u00a0Information\u201d\u00a0means\u00a0confidential,\u00a0non-public\u00a0information,\u00a0know-how\u00a0and\u00a0data\u00a0(technical\u00a0or\u00a0non-technical)\nthat\u00a0is\u00a0disclosed\u00a0in\u00a0writing,\u00a0orally,\u00a0graphically,\u00a0in\u00a0machine\u00a0readable\u00a0form,\u00a0or\u00a0in\u00a0any\u00a0other\u00a0manner\u00a0by\u00a0or\u00a0on\u00a0behalf\u00a0of\u00a0a\u00a0disclosing\u00a0Party\u00a0to\na\u00a0receiving\u00a0Party\u00a0or\u00a0its\u00a0Affiliates\u00a0for\u00a0purposes\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0any\u00a0Study\u00a0Order\u00a0(\u201cPurpose\u201d).\u00a0 Data\u00a0or\u00a0Inventions\u00a0arising\u00a0in\u00a0the\nperformance\u00a0of\u00a0the\u00a0Study\u00a0and\u00a0which\u00a0are\u00a0owned\u00a0by\u00a0Adaptimmune\u00a0will\u00a0also\u00a0constitute\u00a0Confidential\u00a0Information\u00a0of\u00a0Adaptimmune,\u00a0even\nwhere\u00a0first\u00a0disclosed\u00a0by\u00a0MD\u00a0Anderson\u00a0and\u00a0in\u00a0each\u00a0case\u00a0subject\u00a0to\u00a0the\u00a0publication\u00a0rights\u00a0of\u00a0MD\u00a0Anderson\u00a0in\u00a0Section\u00a012\u00a0and\u00a0subject\u00a0to\nSection\u00a07\u00a0below.\u00a0Confidential\u00a0Information\u00a0may\u00a0be\u00a0disclosed\u00a0in\u00a0any\u00a0form\u00a0(e.g.\u00a0oral,\u00a0written,\u00a0graphic,\u00a0electronic\u00a0or\u00a0sample)\u00a0by\u00a0or\u00a0on\nbehalf\u00a0of\u00a0disclosing\u00a0Party\u00a0or\u00a0its\u00a0Affiliates,\u00a0or\u00a0may\u00a0be\u00a0otherwise\u00a0accessible\u00a0to\u00a0receiving\u00a0Party\u00a0or\u00a0its\u00a0Affiliates.\u00a0Exchanges\u00a0of\nConfidential\u00a0Information\u00a0directly\u00a0between\u00a0the\u00a0Affiliates\u00a0and\u00a0Joint\u00a0Research\u00a0Partners\u00a0are\u00a0also\u00a0covered\u00a0by\u00a0this\u00a0Agreement.\u00a0\u201cAffiliates\u201d\nmeans\u00a0any\u00a0individual,\u00a0company,\u00a0partnership\u00a0or\u00a0other\u00a0entity\u00a0which\u00a0directly\u00a0or\u00a0indirectly,\u00a0at\u00a0present\u00a0or\u00a0in\u00a0the\u00a0future,\u00a0controls,\u00a0is\u00a0controlled\nby\u00a0or\u00a0is\u00a0under\u00a0common\u00a0control\u00a0of\u00a0a\u00a0Party,\u00a0and\u00a0\u201ccontrol\u201d\u00a0will\u00a0mean\u00a0direct\u00a0or\u00a0indirect\u00a0beneficial\u00a0ownership\u00a0of\u00a0at\u00a0least\u00a0fifty\u00a0per\u00a0cent\n(50%)\u00a0of\u00a0the\u00a0voting\u00a0share\u00a0capital\u00a0in\u00a0such\u00a0company\u00a0or\u00a0other\u00a0business\u00a0entity,\u00a0or\u00a0to\u00a0hold\u00a0the\u00a0effective\u00a0power\u00a0to\u00a0appoint\u00a0or\u00a0dismiss\nmembers\u00a0of\u00a0the\u00a0management.\n\u00a0\n5.2 \u00a0Without\u00a0disclosing\u00a0Party\u2019s\u00a0prior\u00a0written\u00a0consent,\u00a0receiving\u00a0Party\u00a0will:\u00a0(a)\u00a0not\u00a0use\u00a0any\u00a0part\u00a0of\u00a0or\u00a0the\u00a0whole\u00a0of\u00a0the\u00a0Confidential\nInformation\u00a0for\u00a0any\u00a0purpose\u00a0other\u00a0than\u00a0the\u00a0Purpose\u037e\u00a0(b)\u00a0restrict\u00a0the\u00a0dissemination\u00a0of\u00a0Confidential\u00a0Information\u00a0to\u00a0individuals\u00a0within\u00a0its\nown\u00a0organization\u00a0and\u00a0disclose\u00a0the\u00a0Confidential\u00a0Information\u00a0only\u00a0to\u00a0those\u00a0of\u00a0its\u00a0officers,\u00a0employees\u00a0and\u00a0Affiliates\u00a0and\u00a0Joint\u00a0Research\nPartners\u00a0who\u00a0have\u00a0a\u00a0legitimate\u00a0need\u00a0to\u00a0have\u00a0access\u00a0to\u00a0the\u00a0Confidential\u00a0Information,\u00a0who\u00a0will\u00a0be\u00a0bound\u00a0by\u00a0confidentiality\u00a0and\u00a0non-use\ncommitments\u00a0no\u00a0less\u00a0restrictive\u00a0than\u00a0those\u00a0of\u00a0this\u00a0Agreement,\u00a0and\u00a0who\u00a0will\u00a0have\u00a0been\u00a0made\u00a0aware\u00a0of\u00a0the\u00a0confidential\u00a0nature\u00a0of\u00a0the\nConfidential\u00a0Information\u037e\u00a0(c)\u00a0protect\u00a0the\u00a0Confidential\u00a0Information\u00a0by\u00a0using\u00a0the\u00a0same\u00a0degree\u00a0of\u00a0care,\u00a0but\u00a0not\u00a0less\u00a0than\u00a0a\u00a0reasonable\ndegree\u00a0of\u00a0care,\u00a0to\u00a0prevent\u00a0the\u00a0unauthorized\u00a0use,\u00a0dissemination,\u00a0or\u00a0publication\u00a0of\u00a0the\u00a0Confidential\u00a0Information\u00a0as\u00a0receiving\u00a0Party\u00a0uses\nto\u00a0protect\u00a0its\u00a0own\u00a0confidential\u00a0information\u00a0of\u00a0a\u00a0like\u00a0nature\u037e\u00a0(d)\u00a0preserve\u00a0the\u00a0confidentiality\u00a0of\u00a0the\u00a0Confidential\u00a0Information,\u00a0not\u00a0disclose\nit\u00a0to\u00a0any\u00a0third\u00a0party,\u00a0and\u00a0take\u00a0all\u00a0necessary\u00a0and\u00a0reasonable\u00a0precautions\u00a0to\u00a0prevent\u00a0such\u00a0information\u00a0from\u00a0being\u00a0accessible\u00a0to\u00a0any\u00a0third\nparty\u037e\u00a0and\u00a0(f)\u00a0promptly\u00a0notify\u00a0the\u00a0disclosing\u00a0Party\u00a0upon\u00a0becoming\u00a0aware\u00a0of\u00a0evidence\u00a0or\u00a0suspicion\u00a0of\u00a0any\u00a0unauthorized\u00a0use\u00a0or\ndisclosure\u00a0of\u00a0the\u00a0Confidential\u00a0Information.\u00a0 The\u00a0foregoing\u00a0obligations\u00a0will\u00a0exist\u00a0for\u00a0a\u00a0period\u00a0of\u00a0***\u00a0(***)\u00a0years\u00a0from\u00a0the\u00a0date\u00a0of\ncompletion\u00a0of\u00a0the\u00a0last\u00a0Study\u00a0in\u00a0relation\u00a0to\u00a0which\u00a0the\u00a0Confidential\u00a0Information\u00a0is\u00a0disclosed\u00a0or\u00a0used.\n\u00a0\n5.3 \u00a0The\u00a0obligations\u00a0of\u00a0confidentiality\u00a0and\u00a0non-use\u00a0listed\u00a0in\u00a0this\u00a0Section\u00a05\u00a0will\u00a0not\u00a0apply\u00a0to\u00a0information:\u00a0(a)\u00a0which\u00a0is\u00a0in\u00a0the\u00a0public\u00a0domain\nor\u00a0public\u00a0knowledge\u00a0at\u00a0the\u00a0time\u00a0of\u00a0disclosure,\u00a0or\u00a0which\u00a0subsequently\u00a0enters\u00a0the\u00a0public\u00a0domain\u00a0through\u00a0no\u00a0fault\u00a0of\u00a0receiving\u00a0Party\u037e\u00a0(b)\nwhich\u00a0was\u00a0rightfully\u00a0in\u00a0the\u00a0possession\u00a0of\u00a0receiving\u00a0Party\u00a0at\u00a0the\u00a0time\u00a0of\u00a0disclosure\u00a0by\u00a0disclosing\u00a0Party\u037e\u00a0(c)\u00a0which\u00a0is\u00a0independently\ndeveloped\u00a0by\u00a0receiving\u00a0Party\u00a0without\u00a0use\u00a0of\u00a0disclosing\u00a0Party\u2019s\u00a0Confidential\u00a0Information\u037e\u00a0(d)\u00a0which\u00a0the\u00a0receiving\u00a0Party\u00a0receives\u00a0legally\nfrom\u00a0any\u00a0third\u00a0party\u00a0and\u00a0which\u00a0is\u00a0not\u00a0subject\u00a0to\u00a0an\u00a0obligation\u00a0of\u00a0confidentiality\u037e\u00a0(e)\u00a0 is\u00a0communicated\u00a0to\u00a0the\u00a0receiving\u00a0party\u2019s\u00a0IRB\u00a0or\nother\u00a0scientific\u00a0committee \u037e\u00a0(f)\u00a0is\u00a0required\u00a0to\u00a0be\u00a0disclosed\u00a0in\u00a0order\u00a0to\u00a0obtain\u00a0informed\u00a0consent\u00a0from\u00a0patients\u00a0or\u00a0subjects\u00a0who\u00a0may\u00a0wish\nto\u00a0enroll\u00a0in\u00a0the\u00a0Study,\u00a0provided,\u00a0however,\u00a0that\u00a0the\u00a0information\u00a0will\u00a0be\u00a0disclosed\u00a0only\u00a0to\u00a0the\u00a0extent\u00a0necessary\u00a0and\u00a0will\u00a0not\u00a0be\u00a0provided\u00a0in\nanswer\u00a0to\u00a0unsolicited\u00a0inquiries\u00a0by\u00a0telephone\u00a0or\u00a0to\u00a0individuals\u00a0who\u00a0are\u00a0not\u00a0eligible\u00a0to\u00a0be\u00a0Study\u00a0subjects\u037e\u00a0 or\u00a0(g)\u00a0is\u00a0disclosed\u00a0to\u00a0a\u00a0Study\nsubject\u00a0for\u00a0the\u00a0safety\u00a0or\u00a0well-being\u00a0of\u00a0the\u00a0Study\u00a0subject .\u00a0The\u00a0receiving\u00a0Party\u00a0may\u00a0also\u00a0disclose\u00a0Confidential\u00a0Information\u00a0of\u00a0any\u00a0other\nParty\u00a0where\u00a0it\u00a0is\u00a0required\u00a0to\u00a0disclose\u00a0such\u00a0pursuant\u00a0to\u00a0Applicable\u00a0Law\u037e\u00a0provided,\u00a0however,\u00a0that\u00a0receiving\u00a0Party\u00a0will\u00a0make\u00a0reasonable\nefforts,\u00a0if\u00a0legally\u00a0permissible,\u00a0to\u00a0(i)\u00a0notify\u00a0disclosing\u00a0Party\u00a0prior\u00a0to\u00a0the\u00a0disclosure\u00a0of\u00a0any\u00a0part\u00a0of\u00a0or\u00a0the\u00a0whole\u00a0of\u00a0the\u00a0Confidential\nInformation\u00a0and\u00a0(ii)\u00a0allow\u00a0disclosing\u00a0Party\u00a0the\u00a0opportunity\u00a0to\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n8\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "9c7f7fcc-62f3-4893-9621-2e66adda29e5": {"__data__": {"id_": "9c7f7fcc-62f3-4893-9621-2e66adda29e5", "embedding": null, "metadata": {"page_label": "9", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\ncontest\u00a0and\u00a0avoid\u00a0such\u00a0disclosure,\u00a0and\u00a0provided,\u00a0further,\u00a0that\u00a0receiving\u00a0Party\u00a0will\u00a0disclose\u00a0only\u00a0that\u00a0portion\u00a0of\u00a0such\u00a0Confidential\nInformation\u00a0that\u00a0it\u00a0is\u00a0legally\u00a0required\u00a0to\u00a0disclose.\n\u00a0\n5.4 \u00a0For\u00a0the\u00a0purposes\u00a0of\u00a0this\u00a0Section\u00a05,\u00a0any\u00a0combination\u00a0of\u00a0features\u00a0disclosed\u00a0to\u00a0the\u00a0receiving\u00a0Party\u00a0will\u00a0not\u00a0be\u00a0deemed\u00a0to\u00a0be\u00a0within\u00a0the\nforegoing\u00a0exceptions\u00a0merely\u00a0because\u00a0individual\u00a0features\u00a0are.\u00a0Moreover,\u00a0specific\u00a0disclosures\u00a0made\u00a0to\u00a0the\u00a0receiving\u00a0Party\u00a0will\u00a0not\u00a0be\ndeemed\u00a0to\u00a0be\u00a0within\u00a0the\u00a0foregoing\u00a0exceptions\u00a0merely\u00a0because\u00a0they\u00a0are\u00a0embraced\u00a0by\u00a0general\u00a0disclosures.\n\u00a0\n5.5 \u00a0All\u00a0Confidential\u00a0Information\u00a0disclosed\u00a0to\u00a0receiving\u00a0Party\u00a0pursuant\u00a0to\u00a0this\u00a0Agreement\u00a0will\u00a0be\u00a0and\u00a0remain\u00a0the\u00a0disclosing\u00a0Party\u2019s\nproperty.\u00a0Nothing\u00a0contained\u00a0herein\u00a0will\u00a0be\u00a0construed\u00a0as\u00a0granting\u00a0to\u00a0receiving\u00a0Party\u00a0any\u00a0proprietary\u00a0right\u00a0on\u00a0or\u00a0in\u00a0relation\u00a0to\u00a0any\u00a0part\u00a0of\nor\u00a0the\u00a0whole\u00a0of\u00a0the\u00a0Confidential\u00a0Information,\u00a0or\u00a0any\u00a0right\u00a0to\u00a0use\u00a0any\u00a0of\u00a0the\u00a0Confidential\u00a0Information\u00a0except\u00a0for\u00a0the\u00a0Purpose.\u00a0 Receiving\nParty\u00a0will\u00a0return\u00a0to\u00a0disclosing\u00a0Party\u00a0all\u00a0documents\u00a0and\u00a0other\u00a0materials\u00a0which\u00a0constitute\u00a0Confidential\u00a0Information,\u00a0as\u00a0well\u00a0as\u00a0all\u00a0copies\nthereof,\u00a0promptly\u00a0upon\u00a0request\u00a0or\u00a0upon\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0(whichever\u00a0is\u00a0earlier)\u037e\u00a0provided,\u00a0however,\u00a0that\u00a0receiving\u00a0Party\nmay\u00a0keep\u00a0one\u00a0copy\u00a0of\u00a0the\u00a0Confidential\u00a0Information\u00a0received\u00a0under\u00a0this\u00a0Agreement\u00a0in\u00a0its\u00a0secure\u00a0files\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0terms\u00a0of\nthis\u00a0Agreement\u00a0for\u00a0the\u00a0sole\u00a0purpose\u00a0of\u00a0maintaining\u00a0a\u00a0record\u00a0of\u00a0the\u00a0Confidential\u00a0Information\u00a0received\u00a0hereunder\u00a0and\u00a0for\u00a0compliance\nwith\u00a0this\u00a0Agreement\u00a0and/or\u00a0Applicable\u00a0Laws.\n\u00a0\n5.6 \u00a0Adaptimmune\u00a0will\u00a0not\u00a0require\u00a0MD\u00a0Anderson\u00a0to\u00a0disclose\u00a0any\u00a0Protected\u00a0Health\u00a0Information.\u00a0Notwithstanding\u00a0the\u00a0foregoing,\u00a0if\nAdaptimmune\u00a0comes\u00a0into\u00a0knowledge\u00a0or\u00a0possession\u00a0of\u00a0any\u00a0\u201cProtected\u00a0Health\u00a0Information\u201d\u00a0(as\u00a0such\u00a0term\u00a0is\u00a0defined\u00a0under\u00a0HIPAA)\u00a0by\nor\u00a0through\u00a0MD\u00a0Anderson\u00a0or\u00a0any\u00a0information\u00a0that\u00a0could\u00a0be\u00a0used\u00a0to\u00a0identify\u00a0any\u00a0Study\u00a0subject\u00a0or\u00a0other\u00a0MD\u00a0Anderson\u00a0patients\u00a0or\nresearch\u00a0subjects,\u00a0Adaptimmune\u00a0will\u00a0maintain\u00a0any\u00a0such\u00a0Protected\u00a0Health\u00a0Information\u00a0or\u00a0other\u00a0information\u00a0confidential\u00a0in\u00a0accordance\nwith\u00a0laws\u00a0and\u00a0regulations\u00a0as\u00a0applicable\u00a0to\u00a0MD\u00a0Anderson,\u00a0including\u00a0without\u00a0limitation\u00a0HIPAA,\u00a0will\u00a0use\u00a0any\u00a0such\u00a0Protected\u00a0Health\nInformation\u00a0solely\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0Applicable\u00a0Laws,\u00a0the\u00a0IRB\u00a0and\u00a0the\u00a0Consent/Authorization\u00a0of\u00a0the\u00a0patient/research\u00a0subject,\nand\u00a0will\u00a0not\u00a0use\u00a0or\u00a0disclose\u00a0any\u00a0such\u00a0Protected\u00a0Health\u00a0Information\u00a0or\u00a0other\u00a0information\u00a0in\u00a0any\u00a0manner\u00a0that\u00a0would\u00a0constitute\u00a0a\u00a0violation\nof\u00a0any\u00a0Applicable\u00a0Laws\u00a0or\u00a0regulation\u00a0if\u00a0such\u00a0use\u00a0or\u00a0disclosure\u00a0was\u00a0made\u00a0by\u00a0MD\u00a0Anderson.\u00a0 It\u00a0is\u00a0intended\u00a0that\u00a0MD\u00a0Anderson\u00a0will\u00a0not\ndisclose\u00a0any\u00a0Protected\u00a0Health\u00a0Information\u00a0to\u00a0Adaptimmune\u00a0under\u00a0this\u00a0Agreement.\n\u00a0\n5.7 \u00a0Improper\u00a0use\u00a0or\u00a0disclosure\u00a0of\u00a0the\u00a0Confidential\u00a0Information\u00a0by\u00a0receiving\u00a0Party\u00a0is\u00a0likely\u00a0to\u00a0cause\u00a0substantial\u00a0harm\u00a0to\u00a0disclosing\u00a0Party.\nTherefore,\u00a0in\u00a0the\u00a0event\u00a0of\u00a0a\u00a0breach,\u00a0threatened\u00a0breach,\u00a0or\u00a0intended\u00a0breach\u00a0of\u00a0this\u00a0Agreement\u00a0by\u00a0receiving\u00a0Party,\u00a0in\u00a0addition\u00a0to\u00a0any\nother\u00a0rights\u00a0and\u00a0remedies\u00a0available\u00a0to\u00a0it\u00a0at\u00a0law\u00a0or\u00a0in\u00a0equity,\u00a0disclosing\u00a0Party\u00a0will\u00a0be\u00a0entitled\u00a0to\u00a0seek\u00a0preliminary\u00a0and\u00a0final\u00a0injunctions\nenjoining\u00a0and\u00a0restraining\u00a0such\u00a0breach,\u00a0threatened\u00a0breach,\u00a0or\u00a0intended\u00a0breach.\n\u00a0\n6.\u00a0Clinical\u00a0Data\u00a0/\u00a0Monitoring\n\u00a0\n6.1 \u00a0MD\u00a0Anderson\u00a0shall\u00a0maintain\u00a0complete,\u00a0accurate\u00a0and\u00a0current\u00a0records\u00a0with\u00a0respect\u00a0to\u00a0the\u00a0conduct\u00a0of\u00a0any\u00a0Study\u00a0as\u00a0set\u00a0forth\u00a0in\u00a0any\nProtocol\u00a0or\u00a0Study\u00a0Order,\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0by\u00a0Applicable\u00a0Laws\u00a0and\u00a0regulations\u00a0(\u201cStudy\u00a0Records\u201d).\u00a0All\u00a0Study\u00a0Records\u00a0shall\u00a0be\nretained\u00a0by\u00a0MD\u00a0Anderson\u00a0in\u00a0accordance\u00a0with\u00a0and\u00a0for\u00a0the\u00a0time\u00a0period\u00a0as\u00a0is\u00a0required\u00a0by\u00a0Applicable\u00a0Law.\u00a0Prior\u00a0to\u00a0any\u00a0disposal\u00a0of\u00a0such\nStudy\u00a0Records,\u00a0MD\u00a0Anderson\u00a0shall\u00a0give\u00a0Adaptimmune\u00a0thirty\u00a0(30)\u00a0days\u2019\u00a0prior\u00a0written\u00a0notice\u00a0thereof\u00a0to\u00a0allow\u00a0Adaptimmune\u00a0the\nopportunity\u00a0to\u00a0request\u00a0in\u00a0writing,\u00a0within\u00a0such\u00a0time\u00a0frame,\u00a0that\u00a0MD\u00a0Anderson\u00a0continue\u00a0to\u00a0store\u00a0such\u00a0Study\u00a0Records\u00a0at\u00a0Adaptimmune\u2019s\nexpense.\u00a0In\u00a0relation\u00a0to\u00a0Clinical\u00a0Studies,\u00a0MD\u00a0Anderson\u00a0will\u00a0keep\u00a0Adaptimmune\u00a0reasonably\u00a0informed\u00a0of\u00a0the\u00a0progress\u00a0of\u00a0the\u00a0Study\u00a0and\nrespond\u00a0to\u00a0any\u00a0reasonable\u00a0queries\u00a0of\u00a0Adaptimmune\u00a0in\u00a0relation\u00a0to\u00a0such\u00a0Study\u00a0promptly.\u00a0In\u00a0relation\u00a0to\u00a0Pre-Clinical\u00a0Studies,\u00a0oral\u00a0reports\nor\u00a0interim\u00a0written\u00a0status\u00a0reports\u00a0of\u00a0the\u00a0progress\u00a0of\u00a0the\u00a0Studies\u00a0will\u00a0be\u00a0provided\u00a0by\u00a0the\u00a0Principal\u00a0Investigator\u00a0to\u00a0Adaptimmune\u00a0on\u00a0a\nregular\u00a0basis\u00a0and\u00a0at\u00a0least\u00a0once\u00a0every\u00a0***\u00a0(***)\u00a0months\u00a0during\u00a0the\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n9\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "ca6ab39c-d41a-4a25-9215-9101fd3bdad8": {"__data__": {"id_": "ca6ab39c-d41a-4a25-9215-9101fd3bdad8", "embedding": null, "metadata": {"page_label": "10", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\ncourse\u00a0of\u00a0a\u00a0Study.\u00a0 Significant\u00a0developments\u00a0arising\u00a0out\u00a0of\u00a0Studies\u00a0will\u00a0be\u00a0communicated\u00a0promptly\u00a0to\u00a0Adaptimmune.\u00a0 In\u00a0the\u00a0context\u00a0of\nany\u00a0Clinical\u00a0Study,\u00a0MD\u00a0Anderson\u00a0shall\u00a0timely\u00a0prepare\u00a0and\u00a0submit\u00a0to\u00a0Adaptimmune\u00a0(a)\u00a0case\u00a0report\u00a0forms,\u00a0as\u00a0soon\u00a0as\u00a0reasonably\npossible\u00a0but\u00a0in\u00a0any\u00a0event\u00a0within\u00a0***\u00a0(***)\u00a0business\u00a0days\u00a0following\u00a0completion\u00a0of\u00a0any\u00a0Study\u00a0patient\u00a0visit\u037e\u00a0and\u00a0(b)\u00a0responses\u00a0to\u00a0data\nresolution\u00a0queries\u00a0as\u00a0soon\u00a0as\u00a0reasonably\u00a0possible\u00a0and\u00a0in\u00a0any\u00a0event\u00a0within\u00a0***\u00a0(***)\u00a0business\u00a0days\u00a0following\u00a0receipt\u00a0of\u00a0such\u00a0query.\n\u00a0\n6.2 \u00a0As\u00a0applicable\u00a0to\u00a0and\u00a0appropriate\u00a0for\u00a0a\u00a0Clinical\u00a0Study,\u00a0Adaptimmune\u00a0may\u00a0monitor\u00a0the\u00a0conduct\u00a0of\u00a0a\u00a0Clinical\u00a0Study\u00a0in\u00a0accordance\nwith\u00a0Good\u00a0Clinical\u00a0Practice\u00a0requirements\u00a0of\u00a0FDA\u00a0Regulations,\u00a0and\u00a0may\u00a0visit\u00a0MD\u00a0Anderson\u00a0for\u00a0the\u00a0purpose\u00a0of\u00a0such\u00a0monitoring.\u00a0Such\nmonitoring\u00a0visits\u00a0shall\u00a0also\u00a0enable\u00a0Adaptimmune\u00a0to\u00a0(a)\u00a0inspect\u00a0and\u00a0review\u00a0any\u00a0or\u00a0all\u00a0Study\u00a0Records\u00a0and\u00a0Study\u00a0source\u00a0documents\u00a0for\ncomparison\u00a0with\u00a0case\u00a0report\u00a0forms\u037e\u00a0and\u00a0(b)\u00a0audit\u00a0financial\u00a0records\u00a0relating\u00a0solely\u00a0to\u00a0the\u00a0performance\u00a0of\u00a0the\u00a0Study\u00a0under\u00a0this\nAgreement.\u00a0During\u00a0any\u00a0visit,\u00a0MD\u00a0Anderson\u00a0and\u00a0Principal\u00a0Investigator\u00a0shall\u00a0reasonably\u00a0cooperate\u00a0with\u00a0Adaptimmune\u00a0and\u00a0will\u00a0use\nreasonably\u00a0efforts\u00a0to\u00a0promptly\u00a0provide\u00a0any\u00a0reasonably\u00a0Study\u00a0Records\u00a0or\u00a0Study\u00a0information\u00a0requested\u00a0by\u00a0Adaptimmune\u00a0in\u00a0accordance\nwith\u00a0this\u00a0Section.\u00a0Any\u00a0such\u00a0visits\u00a0shall\u00a0be\u00a0scheduled\u00a0in\u00a0coordination\u00a0with\u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0during\u00a0normal\nadministrative\u00a0business\u00a0hours,\u00a0and\u00a0shall\u00a0be\u00a0subject\u00a0Adaptimmune\u2019s\u00a0and\u00a0Adaptimmune\u00a0Limited\u2019s\u00a0compliance\u00a0with\u00a0MD\u00a0Anderson\u2019s\nreasonable\u00a0measures\u00a0for\u00a0confidentiality,\u00a0safety\u00a0and\u00a0security,\u00a0and\u00a0shall\u00a0also\u00a0be\u00a0subject\u00a0to\u00a0compliance\u00a0with\u00a0generally\u00a0applicable\u00a0premises\nrules\u00a0at\u00a0MD\u00a0Anderson.\n\u00a0\n6.3 \u00a0MD\u00a0Anderson\u00a0and\u00a0Principal\u00a0Investigator\u00a0shall,\u00a0during\u00a0a\u00a0Study,\u00a0permit\u00a0inspections\u00a0by\u00a0responsible\u00a0legal\u00a0and\u00a0regulatory\u00a0authorities\nwith\u00a0respect\u00a0to\u00a0such\u00a0Clinical\u00a0Study.\u00a0To\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0law\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0practicable,\u00a0MD\u00a0Anderson\u00a0shall\u00a0notify\nAdaptimmune\u00a0of\u00a0such\u00a0inspection\u00a0and\u00a0provide\u00a0Adaptimmune\u00a0with\u00a0an\u00a0opportunity\u00a0to\u00a0be\u00a0present\u00a0at\u00a0such\u00a0inspection\u00a0(to\u00a0the\u00a0extent\nreasonably\u00a0possible).\u00a0MD\u00a0Anderson\u00a0shall,\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0Applicable\u00a0Law,\u00a0inform\u00a0Adaptimmune\u00a0of\u00a0any\u00a0findings\u00a0resulting\nfrom\u00a0any\u00a0such\u00a0inspection\u00a0and\u00a0MD\u00a0Anderson\u00a0shall\u00a0promptly\u00a0correct\u00a0any\u00a0non-conformances\u00a0or\u00a0requests\u00a0for\u00a0correction\u00a0identified\u00a0as\u00a0a\nresult\u00a0of\u00a0such\u00a0inspection.\u00a0MD\u00a0Anderson\u00a0shall\u00a0promptly\u00a0notify\u00a0Adaptimmune\u00a0of,\u00a0and\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0law,\u00a0provide\nAdaptimmune\u00a0with\u00a0copies\u00a0of,\u00a0any\u00a0inquiries,\u00a0correspondence\u00a0or\u00a0communications\u00a0with\u00a0any\u00a0legal\u00a0or\u00a0regulatory\u00a0authority\u00a0with\u00a0authority\nover\u00a0any\u00a0Study,\u00a0to\u00a0the\u00a0extent\u00a0in\u00a0each\u00a0case\u00a0applicable\u00a0to\u00a0any\u00a0Study\u00a0or\u00a0the\u00a0performance\u00a0of\u00a0such\u00a0Study\u00a0by\u00a0MD\u00a0Anderson.\u00a0Where\u00a0MD\nAnderson\u00a0intends\u00a0to\u00a0respond\u00a0to\u00a0any\u00a0such\u00a0communication,\u00a0MD\u00a0Anderson\u00a0shall\u00a0provide,\u00a0to\u00a0the\u00a0extent\u00a0permitted\u00a0by\u00a0law,\u00a0Adaptimmune\nwith\u00a0a\u00a0copy\u00a0of\u00a0such\u00a0response\u00a0and\u00a0an\u00a0opportunity\u00a0to\u00a0comment\u00a0on\u00a0such\u00a0response\u00a0(to\u00a0the\u00a0extent\u00a0reasonably\u00a0practicable)\u00a0in\u00a0advance\u00a0of\nthe\u00a0due\u00a0date\u00a0for\u00a0the\u00a0response.\u00a0MD\u00a0Anderson\u00a0will\u00a0review\u00a0any\u00a0comments\u00a0provided\u00a0by\u00a0Adaptimmune\u00a0in\u00a0good\u00a0faith.\n\u00a0\n6.4 \u00a0Notwithstanding\u00a0any\u00a0provision\u00a0of\u00a0this\u00a0Section\u00a06,\u00a0to\u00a0the\u00a0extent\u00a0that\u00a0MD\u00a0Anderson\u00a0is\u00a0the\u00a0holder\u00a0of\u00a0an\u00a0Investigational\u00a0New\u00a0Drug\nApplication\u00a0(\u201c IND\u201d)\u00a0or\u00a0other\u00a0applicable\u00a0regulatory\u00a0application\u00a0or\u00a0approval\u00a0for\u00a0a\u00a0Study,\u00a0the\u00a0provisions\u00a0of\u00a0Section\u00a06.2\u00a0and\u00a06.3\u00a0shall\u00a0not\napply,\u00a0and\u00a0MD\u00a0Anderson\u00a0shall\u00a0have\u00a0the\u00a0sole\u00a0responsibility\u00a0for\u00a0monitoring,\u00a0auditing,\u00a0and\u00a0reporting\u00a0for\u00a0such\u00a0Study,\u00a0provided\u00a0that\u00a0MD\nAnderson\u00a0agrees\u00a0to\u00a0reasonably\u00a0negotiate\u00a0access\u00a0to\u00a0Study\u00a0documentation\u00a0and\u00a0records\u00a0relevant\u00a0to\u00a0the\u00a0applicable\u00a0Study\u00a0Drug\u00a0and\ndocumentation\u00a0and\u00a0facilities\u00a0applicable\u00a0to\u00a0the\u00a0Study\u00a0upon\u00a0the\u00a0request\u00a0of\u00a0Adaptimmune\u00a0and\u00a0provided\u00a0that\u00a0Adaptimmune\u00a0shall\u00a0be\nsubject\u00a0to\u00a0compliance\u00a0with\u00a0MD\u00a0Anderson\u2019s\u00a0reasonable\u00a0measures\u00a0for\u00a0confidentiality,\u00a0safety\u00a0and\u00a0security,\u00a0and\u00a0shall\u00a0also\u00a0be\u00a0subject\u00a0to\ncompliance\u00a0with\u00a0generally\u00a0applicable\u00a0premises\u00a0rules\u00a0at\u00a0MD\u00a0Anderson.\n\u00a0\n7.\u00a0Data\u00a0&\u00a0Inventions.\n\u00a0\n7.1 \u00a0Each\u00a0Party\u00a0will\u00a0retain\u00a0all\u00a0right,\u00a0title\u00a0and\u00a0interest\u00a0in\u00a0and\u00a0to\u00a0its\u00a0own\u00a0Background\u00a0IP\u00a0and\u00a0no\u00a0license\u00a0to\u00a0use\u00a0such\u00a0Background\u00a0IP\u00a0is\ngranted\u00a0to\u00a0the\u00a0other\u00a0party\u00a0except\u00a0for\u00a0MD\u00a0Anderson\u2019s\u00a0use\u00a0of\u00a0Study\u00a0Drug\u00a0in\u00a0a\u00a0Study\u00a0as\u00a0set\u00a0forth\u00a0in\u00a0Section\u00a03.2\u00a0above\u00a0and\u00a0in\u00a0the\nProtocol\u00a0and\u00a0each\u00a0Party\u2019s\u00a0use\u00a0of\u00a0the\u00a0other\u00a0Party\u2019s\n\u00a0\n*** \u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n10\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "8699ea14-6024-4097-a3a8-b266941a651e": {"__data__": {"id_": "8699ea14-6024-4097-a3a8-b266941a651e", "embedding": null, "metadata": {"page_label": "11", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nProprietary\u00a0Material\u00a0as\u00a0set\u00a0forth\u00a0in\u00a0Section\u00a03.3\u00a0above.\u00a0\u201c Background\u00a0IP \u201d\u00a0means\u00a0all\u00a0intellectual\u00a0property\u00a0(including\u00a0rights\u00a0in\u00a0Confidential\nInformation)\u00a0of\u00a0a\u00a0Party\u00a0that:\u00a0(a)\u00a0was\u00a0generated\u00a0by\u00a0such\u00a0Party\u00a0before\u00a0the\u00a0Effective\u00a0Date\u037e\u00a0(b)\u00a0is\u00a0generated\u00a0by\u00a0such\u00a0Party\u00a0outside\u00a0the\nscope\u00a0or\u00a0after\u00a0expiration\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0any\u00a0Study\u00a0under\u00a0this\u00a0Agreement\u037e\u00a0and\u00a0in\u00a0each\u00a0such\u00a0case\u037e\u00a0(c)\u00a0is\u00a0owned\u00a0by\u00a0such\u00a0Party,\neither\u00a0partially\u00a0or\u00a0wholly,\u00a0or\u00a0is\u00a0licensed\u00a0to,\u00a0or\u00a0otherwise\u00a0controlled\u00a0by\u00a0such\u00a0Party,\u00a0and\u00a0which\u00a0is\u00a0not\u00a0an\u00a0Invention\u00a0under\u00a0this\u00a0Agreement.\n\u00a0\n7.2 \u00a0Patient\u00a0records,\u00a0research\u00a0notebooks,\u00a0all\u00a0original\u00a0source\u00a0documents,\u00a0Protected\u00a0Health\u00a0Information\u00a0(as\u00a0such\u00a0term\u00a0is\u00a0defined\u00a0by\nHIPAA),\u00a0MD\u00a0Anderson\u2019s\u00a0business\u00a0records,\u00a0regulatory\u00a0and\u00a0compliance\u00a0documents,\u00a0original\u00a0medical\u00a0records\u00a0or\u00a0any\u00a0information\nrequired\u00a0to\u00a0be\u00a0maintained\u00a0by\u00a0MD\u00a0Anderson\u00a0in\u00a0accordance\u00a0with\u00a0Applicable\u00a0Laws,\u00a0that\u00a0is\u00a0generated\u00a0in\u00a0the\u00a0conduct\u00a0of\u00a0the\u00a0Studies\n(collectively,\u00a0\u201cMD\u00a0Anderson\u00a0Records\u201d)\u00a0will\u00a0be\u00a0owned\u00a0by\u00a0MD\u00a0Anderson.\u00a0All\u00a0results,\u00a0data\u00a0and\u00a0work\u00a0product\u00a0(excluding\u00a0MD\u00a0Anderson\nRecords)\u00a0generated\u00a0in\u00a0the\u00a0conduct\u00a0of\u00a0the\u00a0Studies\u00a0(\u201cData\u201d)\u00a0shall\u00a0be\u00a0owned\u00a0by\u00a0Adaptimmune\u00a0Limited.\u00a0MD\u00a0Anderson\u00a0shall\u00a0maintain\u00a0all\nsuch\u00a0Data\u00a0as\u00a0confidential,\u00a0subject\u00a0to\u00a0the\u00a0publication\u00a0rights\u00a0granted\u00a0in\u00a0Section\u00a012\u00a0below.\u00a0Data\u00a0will\u00a0be\u00a0promptly\u00a0disclosed\u00a0by\u00a0MD\nAnderson\u00a0to\u00a0Adaptimmune\u00a0in\u00a0the\u00a0form\u00a0of\u00a0a\u00a0Study\u00a0report\u00a0or\u00a0as\u00a0otherwise\u00a0reasonably\u00a0requested\u00a0by\u00a0Adaptimmune.\u00a0 Notwithstanding\u00a0any\nother\u00a0provision\u00a0of\u00a0this\u00a0Agreement,\u00a0MD\u00a0Anderson\u00a0shall\u00a0have\u00a0the\u00a0right\u00a0to\u00a0use\u00a0results\u00a0and\u00a0Data\u00a0of\u00a0the\u00a0Study\u00a0for\u00a0its\u00a0internal\u00a0research,\nacademic,\u00a0and\u00a0patient\u00a0care\u00a0purposes\u00a0and\u00a0for\u00a0publication\u00a0in\u00a0accordance\u00a0with\u00a0Section\u00a012\u00a0below,\u00a0save\u00a0that\u00a0no\u00a0right\u00a0or\u00a0license\u00a0is\u00a0granted\nto\u00a0MD\u00a0Anderson\u00a0under\u00a0any\u00a0of\u00a0Adaptimmune\u2019s\u00a0Background\u00a0IP.\u00a0Adaptimmune\u00a0shall\u00a0promptly\u00a0disclose\u00a0any\u00a0Data\u00a0it\u00a0generates\u00a0to\u00a0MD\nAnderson.\n\u00a0\n7.3 \u00a0MD\u00a0Anderson\u00a0will\u00a0provide\u00a0to\u00a0Adaptimmune\u00a0a\u00a0detailed\u00a0written\u00a0disclosure\u00a0of\u00a0each\u00a0patentable\u00a0invention\u00a0and/or\u00a0discovery\u00a0(and\u00a0all\nintellectual\u00a0property\u00a0rights\u00a0therein)\u00a0conceived\u00a0and\u00a0reduced\u00a0to\u00a0practice\u00a0in\u00a0the\u00a0conduct\u00a0of\u00a0a\u00a0Study\u00a0and\u00a0arising\u00a0from\u00a0the\u00a0performance\u00a0of\u00a0a\nStudy\u00a0(\u201cInvention\u201d)\u00a0promptly\u00a0after\u00a0a\u00a0written\u00a0invention\u00a0disclosure\u00a0report\u00a0for\u00a0such\u00a0Invention\u00a0is\u00a0received\u00a0by\u00a0MD\u00a0Anderson\u2019s\u00a0Office\u00a0of\nTechnology\u00a0Commercialization.\n\u00a0\n7.4 \u00a0Inventions\u00a0shall\u00a0be\u00a0owned\u00a0by\u00a0the\u00a0Parties\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0following:\n(a)\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u201cAdaptimmune\u00a0Inventions\u201d\u00a0shall\u00a0be\u00a0the\u00a0sole\u00a0property\u00a0of\u00a0Adaptimmune\u00a0Limited.\n\u00a0\n(b)\u00a0With\u00a0respect\u00a0to\u00a0any\u00a0Inventions\u00a0that\u00a0are\u00a0not\u00a0Adaptimmune\u00a0Inventions\u00a0(\u201cOther\u00a0Inventions\u201d),\u00a0where\u00a0made\u00a0solely\u00a0by\u00a0MD\nAnderson\u00a0or\u00a0its\u00a0employees\u00a0and\u00a0agents,\u00a0such\u00a0Inventions\u00a0will\u00a0be\u00a0solely\u00a0owned\u00a0by\u00a0MD\u00a0Anderson\u037e\u00a0where\u00a0made\u00a0jointly\u00a0by\u00a0MD\u00a0Anderson\nand\u00a0Adaptimmune\u00a0and/or\u00a0Adaptimmune\u00a0Limited\u00a0and\u00a0their\u00a0employees\u00a0and\u00a0agents\u00a0will\u00a0be\u00a0jointly\u00a0owned\u00a0by\u00a0MD\u00a0Anderson\u00a0and\nAdaptimmune\u00a0Limited.\u00a0 Inventions\u00a0that\u00a0are\u00a0made\u00a0solely\u00a0by\u00a0Adaptimmune,\u00a0Adaptimmune\u00a0Limited\u00a0or\u00a0its\u00a0employees\u00a0and\u00a0agents\u00a0will\u00a0be\nsolely\u00a0owned\u00a0by\u00a0Adaptimmune\u00a0Limited.\u00a0 Inventorship\u00a0will\u00a0be\u00a0determined\u00a0in\u00a0accordance\u00a0with\u00a0United\u00a0States\u00a0patent\u00a0law.\n\u00a0\n7.5 \u00a0MD\u00a0Anderson\u00a0hereby\u00a0grants\u00a0Adaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited\u00a0a\u00a0non-exclusive,\u00a0worldwide,\u00a0irrevocable\u00a0royalty-free\nlicense\u00a0to\u00a0any\u00a0Invention\u00a0in\u00a0which\u00a0MD\u00a0Anderson\u00a0has\u00a0an\u00a0ownership\u00a0interest,\u00a0for\u00a0any\u00a0purpose.\u00a0 Such\u00a0license\u00a0shall\u00a0include\u00a0an\u00a0unrestricted\nright\u00a0to\u00a0sublicense\u00a0through\u00a0multiple\u00a0tiers.\u00a0MD\u00a0Anderson\u00a0also\u00a0hereby\u00a0grants\u00a0to\u00a0Adaptimmune\u00a0Limited\u00a0an\u00a0exclusive\u00a0option\u00a0to\u00a0negotiate\nan\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n11\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "0279ccce-e4ff-4e1b-a6c3-bef6f57f7358": {"__data__": {"id_": "0279ccce-e4ff-4e1b-a6c3-bef6f57f7358", "embedding": null, "metadata": {"page_label": "12", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nexclusive\u00a0(subject\u00a0to\u00a0MD\u00a0Anderson\u2019s\u00a0perpetual,\u00a0irrevocable,\u00a0no-cost\u00a0right\u00a0to\u00a0use\u00a0such\u00a0Invention\u00a0for\u00a0non-commercial\u00a0internal\u00a0research,\nacademic\u00a0and\u00a0patient\u00a0care\u00a0purposes),\u00a0royalty-bearing\u00a0license\u00a0to\u00a0any\u00a0Invention\u00a0in\u00a0which\u00a0MD\u00a0Anderson\u00a0has\u00a0an\u00a0ownership\u00a0interest,\nprovided\u00a0that\u00a0Adaptimmune\u00a0Limited\u00a0pays\u00a0all\u00a0reasonably\u00a0incurred\u00a0patent\u00a0expenses\u00a0for\u00a0such\u00a0Invention\u00a0in\u00a0the\u00a0event\u00a0Adaptimmune\nLimited\u00a0exercises\u00a0its\u00a0option.\u00a0 Adaptimmune\u00a0Limited\u00a0must\u00a0exercise\u00a0its\u00a0option\u00a0to\u00a0negotiate\u00a0a\u00a0license\u00a0to\u00a0any\u00a0Invention\u00a0by\u00a0notifying\u00a0MD\nAnderson\u00a0in\u00a0writing\u00a0within\u00a0six\u00a0months\u2019\u00a0of\u00a0MD\u00a0Anderson\u00a0disclosing\u00a0such\u00a0Invention\u00a0to\u00a0Adaptimmune\u00a0(the\u00a0\u201cOption\u00a0Period\u201d).\u00a0 If\nAdaptimmune\u00a0Limited\u00a0fails\u00a0to\u00a0timely\u00a0exercise\u00a0its\u00a0option\u00a0within\u00a0the\u00a0Option\u00a0Period\u00a0with\u00a0respect\u00a0to\u00a0any\u00a0Invention,\u00a0Adaptimmune\nLimited\u2019s\u00a0right\u00a0to\u00a0negotiate\u00a0a\u00a0license\u00a0agreement\u00a0with\u00a0respect\u00a0to\u00a0such\u00a0Invention\u00a0will\u00a0automatically\u00a0terminate,\u00a0and\u00a0MD\u00a0Anderson\u00a0will\u00a0be\nfree\u00a0to\u00a0negotiate\u00a0and\u00a0enter\u00a0into\u00a0a\u00a0license\u00a0with\u00a0any\u00a0other\u00a0party.\u00a0 If\u00a0Adaptimmune\u00a0Limited\u00a0timely\u00a0exercises\u00a0its\u00a0option,\u00a0the\u00a0terms\u00a0of\u00a0the\nlicense\u00a0shall\u00a0be\u00a0negotiated\u00a0in\u00a0good\u00a0faith\u00a0within\u00a0six\u00a0months\u00a0of\u00a0the\u00a0date\u00a0such\u00a0option\u00a0is\u00a0exercised,\u00a0or\u00a0within\u00a0such\u00a0time\u00a0the\u00a0parties\u00a0may\nmutually\u00a0agree\u00a0in\u00a0writing\u00a0(the\u00a0\u201cNegotiation\u00a0Period\u201d).\u00a0 If,\u00a0however,\u00a0Adaptimmune\u00a0Limited\u00a0timely\u00a0exercises\u00a0its\u00a0option,\u00a0but\u00a0MD\u00a0Anderson\nand\u00a0Adaptimmune\u00a0Limited\u00a0are\u00a0unable\u00a0to\u00a0agree\u00a0upon\u00a0the\u00a0terms\u00a0of\u00a0the\u00a0license\u00a0during\u00a0the\u00a0Negotiation\u00a0Period,\u00a0Adaptimmune\u00a0Limited\u2019s\nright\u00a0to\u00a0exclusively\u00a0license\u00a0such\u00a0Invention\u00a0will\u00a0terminate,\u00a0and\u00a0MD\u00a0Anderson\u00a0will\u00a0be\u00a0free\u00a0to\u00a0enter\u00a0into\u00a0a\u00a0license\u00a0with\u00a0any\u00a0other\u00a0party\n(subject\u00a0to\u00a0the\u00a0grant\u00a0of\u00a0the\u00a0non-exclusive\u00a0license\u00a0above).\n\u00a0\n7.6. \u00a0Adaptimmune\u00a0Limited\u00a0hereby\u00a0grants\u00a0MD\u00a0Anderson\u00a0a\u00a0perpetual,\u00a0irrevocable,\u00a0no-cost,\u00a0non-exclusive,\u00a0royalty-free\u00a0license\u00a0to\u00a0any\nAdaptimmune\u00a0Invention\u00a0or\u00a0Other\u00a0Invention\u00a0in\u00a0which\u00a0Adaptimmune\u00a0Limited\u00a0has\u00a0an\u00a0ownership\u00a0interest\u00a0for\u00a0MD\u00a0Anderson\u2019s\u00a0internal\nnon-commercial\u00a0research,\u00a0academic\u00a0and\u00a0patient\u00a0care\u00a0purposes.\u00a0 For\u00a0clarity\u00a0the\u00a0grant\u00a0of\u00a0any\u00a0license\u00a0under\u00a0any\u00a0Invention\u00a0or\u00a0assignment\nof\u00a0any\u00a0Invention\u00a0by\u00a0either\u00a0Party\u00a0does\u00a0not\u00a0include\u00a0any\u00a0license\u00a0under\u00a0any\u00a0of\u00a0such\u00a0Party\u2019s\u00a0Background\u00a0IP,\u00a0even\u00a0where\u00a0such\u00a0Background\nIP\u00a0dominates\u00a0or\u00a0encompasses\u00a0any\u00a0Invention.\n\u00a0\n7.7 \u00a0As\u00a0between\u00a0the\u00a0Parties,\u00a0the\u00a0sole\u00a0owner\u00a0of\u00a0any\u00a0Invention\u00a0will\u00a0have\u00a0the\u00a0sole\u00a0right\u00a0to\u00a0prepare,\u00a0file,\u00a0prosecute,\u00a0maintain,\u00a0enforce\u00a0and\ndefend\u00a0all\u00a0U.S.\u00a0and\u00a0foreign\u00a0patents,\u00a0registrations\u00a0and\u00a0other\u00a0forms\u00a0of\u00a0intellectual\u00a0property\u00a0in\u00a0such\u00a0Invention\u00a0but\u00a0nothing\u00a0herein\u00a0will\nobligate\u00a0the\u00a0owner\u00a0to\u00a0take\u00a0any\u00a0such\u00a0actions.\u00a0As\u00a0between\u00a0the\u00a0Parties,\u00a0Adaptimmune\u00a0will\u00a0have\u00a0the\u00a0first\u00a0right\u00a0to\u00a0prepare,\u00a0file,\u00a0prosecute,\nmaintain,\u00a0enforce\u00a0and\u00a0defend\u00a0all\u00a0U.S.\u00a0and\u00a0foreign\u00a0patents,\u00a0registrations\u00a0and\u00a0other\u00a0forms\u00a0of\u00a0intellectual\u00a0property\u00a0in\u00a0any\u00a0jointly-owned\nInvention\u00a0using\u00a0patent\u00a0counsel\u00a0of\u00a0its\u00a0choice\u00a0that\u00a0is\u00a0subject\u00a0to\u00a0the\u00a0written\u00a0approval\u00a0of\u00a0MD\u00a0Anderson\u00a0not\u00a0to\u00a0be\u00a0unreasonably\u00a0withheld\nand\u00a0at\u00a0the\u00a0sole\u00a0cost\u00a0and\u00a0expense\u00a0of\u00a0Adaptimmune,\u00a0with\u00a0accounting\u00a0to\u00a0MD\u00a0Anderson.\u00a0 Adaptimmune\u00a0will\u00a0keep\u00a0MD\u00a0Anderson\nreasonably\u00a0informed\u00a0of\u00a0all\u00a0such\u00a0material\u00a0preparations,\u00a0filings,\u00a0material\u00a0prosecution,\u00a0material\u00a0maintenance,\u00a0material\u00a0enforcement\u00a0and\ndefense\u00a0and\u00a0will\u00a0consider\u00a0MD\u00a0Anderson\u2019s\u00a0recommendations\u00a0in\u00a0good\u00a0faith\u00a0(provided\u00a0such\u00a0recommendations\u00a0are\u00a0provided\u00a0on\u00a0a\u00a0timely\nbasis)\u00a0If\u00a0Adaptimmune\u00a0elects\u00a0not\u00a0to\u00a0file\u00a0in\u00a0the\u00a0United\u00a0States\u00a0or\u00a0not\u00a0to\u00a0maintain\u00a0an\u00a0application\u00a0or\u00a0patent\u00a0arising\u00a0from\u00a0any\u00a0jointly-owned\nInvention,\u00a0Adaptimmune\u00a0will\u00a0promptly\u00a0notify\u00a0MD\u00a0Anderson\u00a0within\u00a0reasonable\u00a0time\u00a0for\u00a0MD\u00a0Anderson\u00a0to\u00a0file,\u00a0prosecute\u00a0or\u00a0maintain\nsuch\u00a0application\u00a0or\u00a0patent,\u00a0and\u00a0MD\u00a0Anderson\u00a0will\u00a0have\u00a0the\u00a0right\u00a0to\u00a0file,\u00a0prosecute\u00a0or\u00a0maintain\u00a0such\u00a0application\u00a0or\u00a0patent,\u00a0at\u00a0MD\nAnderson\u2019s\u00a0expense.\u00a0 MD\u00a0Anderson\u00a0will\u00a0keep\u00a0Adaptimmune\u00a0reasonably\u00a0informed\u00a0of\u00a0all\u00a0such\u00a0material\u00a0preparations,\u00a0material\u00a0filings,\nmaterial\u00a0prosecution,\u00a0material\u00a0maintenance,\u00a0material\u00a0enforcement\u00a0and\u00a0defense\u00a0it\u00a0makes\u00a0in\u00a0relation\u00a0to\u00a0any\u00a0jointly-owned\u00a0Invention.\u00a0The\nParties\u00a0will\u00a0reasonably\u00a0cooperate\u00a0with\u00a0each\u00a0other\u00a0with\u00a0respect\u00a0to\u00a0matters\u00a0concerning\u00a0jointly-owned\u00a0Inventions\u00a0to\u00a0the\u00a0extent\nreasonably\u00a0necessary\u00a0for\u00a0filing,\u00a0prosecuting,\u00a0maintaining,\u00a0defending\u00a0or\u00a0enforcing\u00a0any\u00a0such\u00a0patents,\u00a0registrations\u00a0and\u00a0other\u00a0forms\u00a0of\nintellectual\u00a0property\u00a0protection.\u00a0MD\u00a0Anderson\u00a0will\u00a0keep\u00a0Adaptimmune\u00a0reasonably\u00a0informed\u00a0of\u00a0any\u00a0material\u00a0filings,\u00a0material\nprosecution,\u00a0enforcement\u00a0and\u00a0defense\u00a0patents,\u00a0new\u00a0patent\u00a0applications,\u00a0material\u00a0registrations\u00a0or\u00a0other\u00a0forms\u00a0of\u00a0intellectual\u00a0property\ncovering\u00a0Other\u00a0Inventions.\n\u00a0\n7.8 \u00a0***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n12\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "67e8ffaf-0c1d-4296-b33e-a446c4bb1b56": {"__data__": {"id_": "67e8ffaf-0c1d-4296-b33e-a446c4bb1b56", "embedding": null, "metadata": {"page_label": "13", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n8.\u00a0Term\u00a0and\u00a0Termination\n\u00a0\n8.1 \u00a0The\u00a0term\u00a0of\u00a0this\u00a0Agreement\u00a0shall\u00a0be\u00a0five\u00a0(5)\u00a0years\u00a0following\u00a0the\u00a0Effective\u00a0Date\u00a0or\u00a0until\u00a0the\u00a0Studies\u00a0are\u00a0completed,\u00a0whichever\u00a0is\nlater,\u00a0unless\u00a0extended\u00a0or\u00a0unless\u00a0terminated\u00a0earlier\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0provisions\u00a0hereof.\u00a0 In\u00a0the\u00a0event\u00a0of\u00a0expiration\u00a0or\u00a0early\ntermination\u00a0of\u00a0this\u00a0Agreement,\u00a0the\u00a0terms\u00a0and\u00a0conditions\u00a0of\u00a0this\u00a0Agreement\u00a0shall\u00a0remain\u00a0binding\u00a0with\u00a0respect\u00a0to\u00a0any\u00a0ongoing\u00a0Studies\n(including\u00a0any\u00a0new\u00a0studies\u00a0to\u00a0which\u00a0any\u00a0remaining\u00a0Alliance\u00a0Funding\u00a0is\u00a0allocated\u00a0under\u00a0Section\u00a01.3)\u00a0until\u00a0completion\u00a0of\u00a0the\u00a0Studies\u00a0or\ntermination\u00a0of\u00a0the\u00a0respective\u00a0Study\u00a0Order/s.\n\u00a0\n8.2 \u00a0A\u00a0Party\u00a0will\u00a0have\u00a0the\u00a0right\u00a0to\u00a0terminate\u00a0this\u00a0Agreement\u00a0if\u00a0the\u00a0other\u00a0Party\u00a0commits\u00a0a\u00a0material\u00a0breach\u00a0of\u00a0the\u00a0Agreement\u00a0and\u00a0fails\u00a0to\ncure\u00a0such\u00a0breach\u00a0within\u00a0thirty\u00a0(30)\u00a0days\u00a0of\u00a0receiving\u00a0notice\u00a0from\u00a0the\u00a0non-breaching\u00a0Party\u00a0of\u00a0such\u00a0breach.\u00a0 Any\u00a0expiration\u00a0or\ntermination\u00a0of\u00a0this\u00a0Agreement\u00a0will\u00a0not\u00a0affect\u00a0any\u00a0then\u00a0existing\u00a0Study\u00a0Orders,\u00a0and\u00a0any\u00a0then\u00a0outstanding\u00a0Study\u00a0Orders\u00a0will\u00a0continue\nafter\u00a0the\u00a0expiration\u00a0or\u00a0earlier\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0in\u00a0accordance\u00a0with\u00a0their\u00a0respective\u00a0provisions.\u00a0Upon\u00a0any\u00a0expiration\u00a0or\ntermination\u00a0of\u00a0this\u00a0Agreement,\u00a0provisions\u00a0of\u00a0this\u00a0Agreement\u00a0that\u00a0are\u00a0incorporated\u00a0by\u00a0reference\u00a0into\u00a0any\u00a0then\u00a0outstanding\u00a0Study\nOrders\u00a0will\u00a0survive\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0will\u00a0continue\u00a0to\u00a0apply\u00a0to\u00a0such\u00a0Study\u00a0Orders\u00a0until\u00a0termination\u00a0or\u00a0expiration\u00a0of\neach\u00a0such\u00a0Study\u00a0Orders\u00a0in\u00a0effect\u00a0at\u00a0the\u00a0time\u00a0this\u00a0Agreement\u00a0expires\u00a0or\u00a0is\u00a0terminated.\n\u00a0\n8.3 \u00a0A\u00a0Party\u00a0may\u00a0terminate\u00a0a\u00a0Study\u00a0Order:\u00a0(a)\u00a0if\u00a0the\u00a0other\u00a0Party\u00a0commits\u00a0a\u00a0material\u00a0breach\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0the\u00a0Study\u00a0Order\u00a0and\nfails\u00a0to\u00a0cure\u00a0such\u00a0breach\u00a0within\u00a0thirty\u00a0(30)\u00a0days\u00a0of\u00a0receiving\u00a0notice\u00a0from\u00a0the\u00a0non-breaching\u00a0Party\u00a0of\u00a0such\u00a0breach\u037e\u00a0or\u00a0(b)\u00a0in\u00a0the\u00a0case\u00a0of\nany\u00a0Clinical\u00a0Studies,\u00a0due\u00a0to\u00a0health\u00a0and\u00a0safety\u00a0concerns\u00a0related\u00a0to\u00a0the\u00a0Study\u00a0Drug\u00a0or\u00a0procedures\u00a0in\u00a0the\u00a0Study\u00a0(including\u00a0regulatory\nholds\u00a0due\u00a0to\u00a0the\u00a0health\u00a0and\u00a0safety\u00a0of\u00a0the\u00a0Study\u00a0Subjects)\u037e\u00a0or\u00a0(c)\u00a0in\u00a0the\u00a0case\u00a0of\u00a0MD\u00a0Anderson\u00a0and\u00a0in\u00a0relation\u00a0to\u00a0any\u00a0Clinical\u00a0Studies,\nwhere\u00a0IRB\u00a0requests\u00a0termination\u00a0of\u00a0any\u00a0Study\u037e\u00a0or\u00a0(d)\u00a0in\u00a0the\u00a0case\u00a0of\u00a0Adaptimmune,\u00a0***\u00a0 set\u00a0out\u00a0in\u00a0Section\u00a01.2\u00a0above.\u00a0 The\u00a0Parties\u00a0agree\nthat\u00a0any\u00a0termination\u00a0of\u00a0a\u00a0Study\u00a0Order\u00a0shall\u00a0allow\u00a0for:\u00a0(i)\u00a0the\u00a0wind\u00a0down\u00a0of\u00a0the\u00a0Study\u00a0to\u00a0ensure\u00a0the\u00a0safety\u00a0of\u00a0Study\u00a0subjects\u037e\u00a0and\u00a0(ii)\nAdaptimmune\u2019s\u00a0final\u00a0reconciliation\u00a0of\u00a0Data\u00a0related\u00a0to\u00a0the\u00a0Study\u00a0in\u00a0addition\u00a0to\u00a0Adaptimmune\u2019s\u00a0final\u00a0monitoring\u00a0visit.\u00a0 All\u00a0reasonable\nfees\u00a0associated\u00a0with\u00a0the\u00a0wind-down\u00a0activities\u00a0and\u00a0final\u00a0monitoring\u00a0visit\u00a0shall\u00a0be\u00a0paid\u00a0by\u00a0Adaptimmune,\u00a0to\u00a0the\u00a0extent\u00a0not\u00a0covered\u00a0by\nAlliance\u00a0Funding.\u00a0 Termination\u00a0of\u00a0one\u00a0or\u00a0more\u00a0Study\u00a0Orders\u00a0will\u00a0not\u00a0automatically\u00a0result\u00a0in\u00a0the\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0or\ntermination\u00a0of\u00a0any\u00a0other\u00a0Study\u00a0Orders.\u00a0 Upon\u00a0termination\u00a0of\u00a0a\u00a0Study\u00a0Order,\u00a0MD\u00a0Anderson\u00a0will\u00a0immediately\u00a0return\u00a0(at\u00a0Adaptimmune\u2019s\ncost)\u00a0any\u00a0Study\u00a0Drugs\u00a0provided\u00a0by\u00a0Adaptimmune\u00a0for\u00a0such\u00a0Study\u00a0as\u00a0directed\u00a0by\u00a0Adaptimmune.\n\u00a0\n8.4 \u00a0In\u00a0case\u00a0any\u00a0regulatory\u00a0or\u00a0legal\u00a0authorization\u00a0necessary\u00a0for\u00a0the\u00a0conduct\u00a0of\u00a0the\u00a0Study\u00a0is\u00a0(i)\u00a0finally\u00a0rejected\u00a0or\u00a0(ii)\u00a0withdrawn,\u00a0the\nrelevant\u00a0Study\u00a0Order\u00a0shall\u00a0terminate\u00a0automatically\u00a0at\u00a0the\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0such\u00a0final\u00a0rejection.\u00a0Termination\u00a0or\u00a0cancellation\u00a0of\u00a0this\nAgreement\u00a0or\u00a0a\u00a0Study\u00a0Order\u00a0will\u00a0not\u00a0affect\u00a0the\u00a0rights\u00a0and\u00a0obligations\u00a0of\u00a0the\u00a0Parties\u00a0that\u00a0have\u00a0accrued\u00a0prior\u00a0to\u00a0termination,\u00a0and\u00a0any\nprovisions\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0a\u00a0particular\u00a0Study\u00a0Order\u00a0that\u00a0by\u00a0their\u00a0nature\u00a0extend\u00a0beyond\u00a0expiration\u00a0or\u00a0termination\u00a0will\u00a0survive\u00a0the\nexpiration\u00a0or\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0and/or\u00a0that\u00a0particular\u00a0Study\u00a0Order.\u00a0In\u00a0particular,\u00a0the\u00a0provisions\u00a0of\u00a0Sections\u00a02-13\u00a0as\napplicable\u00a0will\u00a0survive\u00a0any\u00a0expiration\u00a0or\u00a0termination\u00a0of\u00a0this\u00a0Agreement.\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n13\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "546a8002-122d-4970-871e-02af3235128c": {"__data__": {"id_": "546a8002-122d-4970-871e-02af3235128c", "embedding": null, "metadata": {"page_label": "14", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n8.5 \u00a0In\u00a0the\u00a0event\u00a0the\u00a0Parties\u00a0cannot\u00a0reach\u00a0agreement\u00a0on\u00a0a\u00a0new\u00a0Principal\u00a0Investigator\u00a0pursuant\u00a0to\u00a0Section\u00a014.1\u00a0or\u00a0such\u00a0new\u00a0Principal\nInvestigator\u00a0does\u00a0not\u00a0agree\u00a0to\u00a0the\u00a0terms\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0the\u00a0relevant\u00a0Study\u00a0Order,\u00a0either\u00a0Party\u00a0may\u00a0terminate\u00a0such\u00a0Study\nOrder\u00a0upon\u00a0notice\u00a0to\u00a0the\u00a0other\u00a0Party.\n\u00a0\n8.6 \u00a0In\u00a0addition,\u00a0in\u00a0order\u00a0to\u00a0accommodate\u00a0the\u00a0review\u00a0and\u00a0approval\u00a0of\u00a0this\u00a0Agreement\u00a0by\u00a0the\u00a0Office\u00a0of\u00a0General\u00a0Counsel\u00a0of\u00a0UT\u00a0System\n(the\u00a0\u201cOGC\u201d),\u00a0for\u00a0a\u00a0period\u00a0of\u00a0***\u00a0(***)\u00a0days\u00a0following\u00a0the\u00a0Effective\u00a0Date\u00a0(the\u00a0\u201cLimited\u00a0Unilateral\u00a0Termination\u00a0Period\u201d),\u00a0MD\nAnderson\u00a0will\u00a0have\u00a0the\u00a0right\u00a0to\u00a0terminate\u00a0this\u00a0Agreement\u00a0without\u00a0cause\u00a0upon\u00a0ten\u00a0(10)\u00a0days\u2019\u00a0notice\u00a0to\u00a0Adaptimmune\u037e\u00a0provided,\nhowever,\u00a0that\u00a0(i)\u00a0a\u00a0termination\u00a0by\u00a0MD\u00a0Anderson\u00a0will\u00a0be\u00a0effective\u00a0if\u00a0notice\u00a0of\u00a0termination\u00a0is\u00a0sent\u00a0by\u00a0MD\u00a0Anderson\u00a0any\u00a0time\u00a0within\u00a0the\nLimited\u00a0Unilateral\u00a0Termination\u00a0Period\u00a0even\u00a0if\u00a0the\u00a0ten\u00a0day\u00a0notice\u00a0period\u00a0extends\u00a0beyond\u00a0the\u00a0Limited\u00a0Unilateral\u00a0Termination\u00a0Period\u00a0 and\n(ii)\u00a0the\u00a0Limited\u00a0Unilateral\u00a0Termination\u00a0Period\u00a0will\u00a0expire\u00a0on\u00a0the\u00a0earlier\u00a0to\u00a0occur\u00a0of\u00a0(x)\u00a0the\u00a0end\u00a0of\u00a0the\u00a0sixty\u00a0days,\u00a0or\u00a0(y)\u00a0written\u00a0notice\u00a0to\nAdaptimmune\u00a0from\u00a0MD\u00a0Anderson\u00a0that\u00a0the\u00a0Agreement\u00a0has\u00a0been\u00a0approved\u00a0by\u00a0the\u00a0OGC.\u00a0Should\u00a0MD\u00a0Anderson\u00a0terminate\u00a0this\nAgreement\u00a0in\u00a0accordance\u00a0with\u00a0this\u00a0Section\u00a08.6\u00a0then\u00a0the\u00a0Parties\u00a0will\u00a0use\u00a0reasonable\u00a0efforts\u00a0to\u00a0ensure\u00a0that\u00a0any\u00a0Clinical\u00a0Study\u00a0in\u00a0relation\nto\u00a0which\u00a0any\u00a0patient\u00a0has\u00a0been\u00a0screened\u00a0or\u00a0enrolled\u00a0shall\u00a0continue\u00a0under\u00a0a\u00a0separate\u00a0clinical\u00a0trial\u00a0agreement\u00a0to\u00a0be\u00a0entered\u00a0into\u00a0between\nthe\u00a0Parties\u00a0as\u00a0soon\u00a0as\u00a0possible\u00a0after\u00a0receipt\u00a0of\u00a0notice\u00a0of\u00a0termination\u00a0by\u00a0Adaptimmune.\u00a0The\u00a0terms\u00a0of\u00a0such\u00a0clinical\u00a0trial\u00a0agreement\u00a0shall\nbe\u00a0in\u00a0substantially\u00a0similar\u00a0form\u00a0to\u00a0terms\u00a0agreed\u00a0for\u00a0other\u00a0clinical\u00a0trial\u00a0agreements\u00a0between\u00a0the\u00a0Parties\u00a0and\u00a0a\u00a0separate\u00a0budget\u00a0shall\u00a0be\nagreed\u00a0pursuant\u00a0to\u00a0such\u00a0clinical\u00a0trial\u00a0agreement.\n\u00a0\n8.7 \u00a0For\u00a0each\u00a0Study,\u00a0Adaptimmune\u00a0shall\u00a0make\u00a0all\u00a0payments\u00a0due\u00a0for\u00a0Study\u00a0performance\u00a0reasonably\u00a0incurred\u00a0or\u00a0obligated\u00a0in\u00a0good\u00a0faith\nhereunder\u00a0which\u00a0have\u00a0accrued\u00a0up\u00a0to\u00a0the\u00a0date\u00a0of\u00a0termination\u00a0of\u00a0a\u00a0Study\u00a0Order\u00a0or\u00a0this\u00a0Agreement,\u00a0or,\u00a0in\u00a0case\u00a0of\u00a0a\u00a0termination\u00a0of\u00a0this\nAgreement\u00a0or\u00a0the\u00a0relevant\u00a0Study\u00a0Order\u00a0pursuant\u00a0to\u00a0Section\u00a08.4,\u00a0up\u00a0to\u00a0the\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0such\u00a0final\u00a0rejection.\n\u00a0\n9.\u00a0Indemnification\n\u00a0\n9.1 \u00a0Adaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited\u00a0agree\u00a0to\u00a0defend,\u00a0indemnify,\u00a0and\u00a0hold\u00a0harmless\u00a0MD\u00a0Anderson,\u00a0System,\u00a0each\u00a0Principal\nInvestigator\u00a0and\u00a0its/their\u00a0Regents,\u00a0trustees,\u00a0directors,\u00a0officers,\u00a0staff,\u00a0employees,\u00a0students,\u00a0faculty\u00a0members,\u00a0and\u00a0its/their\u00a0affiliates\u00a0and\ncontracted\u00a0clients\u00a0and\u00a0other\u00a0parties\u00a0as\u00a0may\u00a0be\u00a0listed\u00a0on\u00a0a\u00a0Study\u00a0Order\u00a0(\u201c Indemnified\u00a0Party/ies \u201d):\u00a0(a)\u00a0from\u00a0and\u00a0against\u00a0any\u00a0and\u00a0all\nliability,\u00a0claims,\u00a0lawsuits,\u00a0losses,\u00a0demands,\u00a0damages,\u00a0costs,\u00a0and\u00a0expenses\u00a0as\u00a0a\u00a0result\u00a0of\u00a0third\u00a0party\u00a0claims\u00a0or\u00a0judgments\u00a0(\u201c Indemnified\nLosses\u201d)\u00a0resulting\u00a0from\u00a0(i)\u00a0personal\u00a0injury\u00a0(including\u00a0death)\u00a0to\u00a0any\u00a0person\u00a0or\u00a0damage\u00a0to\u00a0property\u00a0to\u00a0the\u00a0extent\u00a0arising\u00a0from\u00a0the\u00a0design\nor\u00a0manufacture\u00a0of\u00a0the\u00a0Study\u00a0Drug,\u00a0and\u00a0(ii)\u00a0the\u00a0use\u00a0of\u00a0the\u00a0Data\u00a0or\u00a0results\u00a0of\u00a0the\u00a0Study\u00a0by\u00a0or\u00a0on\u00a0behalf\u00a0of\u00a0Adaptimmune,\u00a0Adaptimmune\nLimited\u00a0or\u00a0any\u00a0Joint\u00a0Research\u00a0Partner\u00a0and\u00a0(iii)\u00a0Adaptimmune\u2019s\u00a0or\u00a0Adaptimmune\u00a0Limited\u2019s\u00a0negligence\u00a0in\u00a0connection\u00a0with\u00a0a\u00a0Study\u00a0or\nthis\u00a0Agreement\u037e\u00a0(b)\u00a0from\u00a0and\u00a0against\u00a0any\u00a0Indemnified\u00a0Losses\u00a0arising\u00a0from\u00a0an\u00a0injury\u00a0to\u00a0a\u00a0Study\u00a0subject\u00a0caused\u00a0by\u00a0the\u00a0Study\u00a0Drug\u00a0or\nany\u00a0procedure\u00a0required\u00a0by\u00a0the\u00a0Protocol.\u00a0 The\u00a0completion\u00a0or\u00a0termination\u00a0of\u00a0a\u00a0Study\u00a0shall\u00a0not\u00a0affect\u00a0Adaptimmune\u2019s\u00a0obligation\u00a0to\nindemnify\u00a0with\u00a0respect\u00a0to\u00a0any\u00a0claim\u00a0or\u00a0suit\u00a0based\u00a0upon\u00a0the\u00a0aforementioned\u00a0Indemnified\u00a0Losses.\u00a0 Notwithstanding\u00a0the\u00a0foregoing,\nAdaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited\u00a0will\u00a0not\u00a0be\u00a0responsible\u00a0for\u00a0any\u00a0Indemnified\u00a0Losses\u00a0to\u00a0the\u00a0extent\u00a0that\u00a0they\u00a0arise\u00a0from\u00a0the\nnegligence,\u00a0intentional\u00a0misconduct,\u00a0or\u00a0malpractice\u00a0of\u00a0the\u00a0Indemnified\u00a0Parties\u00a0or\u00a0of\u00a0any\u00a0breach\u00a0of\u00a0the\u00a0terms\u00a0of\u00a0this\u00a0Agreement\u00a0by\u00a0any\nIndemnified\u00a0Party,\u00a0it\u00a0being\u00a0understood\u00a0that\u00a0the\u00a0proper\u00a0administration\u00a0of\u00a0the\u00a0Study\u00a0Drug\u00a0in\u00a0accordance\u00a0with\u00a0the\u00a0Protocol\u00a0(including\npermitted\u00a0deviations)\u00a0shall\u00a0not\u00a0constitute\u00a0negligence,\u00a0intentional\u00a0misconduct,\u00a0or\u00a0malpractice\u00a0for\u00a0the\u00a0purposes\u00a0of\u00a0this\u00a0Agreement.\u00a0For\nclarity,\u00a0a\u00a0request\u00a0for\u00a0indemnity\u00a0by\u00a0any\u00a0Indemnified\u00a0Party\u00a0under\u00a0this\u00a0Section\u00a09.1\u00a0may\u00a0only\u00a0be\u00a0made\u00a0against\u00a0one\u00a0of\u00a0Adaptimmune\u00a0or\nAdaptimmune\u00a0Limited.\n\u00a0\n9.2 \u00a0To\u00a0the\u00a0extent\u00a0authorized\u00a0by\u00a0the\u00a0constitution\u00a0and\u00a0laws\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas,\u00a0MD\u00a0Anderson,\u00a0agrees\u00a0indemnify,\u00a0and\u00a0hold\u00a0harmless\nAdaptimmune\u00a0and\u00a0Adaptimmune\u00a0Limited:\u00a0(a)\u00a0from\u00a0and\u00a0against\u00a0any\u00a0and\u00a0all\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n14\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "b5f68e89-4f15-4bd9-8bbc-3ba3bdb12f00": {"__data__": {"id_": "b5f68e89-4f15-4bd9-8bbc-3ba3bdb12f00", "embedding": null, "metadata": {"page_label": "15", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nIndemnified\u00a0Losses\u00a0resulting\u00a0from\u00a0any\u00a0negligent\u00a0or\u00a0intentional\u00a0act\u00a0or\u00a0omission\u00a0of\u00a0MD\u00a0Anderson\u00a0in\u00a0conducting\u00a0a\u00a0Study\u00a0hereunder\u037e\u00a0(b)\nfailure\u00a0of\u00a0MD\u00a0Anderson\u00a0or\u00a0Principal\u00a0Investigator\u00a0to\u00a0comply\u00a0with\u00a0Applicable\u00a0Laws\u00a0or\u00a0to\u00a0adhere\u00a0to\u00a0Protocol\u037e\u00a0or\u00a0(c)\u00a0any\u00a0use\u00a0by\u00a0MD\nAnderson\u00a0of\u00a0the\u00a0results\u00a0and\u00a0Data\u00a0of\u00a0the\u00a0Study\u00a0outside\u00a0of\u00a0the\u00a0performance\u00a0of\u00a0any\u00a0Study.\u00a0 The\u00a0completion\u00a0or\u00a0termination\u00a0of\u00a0a\u00a0Study\nshall\u00a0not\u00a0affect\u00a0MD\u00a0Anderson\u2019s\u00a0obligation\u00a0to\u00a0indemnify\u00a0with\u00a0respect\u00a0to\u00a0any\u00a0claim\u00a0or\u00a0suit\u00a0based\u00a0upon\u00a0the\u00a0aforementioned\u00a0Indemnified\nLosses.\u00a0Notwithstanding\u00a0the\u00a0foregoing,\u00a0MD\u00a0Anderson\u00a0will\u00a0not\u00a0be\u00a0responsible\u00a0for\u00a0any\u00a0Indemnified\u00a0Losses\u00a0to\u00a0the\u00a0extent\u00a0that\u00a0they\u00a0arise\nfrom\u00a0the\u00a0negligence,\u00a0intentional\u00a0misconduct,\u00a0or\u00a0malpractice\u00a0of\u00a0Adaptimmune\u00a0or\u00a0Adaptimmune\u00a0Limited\u00a0or\u00a0from\u00a0a\u00a0breach\u00a0of\u00a0Agreement\nby\u00a0Adaptimmune\u00a0or\u00a0Adaptimmune\u00a0Limited.\n\u00a0\n9.3 \u00a0Subject\u00a0to\u00a0the\u00a0statutory\u00a0duties\u00a0of\u00a0the\u00a0Texas\u00a0State\u00a0Attorney\u00a0General,\u00a0any\u00a0indemnified\u00a0Party\u00a0shall:\u00a0(a)\u00a0notify\u00a0the\u00a0indemnifying\u00a0Party\nin\u00a0writing\u00a0as\u00a0soon\u00a0as\u00a0is\u00a0reasonably\u00a0possible\u00a0after\u00a0receipt\u00a0of\u00a0notice\u00a0of\u00a0any\u00a0and\u00a0all\u00a0claims,\u00a0lawsuits,\u00a0and\u00a0demands,\u00a0or\u00a0any\u00a0action,\u00a0suit,\u00a0or\nproceeding\u00a0giving\u00a0rise\u00a0to\u00a0the\u00a0right\u00a0of\u00a0indemnification\u037e\u00a0(b)\u00a0permit\u00a0the\u00a0indemnifying\u00a0Party\u00a0to\u00a0retain\u00a0counsel\u00a0to\u00a0represent\u00a0the\u00a0named\nindemnified\u00a0Party\u037e\u00a0and\u00a0(c)\u00a0permit\u00a0the\u00a0indemnifying\u00a0Party\u00a0to\u00a0retain\u00a0control\u00a0of\u00a0 any\u00a0such\u00a0claims,\u00a0lawsuits,\u00a0and\u00a0demands,\u00a0including\u00a0the\nright\u00a0to\u00a0make\u00a0any\u00a0settlement,\u00a0except\u00a0that\u00a0the\u00a0indemnifying\u00a0Party\u00a0shall\u00a0not\u00a0make\u00a0any\u00a0settlement\u00a0or\u00a0take\u00a0any\u00a0other\u00a0action\u00a0which\u00a0would\nbe\u00a0deemed\u00a0to\u00a0confess\u00a0wrongdoing\u00a0by\u00a0any\u00a0of\u00a0the\u00a0indemnified\u00a0Parties\u00a0without\u00a0the\u00a0prior\u00a0written\u00a0consent\u00a0of\u00a0the\u00a0applicable\u00a0indemnified\nParty.\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n10. \u00a0Subject\u00a0Injury\u00a0Medical\u00a0Costs\n\u00a0\n10.1 \u00a0Adaptimmune\u00a0shall\u00a0assume\u00a0responsibility\u00a0for\u00a0reasonable\u00a0medical\u00a0expenses\u00a0incurred\u00a0by\u00a0a\u00a0Study\u00a0subject\u00a0for\u00a0reasonable\u00a0and\nnecessary\u00a0treatment\u00a0if\u00a0the\u00a0Study\u00a0subject\u00a0experiences\u00a0an\u00a0illness,\u00a0adverse\u00a0event\u00a0or\u00a0injury\u00a0that\u00a0is\u00a0a\u00a0result\u00a0of\u00a0the\u00a0Study\u00a0Drug\u00a0or\u00a0any\nprocedure\u00a0required\u00a0by\u00a0the\u00a0Protocol\u00a0that\u00a0the\u00a0subject\u00a0would\u00a0not\u00a0have\u00a0undergone\u00a0were\u00a0it\u00a0not\u00a0for\u00a0such\u00a0Study\u00a0subject\u2019s\u00a0participation\u00a0in\u00a0the\nStudy.\u00a0Adaptimmune\u00a0shall\u00a0not\u00a0be\u00a0responsible\u00a0for\u00a0expenses\u00a0to\u00a0the\u00a0extent\u00a0that\u00a0they\u00a0are\u00a0due\u00a0to\u00a0pre-existing\u00a0medical\u00a0conditions,\nunderlying\u00a0disease,\u00a0or\u00a0the\u00a0negligence\u00a0or\u00a0intentional\u00a0misconduct\u00a0or\u00a0due\u00a0to\u00a0breach\u00a0of\u00a0this\u00a0Agreement\u00a0by\u00a0MD\u00a0Anderson\u00a0or\u00a0Principal\nInvestigator.\u00a0Adaptimmune\u00a0shall\u00a0have\u00a0no\u00a0obligation\u00a0to\u00a0make\u00a0any\u00a0payments\u00a0for\u00a0any\u00a0Study\u00a0patient\u00a0that\u00a0is\u00a0not\u00a0eligible\u00a0for\u00a0inclusion\u00a0in\u00a0any\nProtocol.\u00a0Any\u00a0payments\u00a0for\u00a0such\u00a0medical\u00a0expenses\u00a0shall\u00a0be\u00a0subject\u00a0to\u00a0Adaptimmune\u00a0receiving\u00a0relevant\u00a0documentation\u00a0supporting\u00a0the\nclaim\u00a0for\u00a0such\u00a0medical\u00a0expenses.\n\u00a0\n11. \u00a0Insurance\n\u00a0\n11.1 \u00a0During\u00a0the\u00a0term\u00a0of\u00a0any\u00a0Study\u00a0Order\u00a0under\u00a0this\u00a0Agreement,\u00a0Adaptimmune\u00a0Limited\u00a0shall\u00a0maintain\u00a0in\u00a0full\u00a0force\u00a0and\u00a0effect\u00a0insurance\nfor\u00a0its\u00a0and\u00a0Adaptimmune\u2019s\u00a0liabilities\u00a0arising\u00a0from\u00a0the\u00a0Study\u00a0with\u00a0limits\u00a0of\u00a0not\u00a0less\u00a0than\u00a0$***\u00a0per\u00a0loss\u00a0and\u00a0$***\u00a0annual\u00a0aggregate.\nAdaptimmune\u00a0shall\u00a0provide\u00a0MD\u00a0Anderson\u00a0with\u00a0evidence\u00a0of\u00a0such\u00a0insurance\u00a0upon\u00a0request.\n\u00a0\n11.2 \u00a0MD\u00a0Anderson\u00a0is\u00a0self-insured\u00a0pursuant\u00a0to\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0Professional\u00a0Medical\u00a0Liability\u00a0Benefit\u00a0Plan\u00a0under\u00a0the\u00a0authority\nof\u00a0Chapter\u00a059,\u00a0Texas\u00a0Education\u00a0Code.\u00a0 MD\u00a0Anderson\u00a0has\u00a0and\u00a0will\u00a0maintain\u00a0in\u00a0force\u00a0during\u00a0the\u00a0term\u00a0of\u00a0this\u00a0Agreement\u00a0adequate\ninsurance\u00a0or\u00a0financial\u00a0resources\u00a0to\u00a0cover\u00a0its\u00a0obligations\u00a0pursuant\u00a0to\u00a0this\u00a0Agreement.\n\u00a0\n12. \u00a0Publications\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n15\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "0a6d4cba-a916-46ec-be92-ba675ef69b3a": {"__data__": {"id_": "0a6d4cba-a916-46ec-be92-ba675ef69b3a", "embedding": null, "metadata": {"page_label": "16", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n12.1 \u00a0Adaptimmune\u00a0recognizes\u00a0the\u00a0value\u00a0of\u00a0disseminating\u00a0research\u00a0results\u00a0and\u00a0accepts\u00a0that\u00a0MD\u00a0Anderson\u00a0will\u00a0have\u00a0the\u00a0right\u00a0to\u00a0publish\nor\u00a0otherwise\u00a0publicly\u00a0disclose\u00a0the\u00a0results\u00a0and\u00a0Data\u00a0of\u00a0any\u00a0Study,\u00a0subject\u00a0in\u00a0each\u00a0case\u00a0to\u00a0this\u00a0Article\u00a012.\n\u00a0\n12.2 \u00a0Clinical\u00a0Studies:\u00a0In\u00a0relation\u00a0to\u00a0any\u00a0Clinical\u00a0Study,\u00a0Adaptimmune\u00a0shall\u00a0have\u00a0the\u00a0***\u00a0 right\u00a0to\u00a0publish\u00a0or\u00a0publicly\u00a0disclose\u00a0any\u00a0Data\u00a0or\nresults\u00a0arising\u00a0from\u00a0such\u00a0Clinical\u00a0Study\u00a0including\u00a0where\u00a0such\u00a0publication\u00a0arises\u00a0from\u00a0the\u00a0submission\u00a0of\u00a0data\u00a0and/or\u00a0results\u00a0to\u00a0the\nregulatory\u00a0authorities.\u00a0Such\u00a0right\u00a0to\u00a0publish\u00a0shall\u00a0not\u00a0include\u00a0any\u00a0MD\u00a0Anderson\u00a0Records\u00a0or\u00a0any\u00a0public\u00a0health\u00a0information\u00a0protected\u00a0by\nHIPAA\u00a0or\u00a0where\u00a0any\u00a0publication\u00a0would\u00a0be\u00a0in\u00a0breach\u00a0of\u00a0the\u00a0Consent\u00a0and/or\u00a0Authorization.\u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\nshall\u00a0have\u00a0the\u00a0right\u00a0to\u00a0independently\u00a0publish\u00a0or\u00a0publicly\u00a0disclose,\u00a0either\u00a0in\u00a0writing\u00a0or\u00a0orally,\u00a0the\u00a0Data\u00a0and\u00a0results\u00a0of\u00a0the\u00a0Clinical\u00a0Study/ies\nafter\u00a0the\u00a0earlier\u00a0of\u00a0the\u00a0(i)\u00a0first\u00a0publication\u00a0(including\u00a0any\u00a0multi-site\u00a0publication)\u00a0of\u00a0such\u00a0Data\u00a0and/or\u00a0results\u037e\u00a0(ii)\u00a0twelve\u00a0(12)\u00a0months\nafter\u00a0completion\u00a0of\u00a0any\u00a0multi-site\u00a0study\u00a0encompassing\u00a0any\u00a0Study\u00a0or\u00a0if\u00a0none,\u00a0six\u00a0(6)\u00a0 months\u00a0after\u00a0completion\u00a0of\u00a0Study.\u00a0MD\u00a0Anderson\nshall,\u00a0at\u00a0least\u00a0thirty\u00a0(30)\u00a0days\u00a0ahead\u00a0of\u00a0any\u00a0proposed\u00a0date\u00a0for\u00a0submission,\u00a0furnish\u00a0Adaptimmune\u00a0with\u00a0a\u00a0written\u00a0copy\u00a0of\u00a0the\u00a0proposed\npublication\u00a0or\u00a0public\u00a0disclosure.\u00a0Within\u00a0such\u00a0thirty\u00a0(30)\u00a0day\u00a0period,\u00a0Adaptimmune\u00a0shall\u00a0review\u00a0such\u00a0proposed\u00a0publication\u00a0for\u00a0any\nConfidential\u00a0Information\u00a0of\u00a0Adaptimmune\u00a0provided\u00a0hereunder\u00a0or\u00a0patentable\u00a0Data.\u00a0Adaptimmune\u00a0may\u00a0also\u00a0comment\u00a0on\u00a0such\u00a0proposed\npublication\u00a0and\u00a0MD\u00a0Anderson\u00a0shall\u00a0consider\u00a0such\u00a0comments\u00a0in\u00a0good\u00a0faith\u00a0during\u00a0the\u00a0aforementioned\u00a0thirty\u00a0(30)\u00a0day\u00a0period.\u00a0MD\nAnderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0remove\u00a0Confidential\u00a0Information\u00a0of\u00a0Adaptimmune\u00a0provided\u00a0hereunder\u00a0that\u00a0has\u00a0been\u00a0so\nidentified\u00a0(other\u00a0than\u00a0Data\u00a0or\u00a0Study\u00a0results),\u00a0provided\u00a0that\u00a0Adaptimmune\u00a0agrees\u00a0to\u00a0act\u00a0in\u00a0good\u00a0faith\u00a0when\u00a0requiring\u00a0the\u00a0deletion\u00a0of\nAdaptimmune\u00a0Confidential\u00a0Information.\u00a0In\u00a0addition\u00a0Adaptimmune\u00a0may\u00a0request\u00a0delay\u00a0of\u00a0publication\u00a0for\u00a0a\u00a0period\u00a0not\u00a0to\u00a0exceed\u00a0***\n(***)\u00a0days\u00a0from\u00a0the\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0request\u00a0by\u00a0MD\u00a0Anderson,\u00a0to\u00a0permit\u00a0Adaptimmune\u00a0or\u00a0Adaptimmune\u00a0Limited\u00a0or\u00a0any\u00a0Joint\nResearch\u00a0Partner\u00a0to\u00a0file\u00a0patent\u00a0applications\u00a0or\u00a0to\u00a0otherwise\u00a0seek\u00a0to\u00a0protect\u00a0any\u00a0intellectual\u00a0property\u00a0rights\u00a0contained\u00a0in\u00a0such\npublication\u00a0or\u00a0disclosure.\u00a0Upon\u00a0such\u00a0request,\u00a0MD\u00a0Anderson\u00a0shall\u00a0delay\u00a0such\u00a0publication\u00a0until\u00a0the\u00a0relevant\u00a0protection\u00a0is\u00a0filed\u00a0up\u00a0to\u00a0a\nmaximum\u00a0of\u00a0***\u00a0(***)\u00a0days\u00a0from\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0request\u00a0for\u00a0delay\u00a0by\u00a0MD\u00a0Anderson.\n\u00a0\n12.3 \u00a0Pre-Clinical\u00a0Studies:\u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0have\u00a0the\u00a0***\u00a0right\u00a0to\u00a0publish\u00a0or\u00a0publicly\u00a0disclose,\u00a0either\u00a0in\nwriting\u00a0or\u00a0orally,\u00a0the\u00a0Data\u00a0and\u00a0results\u00a0of\u00a0the\u00a0Pre-Clinical\u00a0Study/ies\u00a0and\u00a0shall\u00a0have\u00a0the\u00a0sole\u00a0determination\u00a0of\u00a0the\u00a0authorship\u00a0and\ncontents,\u00a0provided\u00a0that\u00a0MD\u00a0Anderson\u00a0or\u00a0Principal\u00a0Investigator,\u00a0as\u00a0applicable,\u00a0shall\u00a0provide\u00a0Adaptimmune\u00a0with\u00a0a\u00a0copy\u00a0of\u00a0any\u00a0such\nproposed\u00a0publication\u00a0at\u00a0least\u00a0thirty\u00a0(30)\u00a0days\u00a0prior\u00a0to\u00a0submission\u00a0for\u00a0publication.\u00a0 Within\u00a0such\u00a0thirty\u00a0(30)\u00a0day\u00a0period,\u00a0Adaptimmune\u00a0shall\nreview\u00a0such\u00a0proposed\u00a0publication\u00a0for\u00a0any\u00a0Confidential\u00a0Information\u00a0of\u00a0Adaptimmune\u00a0provided\u00a0hereunder\u00a0or\u00a0patentable\u00a0Data.\nAdaptimmune\u00a0may\u00a0also\u00a0comment\u00a0on\u00a0such\u00a0proposed\u00a0publication\u00a0and\u00a0MD\u00a0Anderson\u00a0shall\u00a0consider\u00a0such\u00a0comments\u00a0in\u00a0good\u00a0faith\u00a0during\nthe\u00a0aforementioned\u00a0thirty\u00a0(30)\u00a0day\u00a0period.\u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0remove\u00a0Confidential\u00a0Information\u00a0of\nAdaptimmune\u00a0provided\u00a0hereunder\u00a0that\u00a0has\u00a0been\u00a0so\u00a0identified\u00a0(other\u00a0than\u00a0Data\u00a0or\u00a0Study\u00a0results),\u00a0provided\u00a0that\u00a0Adaptimmune\u00a0agrees\u00a0to\nact\u00a0in\u00a0good\u00a0faith\u00a0when\u00a0requiring\u00a0the\u00a0deletion\u00a0of\u00a0Adaptimmune\u00a0Confidential\u00a0Information.\u00a0In\u00a0addition\u00a0Adaptimmune\u00a0may\u00a0 request\u00a0delay\nof\u00a0publication\u00a0for\u00a0a\u00a0period\u00a0not\u00a0to\u00a0exceed\u00a0***\u00a0(***)\u00a0days\u00a0from\u00a0the\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0request\u00a0by\u00a0MD\u00a0Anderson,\u00a0which\u00a0delay\u00a0may\u00a0be\u00a0for\nany\u00a0reason\u00a0including\u00a0but\u00a0not\u00a0limited\u00a0to\u00a0permit\u00a0Adaptimmune\u00a0or\u00a0Adaptimmune\u00a0Limited\u00a0or\u00a0any\u00a0Joint\u00a0Research\u00a0Partner\u00a0to\u00a0file\u00a0patent\napplications\u00a0or\u00a0to\u00a0otherwise\u00a0seek\u00a0to\u00a0protect\u00a0any\u00a0intellectual\u00a0property\u00a0rights\u00a0contained\u00a0in\u00a0such\u00a0publication\u00a0or\u00a0disclosure.\u00a0Upon\u00a0such\nrequest,\u00a0MD\u00a0Anderson\u00a0shall\u00a0delay\u00a0such\u00a0publication\u00a0up\u00a0to\u00a0a\u00a0maximum\u00a0of\u00a0***\u00a0(***)\u00a0days\u00a0from\u00a0date\u00a0of\u00a0receipt\u00a0of\u00a0request\u00a0for\u00a0delay\u00a0by\nMD\u00a0Anderson\u00a0or,\u00a0if\u00a0earlier,\u00a0where\u00a0the\u00a0reason\u00a0is\u00a0for\u00a0the\u00a0filing\u00a0of\u00a0a\u00a0patent\u00a0application\u00a0or\u00a0other\u00a0intellectual\u00a0property\u00a0right..\n\u00a0\n12.4 \u00a0MD\u00a0Anderson\u00a0and/or\u00a0Principal\u00a0Investigator\u00a0shall\u00a0give\u00a0Adaptimmune\u00a0acknowledgment\u00a0for\u00a0its\u00a0sponsorship\u00a0of\u00a0a\u00a0Study\u00a0in\u00a0all\napplicable\u00a0Study\u00a0publications.\u00a0Authorship\u00a0and\u00a0acknowledgements\u00a0for\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n16\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "92aee01a-9370-4c77-bb24-4150711972cd": {"__data__": {"id_": "92aee01a-9370-4c77-bb24-4150711972cd", "embedding": null, "metadata": {"page_label": "17", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nscientific\u00a0publications\u00a0shall\u00a0be\u00a0consistent\u00a0with\u00a0the\u00a0principles\u00a0embodied\u00a0in\u00a0the\u00a0International\u00a0Committee\u00a0of\u00a0Medical\u00a0Journal\u00a0Editors\n(\u201cICMJE\u201d)\u00a0Uniform\u00a0Requirements\u00a0for\u00a0Manuscripts.\n\u00a0\n12.5 \u00a0The\u00a0\u201csponsor\u201d\u00a0of\u00a0a\u00a0Study,\u00a0within\u00a0the\u00a0regulatory\u00a0meaning\u00a0of\u00a0such\u00a0term,\u00a0 shall\u00a0register\u00a0the\u00a0Study\u00a0if\u00a0required\u00a0by,\u00a0and\u00a0in\u00a0accordance\nwith,\u00a0Section\u00a0801\u00a0of\u00a0the\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0Amendments\u00a0Act\u00a0of\u00a02007\u00a0on\u00a0 www.clinicaltrials.gov \u00a0and\u00a0on\u00a0any\u00a0other\u00a0database\nrequired\u00a0by\u00a0laws\u00a0or\u00a0regulations\u00a0in\u00a0accordance\u00a0with\u00a0applicable\u00a0standards\u00a0regarding\u00a0scope,\u00a0form\u00a0and\u00a0content\u00a0and\u00a0in\u00a0accordance\u00a0with\nICMJE\u00a0guidelines\u00a0such\u00a0that\u00a0the\u00a0Study\u00a0will\u00a0be\u00a0eligible\u00a0for\u00a0publication\u00a0in\u00a0those\u00a0publications.\n\u00a0\n12.6 \u00a0Nothing\u00a0in\u00a0this\u00a0Agreement\u00a0shall\u00a0prevent\u00a0Adaptimmune\u00a0or\u00a0any\u00a0of\u00a0its\u00a0Affiliates\u00a0from\u00a0complying\u00a0with\u00a0any\u00a0obligations\u00a0it\u00a0has\u00a0to\u00a0make\ndisclosure\u00a0under\u00a0Applicable\u00a0Laws\u00a0or\u00a0under\u00a0the\u00a0rules\u00a0of\u00a0any\u00a0security\u00a0exchange\u00a0or\u00a0listing\u00a0authority\u00a0applicable\u00a0to\u00a0it.\n\u00a0\n13. \u00a0Use\u00a0of\u00a0Name/Public\u00a0Statements/\u00a0Press\u00a0Release/\u00a0Disclosure\n\u00a0\n13.1 \u00a0Except\u00a0as\u00a0expressly\u00a0set\u00a0forth\u00a0in\u00a0this\u00a0Agreement,\u00a0each\u00a0Party\u00a0agrees\u00a0that\u00a0it\u00a0will\u00a0not\u00a0at\u00a0any\u00a0time\u00a0during\u00a0the\u00a0term\u00a0of\u00a0this\u00a0Agreement\nor\u00a0following\u00a0termination\u00a0of\u00a0this\u00a0Agreement\u00a0use\u00a0any\u00a0name\u00a0of\u00a0the\u00a0other\u00a0Party\u00a0or\u00a0any\u00a0other\u00a0names,\u00a0insignia,\u00a0mark(s),\u00a0symbol(s),\u00a0or\nlogotypes\u00a0associated\u00a0with\u00a0the\u00a0other\u00a0Party\u00a0or\u00a0any\u00a0variant\u00a0or\u00a0variants\u00a0thereof\u00a0in\u00a0any\u00a0advertising,\u00a0or\u00a0promotional\u00a0materials\u00a0without\u00a0the\nprior\u00a0written\u00a0consent\u00a0of\u00a0the\u00a0other\u00a0Party.\n\u00a0\n13.2 \u00a0Except\u00a0as\u00a0expressly\u00a0set\u00a0forth\u00a0in\u00a0this\u00a0Agreement,\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0by\u00a0law\u00a0or\u00a0regulation,\u00a0or\u00a0to\u00a0the\u00a0extent\u00a0necessary\u00a0for\u00a0MD\nAnderson\u00a0or\u00a0Adaptimmune\u00a0for\u00a0the\u00a0recruitment\u00a0of\u00a0subjects\u00a0to\u00a0any\u00a0Study\u00a0hereunder,\u00a0the\u00a0Parties\u00a0agree\u00a0to\u00a0make\u00a0no\u00a0public\u00a0presentations\nabout\u00a0any\u00a0Study\u00a0conducted\u00a0under\u00a0this\u00a0Agreement,\u00a0and\u00a0to\u00a0issue\u00a0no\u00a0news\u00a0releases\u00a0about\u00a0any\u00a0Study,\u00a0without\u00a0the\u00a0prior\u00a0written\u00a0consent\u00a0of\nthe\u00a0other\u00a0Party\u00a0(provided\u00a0that\u00a0this\u00a0statement\u00a0shall\u00a0not\u00a0apply\u00a0to\u00a0any\u00a0information\u00a0already\u00a0in\u00a0the\u00a0public\u00a0domain).\u00a0 Any\u00a0advertisements\ndirected\u00a0at\u00a0recruitment\u00a0of\u00a0study\u00a0subjects\u00a0for\u00a0a\u00a0Study\u00a0must\u00a0comply\u00a0with\u00a0all\u00a0Applicable\u00a0Laws,\u00a0rules\u00a0and\u00a0regulations\u00a0(including\u00a0the\u00a0need\nfor\u00a0IRB\u00a0review),\u00a0the\u00a0confidentiality\u00a0obligations\u00a0herein,\u00a0and\u00a0shall\u00a0not\u00a0include\u00a0the\u00a0trademarked\u00a0insignia,\u00a0symbol(s),\u00a0or\u00a0logotypes,\u00a0or\u00a0any\nvariant\u00a0or\u00a0variants\u00a0thereof,\u00a0of\u00a0the\u00a0other\u00a0Party.\u00a0Except\u00a0as\u00a0required\u00a0by\u00a0law\u00a0or\u00a0for\u00a0regulatory\u00a0purposes,\u00a0neither\u00a0Party\u00a0will\u00a0use\u00a0the\u00a0name\n(including\u00a0trademark\u00a0or\u00a0other\u00a0identifier)\u00a0of\u00a0the\u00a0other\u00a0Party\u00a0or\u00a0such\u00a0other\u00a0Party\u2019s\u00a0employee\u00a0or\u00a0staff\u00a0member\u00a0(except\u00a0in\u00a0an\nacknowledgment\u00a0of\u00a0sponsorship)\u00a0in\u00a0publications,\u00a0advertising,\u00a0press\u00a0releases\u00a0(except\u00a0as\u00a0permitted\u00a0below\u00a0in\u00a0Section\u00a013.3)\u00a0or\u00a0for\u00a0any\nother\u00a0commercial\u00a0purpose\u00a0without\u00a0the\u00a0written\u00a0approval\u00a0of\u00a0the\u00a0other\u00a0Party.\u00a0 Adaptimmune\u00a0will\u00a0not\u00a0state\u00a0or\u00a0imply\u00a0in\u00a0any\u00a0publication,\nadvertisement,\u00a0or\u00a0other\u00a0medium\u00a0that\u00a0any\u00a0product\u00a0or\u00a0service\u00a0bearing\u00a0any\u00a0of\u00a0Adaptimmune\u2019s\u00a0names\u00a0or\u00a0trademarks\u00a0and/or\nmanufactured,\u00a0sold\u00a0or\u00a0distributed\u00a0by\u00a0Adaptimmune\u00a0has\u00a0been\u00a0tested,\u00a0approved,\u00a0or\u00a0endorsed\u00a0by\u00a0MD\u00a0Anderson.\u00a0 Notwithstanding\u00a0any\nother\u00a0provision\u00a0of\u00a0this\u00a0Agreement,\u00a0each\u00a0Party\u00a0and\u00a0its\u00a0researchers\u00a0and\u00a0employees\u00a0will\u00a0have\u00a0the\u00a0right,\u00a0to\u00a0acknowledge\u00a0the\u00a0other\u00a0Party\nand\u00a0its\u00a0involvement\u00a0with\u00a0a\u00a0Study\u00a0in\u00a0scientific\u00a0or\u00a0academic\u00a0publications\u00a0describing\u00a0the\u00a0Study\u00a0or\u00a0reporting\u00a0the\u00a0results\u00a0of\u00a0the\u00a0Study.\n\u00a0\n13.3. \u00a0The\u00a0Parties\u00a0agree\u00a0to\u00a0have\u00a0a\u00a0joint\u00a0press\u00a0release\u00a0after\u00a0the\u00a0Effective\u00a0Date,\u00a0to\u00a0be\u00a0issued\u00a0at\u00a0a\u00a0time\u00a0mutually\u00a0agreed\u00a0by\u00a0the\u00a0Parties\u00a0but\nin\u00a0any\u00a0event\u00a0within\u00a030\u00a0days\u00a0of\u00a0Effective\u00a0Date.\u00a0The\u00a0text\u00a0of\u00a0such\u00a0press\u00a0release\u00a0is\u00a0set\u00a0out\u00a0at\u00a0Exhibit\u00a0IV\u00a0to\u00a0this\u00a0Agreement.\u00a0Any\u00a0press\nrelease\u00a0by\u00a0either\u00a0Party\u00a0relating\u00a0to\u00a0this\u00a0Agreement,\u00a0the\u00a0Alliance,\u00a0or\u00a0any\u00a0Study\u00a0shall\u00a0require\u00a0the\u00a0prior\u00a0review\u00a0and\u00a0written\u00a0approval\u00a0of\u00a0the\nother\u00a0Party,\u00a0which\u00a0approval\u00a0shall\u00a0not\u00a0be\u00a0unreasonably\u00a0withheld,\u00a0delayed\u00a0or\u00a0conditioned\u00a0unless\u00a0such\u00a0press\u00a0release\u00a0is\u00a0required\u00a0to\u00a0be\nissued\u00a0by\u00a0a\u00a0Party\u00a0to\u00a0the\u00a0extent\u00a0required\u00a0by\u00a0it\u00a0to\u00a0comply\u00a0with\u00a0its\u00a0legally\u00a0required\u00a0obligation\u00a0to\u00a0any\u00a0securities\u00a0exchange\u00a0on\u00a0which\u00a0it\u00a0is\nlisted.\n\u00a0\n13.4 \u00a0Either\u00a0Party\u00a0may\u00a0use\u00a0the\u00a0name\u00a0of\u00a0the\u00a0other\u00a0Party\u00a0in\u00a0any\u00a0document\u00a0filed\u00a0with\u00a0any\u00a0governmental\u00a0authority\u00a0or\u00a0regulatory\u00a0agency\napplicable\u00a0to\u00a0a\u00a0Study,\u00a0and\u00a0to\u00a0comply\u00a0with\u00a0any\u00a0applicable\u00a0legal\u00a0or\u00a0regulatory\u00a0requirements.\u00a0Further,\u00a0each\u00a0Party\u00a0is\u00a0permitted\u00a0to\u00a0disclose\nthe\u00a0other\u00a0Party\u2019s\u00a0name,\u00a0the\u00a0title\u00a0of\n\u00a0\n17\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "e80d898f-3614-4109-b8d8-6567ba868d2a": {"__data__": {"id_": "e80d898f-3614-4109-b8d8-6567ba868d2a", "embedding": null, "metadata": {"page_label": "18", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nthe\u00a0Study,\u00a0the\u00a0name\u00a0of\u00a0the\u00a0Principal\u00a0Investigator,\u00a0and\u00a0an\u00a0overall\u00a0Study\u00a0budget\u00a0amount\u00a0projected\u00a0to\u00a0be\u00a0paid/actual\u00a0total\u00a0amount\u00a0paid\u00a0for\nconducting\u00a0the\u00a0Study,\u00a0provided\u00a0that\u00a0this\u00a0information\u00a0is\u00a0presented\u00a0together\u00a0as\u00a0part\u00a0of\u00a0mandatory\u00a0disclosure\u00a0in\u00a0accordance\u00a0with\u00a0and\u00a0to\nthe\u00a0extent\u00a0required\u00a0Applicable\u00a0Law.\n\u00a0\n14. \u00a0Principal\u00a0Investigator\n\u00a0\n14.1 \u00a0If\u00a0a\u00a0designated\u00a0Principal\u00a0Investigator\u00a0is\u00a0terminated\u00a0from\u00a0a\u00a0Study,\u00a0or\u00a0in\u00a0the\u00a0event\u00a0of\u00a0the\u00a0death\u00a0or\u00a0other\u00a0non-availability\u00a0of\u00a0the\nPrincipal\u00a0Investigator,\u00a0MD\u00a0Anderson\u00a0shall\u00a0use\u00a0reasonable\u00a0efforts\u00a0to\u00a0designate\u00a0a\u00a0duly\u00a0qualified\u00a0person\u00a0to\u00a0act\u00a0as\u00a0new\u00a0Principal\nInvestigator,\u00a0subject\u00a0to\u00a0the\u00a0reasonable\u00a0agreement\u00a0of\u00a0Adaptimmune.\u00a0If\u00a0the\u00a0Parties\u00a0are\u00a0unable\u00a0to\u00a0agree\u00a0on\u00a0a\u00a0new\u00a0Principal\u00a0Investigator\nor\u00a0if\u00a0the\u00a0new\u00a0Principal\u00a0Investigator\u00a0is\u00a0unwilling\u00a0to\u00a0agree\u00a0to\u00a0the\u00a0terms\u00a0and\u00a0conditions\u00a0of\u00a0this\u00a0Agreement\u00a0and\u00a0the\u00a0relevant\u00a0Study\u00a0Order,\neither\u00a0Party\u00a0shall\u00a0be\u00a0entitled\u00a0to\u00a0terminate\u00a0the\u00a0respective\u00a0Study\u00a0Order\u00a0in\u00a0accordance\u00a0with\u00a0Section\u00a08.5.\n\u00a0\n15. \u00a0General\u00a0Provisions\n\u00a0\n15.1 \u00a0Warranties.\u00a0 EXCEPT\u00a0AS\u00a0EXPRESSLY\u00a0PROVIDED\u00a0HEREIN,\u00a0NEITHER\u00a0PARTY\u00a0MAKES\u00a0ANY\u00a0WARRANTIES,\u00a0EXPRESS\nOR\u00a0IMPLIED,\u00a0CONCERNING\u00a0THE\u00a0RESULTS\u00a0OF\u00a0ANY\u00a0STUDY\u00a0OR\u00a0THE\u00a0STUDY\u00a0DRUG,\u00a0OR\u00a0OF\u00a0THE\nMERCHANTABILITY,\u00a0OR\u00a0FITNESS\u00a0FOR\u00a0A\u00a0PARTICULAR\u00a0PURPOSE\u00a0OF\u00a0SUCH\u00a0DATA,\u00a0RESULTS\u00a0OR\u00a0STUDY\u00a0DRUG.\nNEITHER\u00a0PARTY\u00a0SHALL\u00a0BE\u00a0LIABLE\u00a0FOR\u00a0ANY\u00a0INDIRECT\u00a0OR\u00a0CONSEQUENTIAL\u00a0DAMAGES\u00a0SUFFERED\u00a0BY\u00a0THE\nOTHER\u00a0PARTY\u00a0AS\u00a0A\u00a0RESULT\u00a0OF\u00a0PERFORMANCE\u00a0OF\u00a0ANY\u00a0STUDY\u00a0UNDER\u00a0THIS\u00a0AGREEMENT.\u00a0 ADAPTIMMUNE\nREPRESENTS\u00a0AND\u00a0WARRANTS\u00a0THAT\u00a0EACH\u00a0STUDY\u00a0DRUG\u00a0HEREUNDER\u00a0SHALL\u00a0HAVE\u00a0BEEN\u00a0MANUFACTURED\u00a0IN\nACCORDANCE\u00a0WITH\u00a0CURRENT\u00a0GOOD\u00a0MANUFACTURING\u00a0PRACTICES\u00a0IN\u00a0THE\u00a0UNITED\u00a0STATES\u00a0AND\u00a0THAT\u00a0AS\u00a0AT\nTHE\u00a0EFFECTIVE\u00a0DATE\u00a0OF\u00a0THIS\u00a0AGREEMENT\u00a0IT\u00a0HAS\u00a0NOT\u00a0RECEIVED\u00a0ANY\u00a0CLAIM\u00a0THAT\u00a0USE\u00a0OF\u00a0ANY\u00a0STUDY\nDRUG\u00a0IN\u00a0THE\u00a0PERFORMANCE\u00a0OF\u00a0A\u00a0STUDY\u00a0WOULD\u00a0INFRINGE\u00a0THE\u00a0RIGHTS\u00a0OF\u00a0ANY\u00a0THIRD\u00a0PARTY.\nADAPTIMMUNE\u00a0REPRESENTS\u00a0THAT\u00a0AS\u00a0AT\u00a0THE\u00a0EFFECTIVE\u00a0DATE\u00a0TO\u00a0ITS\u00a0KNOWLEDGE\u00a0THERE\u00a0ARE\u00a0NO\u00a0KNOWN\nDEFECTS\u00a0IN\u00a0ANY\u00a0STUDY\u00a0DRUG\u037e\u00a0 ADAPTIMMUNE\u00a0UNDERSTANDS\u00a0AND\u00a0ACKNOWLEDGES\u00a0THAT\u00a0THE\nDEVELOPMENT\u00a0AND\u00a0DISSEMINATION\u00a0OF\u00a0SCIENTIFIC\u00a0KNOWLEDGE\u00a0IS\u00a0A\u00a0FUNDAMENTAL\u00a0COMPONENT\u00a0OF\u00a0MD\nANDERSON\u2019S\u00a0MISSION,\u00a0AND\u00a0THAT\u00a0MD\u00a0ANDERSON\u00a0MAKES\u00a0NO\u00a0REPRESENTATIONS,\u00a0WARRANTIES,\u00a0OR\nGUARANTEES\u00a0WITH\u00a0RESPECT\u00a0TO\u00a0ANY\u00a0SPECIFIC\u00a0RESULTS\u00a0OF\u00a0THE\u00a0STUDIES.\n\u00a0\n15.2 \u00a0Assignment. \u00a0This\u00a0Agreement\u00a0and/or\u00a0any\u00a0Study\u00a0Order\u00a0may\u00a0not\u00a0be\u00a0assigned\u00a0by\u00a0either\u00a0Party\u00a0except\u00a0as\u00a0agreed\u00a0upon\u00a0in\u00a0writing\u00a0by\nthe\u00a0other\u00a0Party.\u00a0Any\u00a0assignment\u00a0or\u00a0attempt\u00a0to\u00a0assign,\u00a0or\u00a0any\u00a0delegation\u00a0or\u00a0attempt\u00a0to\u00a0delegate,\u00a0not\u00a0in\u00a0accordance\u00a0with\u00a0this\u00a0Section\nshall\u00a0be\u00a0void\u00a0and\u00a0without\u00a0effect.\u00a0For\u00a0any\u00a0permitted\u00a0assignment,\u00a0the\u00a0rights\u00a0and\u00a0obligations\u00a0of\u00a0the\u00a0Parties\u00a0hereunder\u00a0will\u00a0inure\u00a0to\u00a0the\nbenefit\u00a0of\u00a0and\u00a0be\u00a0binding\u00a0upon\u00a0their\u00a0permitted\u00a0successors\u00a0and\u00a0assigns.\n\u00a0\n15.3 \u00a0Independent\u00a0Contractors.\u00a0 MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0shall\u00a0be\u00a0independent\u00a0parties\u00a0and\u00a0nothing\u00a0contained\u00a0in\u00a0this\u00a0Agreement\nshall\u00a0be\u00a0construed\u00a0or\u00a0implied\u00a0to\u00a0create\u00a0an\u00a0agency\u00a0or\u00a0partnership.\u00a0 No\u00a0Party\u00a0shall\u00a0have\u00a0the\u00a0authority\u00a0to\u00a0agree\u00a0to\u00a0or\u00a0incur\u00a0expenses\u00a0on\nbehalf\u00a0of\u00a0another\u00a0except\u00a0as\u00a0may\u00a0be\u00a0expressly\u00a0authorized\u00a0by\u00a0this\u00a0Agreement\u00a0or\u00a0a\u00a0Study\u00a0Order.\n\u00a0\n15.4 \u00a0Notices.\u00a0Any\u00a0notice\u00a0or\u00a0communication\u00a0required\u00a0or\u00a0permitted\u00a0to\u00a0be\u00a0given\u00a0or\u00a0made\u00a0under\u00a0this\u00a0Agreement\u00a0by\u00a0one\u00a0of\u00a0the\u00a0Parties\nhereto\u00a0to\u00a0the\u00a0other\u00a0shall\u00a0be\u00a0in\u00a0writing\u00a0and\u00a0shall\u00a0be\u00a0deemed\u00a0to\u00a0have\u00a0been\u00a0sufficiently\u00a0given\u00a0or\u00a0made\u00a0for\u00a0all\u00a0purposes\u00a0on\u00a0the\u00a0date\u00a0of\nmailing\u00a0by\u00a0certified\u00a0mail,\u00a0postage\u00a0prepaid,\u00a0overnight\u00a0courier\u00a0service,\u00a0and/or\u00a0fax\u00a0to\u00a0be\u00a0followed\u00a0by\u00a0mailed\u00a0original\u00a0addressed\u00a0to\u00a0such\nother\u00a0Party\u00a0at\u00a0its\u00a0respective\u00a0address\u00a0as\u00a0referenced\u00a0in\u00a0the\u00a0Study\u00a0Order.\n\u00a0\n18\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "75dd04ae-8144-4945-ab81-7a10648599d2": {"__data__": {"id_": "75dd04ae-8144-4945-ab81-7a10648599d2", "embedding": null, "metadata": {"page_label": "19", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n15.5 \u00a0Severability. \u00a0If\u00a0any\u00a0one\u00a0or\u00a0more\u00a0of\u00a0the\u00a0provisions\u00a0of\u00a0this\u00a0Agreement\u00a0shall\u00a0be\u00a0held\u00a0to\u00a0be\u00a0invalid,\u00a0illegal\u00a0or\u00a0unenforceable,\u00a0the\u00a0validity,\nlegality\u00a0or\u00a0enforceability\u00a0of\u00a0the\u00a0remaining\u00a0provisions\u00a0of\u00a0this\u00a0Agreement\u00a0shall\u00a0not\u00a0in\u00a0any\u00a0way\u00a0be\u00a0affected\u00a0or\u00a0impaired\u00a0thereby.\n\u00a0\n15.6 \u00a0Entirety.\u00a0This\u00a0Agreement\u00a0(including\u00a0its\u00a0Exhibits\u00a0and\u00a0Appendices)\u00a0represents\u00a0the\u00a0entire\u00a0agreement\u00a0of\u00a0the\u00a0Parties\u00a0with\u00a0respect\u00a0to\nthe\u00a0subject\u00a0matter\u00a0hereof\u00a0and\u00a0it\u00a0expressly\u00a0supersedes\u00a0all\u00a0previous\u00a0written\u00a0and\u00a0oral\u00a0communications\u00a0between\u00a0the\u00a0Parties.\u00a0 No\namendment,\u00a0alteration,\u00a0or\u00a0modification\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0any\u00a0Study\u00a0Orders\u00a0attached\u00a0hereto\u00a0shall\u00a0be\u00a0valid\u00a0unless\u00a0executed\u00a0in\nwriting\u00a0by\u00a0authorized\u00a0signatories\u00a0of\u00a0all\u00a0Parties.\n\u00a0\n15.7 \u00a0Waiver.\u00a0The\u00a0failure\u00a0of\u00a0any\u00a0Party\u00a0hereto\u00a0to\u00a0insist\u00a0upon\u00a0strict\u00a0performance\u00a0of\u00a0any\u00a0provision\u00a0of\u00a0this\u00a0Agreement\u00a0or\u00a0to\u00a0exercise\u00a0any\nright\u00a0hereunder\u00a0will\u00a0not\u00a0constitute\u00a0a\u00a0waiver\u00a0of\u00a0that\u00a0provision\u00a0or\u00a0right.\n\u00a0\n15.8 \u00a0Force\u00a0Majeure.\u00a0 In\u00a0the\u00a0event\u00a0that\u00a0performance\u00a0of\u00a0the\u00a0obligations\u00a0of\u00a0a\u00a0Party\u00a0hereunder\u00a0are\u00a0prevented\u00a0by\u00a0events\u00a0beyond\u00a0their\nreasonable\u00a0control,\u00a0including,\u00a0but\u00a0not\u00a0limited\u00a0to,\u00a0acts\u00a0of\u00a0God,\u00a0regulations\u00a0or\u00a0acts\u00a0of\u00a0any\u00a0governmental\u00a0authority,\u00a0war,\u00a0civil\u00a0commotion,\nstrikes,\u00a0or\u00a0other\u00a0labor\u00a0disturbances,\u00a0epidemics,\u00a0fire,\u00a0earthquakes,\u00a0storms\u00a0or\u00a0other\u00a0catastrophes\u00a0of\u00a0a\u00a0similar\u00a0nature\u00a0(\u201cForce\u00a0Majeure\u201d),\nthe\u00a0affected\u00a0Party\u00a0 will\u00a0promptly\u00a0notify\u00a0the\u00a0other\u00a0Party\u00a0of\u00a0such\u00a0event\u00a0using\u00a0the\u00a0procedure\u00a0defined\u00a0herein,\u00a0and\u00a0the\u00a0Parties\u00a0shall\u00a0be\nrelieved\u00a0of\u00a0their\u00a0respective\u00a0obligations\u00a0hereunder\u00a0to\u00a0the\u00a0extent\u00a0that\u00a0the\u00a0performance\u00a0of\u00a0such\u00a0obligations\u00a0is\u00a0actually\u00a0prevented\u00a0thereby.\nDuring\u00a0the\u00a0existence\u00a0of\u00a0any\u00a0such\u00a0condition,\u00a0the\u00a0affected\u00a0Party\u00a0shall,\u00a0nevertheless,\u00a0use\u00a0its\u00a0best\u00a0efforts\u00a0to\u00a0remove\u00a0the\u00a0cause\u00a0thereof\u00a0and\nresume\u00a0performance\u00a0of\u00a0its\u00a0obligations\u00a0hereunder.\u00a0 The\u00a0period\u00a0of\u00a0performance\u00a0shall\u00a0be\u00a0extended\u00a0for\u00a0the\u00a0Party\u00a0who\u00a0is\u00a0unable\u00a0to\u00a0perform\ndue\u00a0to\u00a0Force\u00a0Majeure\u00a0reasons\u00a0by\u00a0a\u00a0period\u00a0of\u00a0time\u00a0equal\u00a0to\u00a0the\u00a0length\u00a0of\u00a0the\u00a0period\u00a0during\u00a0which\u00a0the\u00a0Force\u00a0Majeure\u00a0reason\u00a0exists\u00a0or\nfor\u00a0a\u00a0longer\u00a0period\u00a0if\u00a0required\u00a0to\u00a0meet\u00a0the\u00a0requirements\u00a0of\u00a0the\u00a0Study\u00a0Protocol.\n\u00a0\n15.9 \u00a0Counterparts.\u00a0 It\u00a0is\u00a0understood\u00a0that\u00a0this\u00a0Agreement\u00a0may\u00a0be\u00a0executed\u00a0in\u00a0one\u00a0or\u00a0more\u00a0counterpart\u00a0copies,\u00a0each\u00a0of\u00a0equal\u00a0dignity,\nwhich\u00a0when\u00a0joined,\u00a0shall\u00a0together\u00a0constitute\u00a0one\u00a0Agreement.\u00a0 In\u00a0the\u00a0event\u00a0of\u00a0execution\u00a0by\u00a0exchange\u00a0of\u00a0facsimile\u00a0or\u00a0electronic\u00a0signed\ncopies,\u00a0the\u00a0Parties\u00a0agree\u00a0that,\u00a0upon\u00a0being\u00a0signed\u00a0by\u00a0both\u00a0Parties,\u00a0this\u00a0Agreement\u00a0shall\u00a0become\u00a0effective\u00a0and\u00a0binding\u00a0and\u00a0that\u00a0facsimile\nor\u00a0.pdf\u00a0signed\u00a0copies\u00a0will\u00a0constitute\u00a0evidence\u00a0of\u00a0this\u00a0Agreement.\n\u00a0\n15.10\u00a0Export\u00a0Control.\u00a0Notwithstanding\u00a0any\u00a0other\u00a0provision\u00a0of\u00a0this\u00a0Agreement,\u00a0it\u00a0is\u00a0understood\u00a0that\u00a0the\u00a0Parties\u00a0are\u00a0subject\u00a0to,\u00a0and\u00a0shall\ncomply\u00a0with,\u00a0applicable\u00a0United\u00a0States\u00a0laws,\u00a0regulations,\u00a0and\u00a0governmental\u00a0requirements\u00a0and\u00a0restrictions\u00a0controlling\u00a0the\u00a0export\u00a0of\ntechnology,\u00a0technical\u00a0data,\u00a0computer\u00a0software,\u00a0laboratory\u00a0prototypes,\u00a0and\u00a0other\u00a0commodities,\u00a0information\u00a0and\u00a0items\u00a0(individually\u00a0and\ncollectively,\u00a0\u201cTechnology\u00a0and\u00a0Items\u201d),\u00a0including\u00a0without\u00a0limitation,\u00a0the\u00a0Arms\u00a0Export\u00a0Control\u00a0Act,\u00a0the\u00a0Export\u00a0Administration\u00a0Act\u00a0of\n1979,\u00a0relevant\u00a0executive\u00a0orders,\u00a0and\u00a0United\u00a0States\u00a0Treasury\u00a0Department\u00a0embargo\u00a0and\u00a0sanctions\u00a0regulations,\u00a0all\u00a0as\u00a0amended\u00a0from\u00a0time\nto\u00a0time\u00a0(\u201cRestrictions\u201d)\u00a0and\u00a0that\u00a0the\u00a0Parties\u2019\u00a0obligations\u00a0hereunder\u00a0are\u00a0contingent\u00a0on\u00a0compliance\u00a0with\u00a0applicable\u00a0Restrictions.\n\u00a0\n15.11 \u00a0Choice\u00a0of\u00a0Law.\u00a0 Any\u00a0disputes\u00a0or\u00a0claims\u00a0arising\u00a0under\u00a0this\u00a0Agreement\u00a0shall\u00a0be\u00a0governed\u00a0by\u00a0the\u00a0laws\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas.\u00a0 MD\nAnderson\u00a0is\u00a0an\u00a0agency\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas\u00a0and\u00a0under\u00a0the\u00a0constitution\u00a0and\u00a0the\u00a0laws\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas\u00a0possesses\u00a0certain\u00a0rights\nand\u00a0privileges,\u00a0is\u00a0subject\u00a0to\u00a0certain\u00a0limitations\u00a0and\u00a0restrictions,\u00a0and\u00a0only\u00a0has\u00a0such\u00a0authority\u00a0as\u00a0is\u00a0granted\u00a0to\u00a0it\u00a0under\u00a0the\u00a0constitution\u00a0and\nlaws\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas.\u00a0 Notwithstanding\u00a0any\u00a0provision\u00a0hereof,\u00a0nothing\u00a0in\u00a0this\u00a0Agreement\u00a0is\u00a0intended\u00a0to\u00a0be,\u00a0nor\u00a0will\u00a0it\u00a0be\u00a0construed\nto\u00a0be,\u00a0a\u00a0waiver\u00a0of\u00a0the\u00a0sovereign\u00a0immunity\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas\u00a0or\u00a0a\u00a0prospective\u00a0waiver\u00a0or\u00a0restriction\u00a0of\u00a0any\u00a0of\u00a0the\u00a0rights,\u00a0remedies,\nclaims,\u00a0and\u00a0privileges\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas.\u00a0 Moreover,\u00a0notwithstanding\u00a0the\u00a0generality\u00a0or\u00a0specificity\u00a0of\u00a0any\u00a0provision\u00a0hereof,\u00a0the\nprovisions\u00a0of\u00a0this\u00a0Agreement\u00a0as\u00a0they\u00a0pertain\u00a0to\u00a0MD\u00a0Anderson\u00a0are\u00a0enforceable\u00a0only\u00a0to\u00a0the\u00a0extent\u00a0authorized\u00a0by\u00a0the\u00a0constitution\u00a0and\nlaws\u00a0of\u00a0the\u00a0State\u00a0of\u00a0Texas\u037e\u00a0accordingly,\u00a0to\u00a0the\u00a0extent\u00a0any\u00a0provision\u00a0hereof\u00a0conflicts\u00a0with\u00a0the\u00a0constitution\u00a0or\u00a0laws\n\u00a0\n19\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "25575e38-1a2a-4fe2-a406-18d163da8cbf": {"__data__": {"id_": "25575e38-1a2a-4fe2-a406-18d163da8cbf", "embedding": null, "metadata": {"page_label": "20", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nof\u00a0the\u00a0State\u00a0of\u00a0Texas\u00a0or\u00a0exceeds\u00a0the\u00a0right,\u00a0power\u00a0or\u00a0authority\u00a0of\u00a0MD\u00a0Anderson\u00a0to\u00a0agree\u00a0to\u00a0such\u00a0provision,\u00a0then\u00a0that\u00a0provision\u00a0will\u00a0not\nbe\u00a0enforceable\u00a0against\u00a0MD\u00a0Anderson\u00a0or\u00a0the\u00a0State\u00a0of\u00a0Texas.\n\u00a0\n\u00a0\n[Signatures\u00a0of\u00a0Following\u00a0Page]\n\u00a0\n20\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "ac0e77dd-aecb-4623-ada7-46329e33d098": {"__data__": {"id_": "ac0e77dd-aecb-4623-ada7-46329e33d098", "embedding": null, "metadata": {"page_label": "21", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nIn\u00a0witness\u00a0whereof ,\u00a0the\u00a0Parties\u00a0hereto\u00a0have\u00a0caused\u00a0this\u00a0Agreement\u00a0to\u00a0be\u00a0executed\u00a0by\u00a0their\u00a0duly\u00a0authorized\u00a0representatives\u00a0to\u00a0be\neffective\u00a0as\u00a0of\u00a0the\u00a0Effective\u00a0Date.\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nThe\u00a0University\u00a0of\u00a0Texas\u00a0M.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center\n\u00a0\u00a0\n\u00a0Adaptimmune\u00a0LLC\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nDate:\n\u00a09/23/16\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0 Date:\n\u00a023\u00a0September\u00a02016\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n/s/\u00a0Chris\u00a0McKee\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0/s/\u00a0Helen\u00a0Tayton-Martin\n\u00a0\nName\u00a0Chris\u00a0 McKee,\u00a0M.H.A\n\u00a0\u00a0\n\u00a0Name\u00a0Helen\u00a0 Tayton-Martin\n\u00a0\nTitle:\u00a0VP.\u00a0Business\u00a0Operations\n\u00a0\u00a0\n\u00a0Title:\u00a0Authorized\u00a0 Signatory\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nAdaptimmune\u00a0Limited\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nDate:\n\u00a023\u00a0September\u00a02016\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n/s/\u00a0James\u00a0Noble\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nName\u00a0James\u00a0 Noble\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nTitle:\u00a0CEO\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n21\n\u00a0rd\nrd\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5548556f-24b4-4ad1-8fc3-e373f3a36ed0": {"__data__": {"id_": "5548556f-24b4-4ad1-8fc3-e373f3a36ed0", "embedding": null, "metadata": {"page_label": "22", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nExhibit\u00a0I\n\u00a0\n\u00a0\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "e5c819ac-f551-485a-b7b3-582d8d2bb2e1": {"__data__": {"id_": "e5c819ac-f551-485a-b7b3-582d8d2bb2e1", "embedding": null, "metadata": {"page_label": "23", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "22\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "44b70046-78b9-4dbb-9a5d-84485ff02c5a": {"__data__": {"id_": "44b70046-78b9-4dbb-9a5d-84485ff02c5a", "embedding": null, "metadata": {"page_label": "24", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5766bedc-6c38-4888-b641-06eb3524fe7e": {"__data__": {"id_": "5766bedc-6c38-4888-b641-06eb3524fe7e", "embedding": null, "metadata": {"page_label": "25", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n23\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5aa048f3-a174-4b6d-a46e-da4745e805b7": {"__data__": {"id_": "5aa048f3-a174-4b6d-a46e-da4745e805b7", "embedding": null, "metadata": {"page_label": "26", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n***\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\u00a0.\n\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n24\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "1d0896bd-c3ab-4449-a787-2d76f0004005": {"__data__": {"id_": "1d0896bd-c3ab-4449-a787-2d76f0004005", "embedding": null, "metadata": {"page_label": "27", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "adeb6c37-5bf6-472b-85ce-c9b45c7265b1": {"__data__": {"id_": "adeb6c37-5bf6-472b-85ce-c9b45c7265b1", "embedding": null, "metadata": {"page_label": "28", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n***:\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n***\n\u00a0***\n***\n***\n\u00a0***\n***\n\u00a0***\n***\n***\n\u00a0***\n***\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\n***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n***\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\n***\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\n***\n***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n***\n***:\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\n***:\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n***\n\u00a0***\n***\n\u00a0***\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0\n***\n***\n***\n\u00a0***\n\u00a0***\n\u00a0\n***\n***\n\u00a0***\n\u00a0\u00a0\n***\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0\n***:\n\u00a0\u00a0\n\u00a0 ***\n\u00a0\n\u00a0\n\u00a0\n***\u00a0.\n\u00a0\n***\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "a06e998f-a370-422e-8152-be9ff6c637df": {"__data__": {"id_": "a06e998f-a370-422e-8152-be9ff6c637df", "embedding": null, "metadata": {"page_label": "29", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n.\n\u00a0\n***\n\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n25\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "53fc1254-e5a2-4d2f-a45a-063280e62dab": {"__data__": {"id_": "53fc1254-e5a2-4d2f-a45a-063280e62dab", "embedding": null, "metadata": {"page_label": "30", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n:\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00a0\n\u00b7\u00a0***\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n:\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n \n26\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "8e482821-d11b-4ca9-b518-7ea18703ccab": {"__data__": {"id_": "8e482821-d11b-4ca9-b518-7ea18703ccab", "embedding": null, "metadata": {"page_label": "31", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": " \n***\n \n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n***\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n***\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n27\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "0a468ee2-0123-4a56-ad03-3d1ce6cfa897": {"__data__": {"id_": "0a468ee2-0123-4a56-ad03-3d1ce6cfa897", "embedding": null, "metadata": {"page_label": "32", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n:\n\u00a0\n\u00b7\u00a0***\n\u00a0\n.\n\u00a0\no\u00a0***\n\u00a0\n.\n\u00a0\no\u00a0***\n\u00a0\n.\n\u00a0\n\u00b7\u00a0***\n\u00a0\n.\n\u00a0\no\u00a0***\n\u00a0\n.\n\u00a0\no\u00a0***\n\u00a0\n.\n\u00a0\no\u00a0***\n\u00a0\n\u00a0\n.\n\u00a0\n\u00b7\u00a0***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n\u00b7\u00a0***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n28\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "a5bae146-bacc-4ad8-af15-05bcd0f5d996": {"__data__": {"id_": "a5bae146-bacc-4ad8-af15-05bcd0f5d996", "embedding": null, "metadata": {"page_label": "33", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n***\n***\n\u00a0\n\u00a0\n:\n\u00a0\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00b7\u00a0***\n\u00a0\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n***\n***\n\u00a0\n.\n\u00a0\n***\n\u00a0\n1.\u00a0***\n2.\u00a0***\n\u00a0\n.\n\u00a0\n3.\u00a0***\n4.\u00a0***\n5.\u00a0***\n.\n\u00a0\n6.\u00a0***\n\u00a0\n7.\u00a0***\n\u00a0\n***\n\u00a0\n.\n\u00a0\n***\n***\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n29\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5b5af5f4-b103-4b9e-b3b2-de8c71504cb8": {"__data__": {"id_": "5b5af5f4-b103-4b9e-b3b2-de8c71504cb8", "embedding": null, "metadata": {"page_label": "34", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n.\n\u00a0\n***\n\u00a0\n\u00a0\n.\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "e93b6a64-04e0-4ee7-b4e2-219b8ee8a5e0": {"__data__": {"id_": "e93b6a64-04e0-4ee7-b4e2-219b8ee8a5e0", "embedding": null, "metadata": {"page_label": "35", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "30\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "23abea33-5ed6-4f8a-9894-0132e70614c1": {"__data__": {"id_": "23abea33-5ed6-4f8a-9894-0132e70614c1", "embedding": null, "metadata": {"page_label": "36", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***:\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n31\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "0ea005fe-b510-4a38-bdbb-383b6a8f63ce": {"__data__": {"id_": "0ea005fe-b510-4a38-bdbb-383b6a8f63ce", "embedding": null, "metadata": {"page_label": "37", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\u00a0\n***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\n***:\n\u00a0\n***:\u00a0***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n32\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "51e8e912-e942-471f-b12c-fd1acf520ee0": {"__data__": {"id_": "51e8e912-e942-471f-b12c-fd1acf520ee0", "embedding": null, "metadata": {"page_label": "38", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n33\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "629aa127-89d5-477e-b880-d272f3b0f0f2": {"__data__": {"id_": "629aa127-89d5-477e-b880-d272f3b0f0f2", "embedding": null, "metadata": {"page_label": "39", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***:\n\u00a0\n***:\u00a0***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n34\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "15ce442f-424e-4600-aa79-50e802f1143d": {"__data__": {"id_": "15ce442f-424e-4600-aa79-50e802f1143d", "embedding": null, "metadata": {"page_label": "40", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n35\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "25d95052-14f3-4a0c-a1fe-36ea2a4d4ed9": {"__data__": {"id_": "25d95052-14f3-4a0c-a1fe-36ea2a4d4ed9", "embedding": null, "metadata": {"page_label": "41", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***:\n\u00a0\n***:***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n36\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "1503df9a-def1-47ed-a73a-b822ce5d9da9": {"__data__": {"id_": "1503df9a-def1-47ed-a73a-b822ce5d9da9", "embedding": null, "metadata": {"page_label": "42", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n37\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "90907468-c076-4b53-a4f4-8e3ff2995110": {"__data__": {"id_": "90907468-c076-4b53-a4f4-8e3ff2995110", "embedding": null, "metadata": {"page_label": "43", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n38\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "430d2a28-c503-4bb9-99e0-f629831c5b8b": {"__data__": {"id_": "430d2a28-c503-4bb9-99e0-f629831c5b8b", "embedding": null, "metadata": {"page_label": "44", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "b30adf3c-c379-420a-9c2a-588f17312fed": {"__data__": {"id_": "b30adf3c-c379-420a-9c2a-588f17312fed", "embedding": null, "metadata": {"page_label": "45", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nExhibit\u00a0II\nTable\u00a01\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nClinical\u00a0Study\n(excluding\u00a0screening\nand\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0Study\nStart\nDate\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0\n***\n\u00a0***\n\u00a0***\n\u00a0\u00a0\n\u00a0***\n\u00a0***\n\u00a0\n\u00a0\n\u00a0\nTable\u00a02-Payment\u00a0Schedule\n\u00a0\nClinical\u00a0Studies\u00a0(total\u00a0funding\u00a0US$13,374,000):\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nMilestone\n\u00a0Payment\u00a0amount\u00a0(US$)\n\u00a0Date\u00a0on\u00a0which\u00a0Payment\u00a0can\u00a0be\u00a0 invoiced.\n\u00a0\nEffective\u00a0Date\n\u00a0***\n\u00a0On\u00a0expiry\u00a0of\u00a0Limited\u00a0Unilateral\u00a0 Termination\u00a0Period\n\u00a0\nEnrollment\u00a0of\u00a0***\u00a0Patients\u00a0in\u00a0a\nClinical\u00a0Study\u00a0(excluding\nscreening\u00a0and\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0***\n\u00a0On\u00a0notification\u00a0to\u00a0Adaptimmune\u00a0 that\u00a0***\u00a0patient\u00a0is\u00a0eligible\u00a0and\nhas\u00a0been\u00a0enrolled.\n\u00a0\nEnrollment\u00a0of\u00a0***\u00a0Patients\u00a0in\u00a0a\nClinical\u00a0Study\u00a0(excluding\nscreening\u00a0and\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0***\n\u00a0On\u00a0notification\u00a0to\u00a0Adaptimmune\u00a0 that\u00a0***\u00a0patient\u00a0is\u00a0eligible\u00a0and\nhas\u00a0been\u00a0enrolled.\n\u00a0\nEnrollment\u00a0of\u00a0***\u00a0Patients\u00a0in\u00a0a\nClinical\u00a0Study\u00a0(excluding\nscreening\u00a0and\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0***\n\u00a0On\u00a0notification\u00a0to\u00a0Adaptimmune\u00a0 that\u00a0***\u00a0patient\u00a0is\u00a0eligible\u00a0and\nhas\u00a0been\u00a0enrolled.\n\u00a0\nEnrollment\u00a0of\u00a0***\u00a0Patients\u00a0in\u00a0a\nClinical\u00a0Study\u00a0(excluding\nscreening\u00a0and\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0***\n\u00a0On\u00a0notification\u00a0to\u00a0Adaptimmune\u00a0 that\u00a0***\u00a0patient\u00a0is\u00a0eligible\u00a0and\nhas\u00a0been\u00a0enrolled.\n\u00a0\nEnrollment\u00a0of\u00a0***\u00a0Patients\u00a0in\u00a0a\nClinical\u00a0Study\u00a0(excluding\nscreening\u00a0and\u00a0long\u00a0term\u00a0follow-\nup\u00a0studies)\n\u00a0***\n\u00a0On\u00a0notification\u00a0to\u00a0Adaptimmune\u00a0 that\u00a0***\u00a0patient\u00a0is\u00a0eligible\u00a0and\nhas\u00a0been\u00a0enrolled.\n\u00a0\nTotal\u00a0 Alliance\u00a0Funding\npayable:\n\u00a013,374,000\n\u00a0\u00a0\n\u00a0\n\u00a0\nPre-clinical\u00a0Studies\u00a0(total\u00a0funding\u00a0$6,270,000,\u00a0including\u00a0indirect\u00a0costs\u00a0of\u00a0US$***):\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0theth\nth\nth\nth\nth\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "06969e7e-7591-4294-a303-853b528c1440": {"__data__": {"id_": "06969e7e-7591-4294-a303-853b528c1440", "embedding": null, "metadata": {"page_label": "46", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "Commission.\n\u00a0\n39\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "b0f27985-8e4e-46b1-882f-e377ed2128d0": {"__data__": {"id_": "b0f27985-8e4e-46b1-882f-e377ed2128d0", "embedding": null, "metadata": {"page_label": "47", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nMilestone\n\u00a0Payment\u00a0amount\u00a0(US$)\n\u00a0Date\u00a0on\u00a0which\u00a0Payment\u00a0can\u00a0be\u00a0invoiced.\n\u00a0\nEffective\u00a0Date\n\u00a0***\n\u00a0\n\u00a0\n.\n\u00a0On\u00a0expiry\u00a0of\u00a0Limited\u00a0Unilateral\u00a0 Termination\u00a0Period\n\u00a0\nCompletion\u00a0of\u00a0each\u00a0analysis\u00a0of\n***\u00a0patient\u00a0samples\u00a0for\u00a0***\n(Pre-clinical\u00a0Study\u00a01)\n\u00a0***\n\u00a0Completion\u00a0of\u00a0analysis\u00a0of\u00a0 samples\u00a0for\u00a0***\u00a0patients,\u00a0up\u00a0to\u00a0a\nmaximum\u00a0payment\u00a0of\u00a0US$***\u00a0and\u00a0provision\u00a0of\u00a0 results\u00a0of\u00a0such\nanalysis\u00a0to\u00a0Adaptimmune.\u00a0(Max.\u00a0***\u00a0patients)\n\u00a0\nCompletion\u00a0of\u00a0each\u00a0analysis\u00a0of\n***\u00a0patient\u00a0samples\u00a0arising\u00a0from\n***\u00a0(Pre-clinical\u00a0Study\u00a02)\n\u00a0***\n\u00a0Completion\u00a0of\u00a0analysis\u00a0of\u00a0 samples\u00a0for\u00a050\u00a0patients,\u00a0up\u00a0to\u00a0a\nmaximum\u00a0payment\u00a0of\u00a0US$***\u00a0and\u00a0provision\u00a0of\u00a0 results\u00a0of\u00a0such\nanalysis\u00a0to\u00a0Adaptimmune.\u00a0(Max.\u00a0***\u00a0patients)\n\u00a0\nCompletion\u00a0of\u00a0each\u00a0analysis\u00a0of\n***\u00a0patient\u00a0samples\u00a0arising\u00a0from\nthe\u00a0***\u00a0and\u00a0additional\u00a0***\u00a0Study\n(Pre-clinical\u00a0Study\u00a03)\n\u00a0***\n\u00a0Completion\u00a0of\u00a0analysis\u00a0of\u00a0 samples\u00a0for\u00a0***\u00a0patients,\u00a0up\u00a0to\u00a0a\nmaximum\u00a0payment\u00a0of\u00a0US$***\u00a0and\u00a0provision\u00a0of\u00a0 results\u00a0of\u00a0such\nanalysis\u00a0to\u00a0Adaptimmune.\u00a0(max.\u00a0***\u00a0patients)\n\u00a0\nTOTAL\u00a0Alliance\u00a0Funding\npayable:\n\u00a06,270,000\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFor\u00a0clarity:\u00a0milestones\u00a0and\u00a0payments\u00a0of\u00a0Alliance\u00a0Funding\u00a0shall\u00a0only\u00a0be\u00a0payable\u00a0once\u00a0the\u00a0milestones\u00a0set\u00a0out\u00a0above\u00a0have\u00a0been\u00a0met\u00a0by\nMD\u00a0Anderson.\u00a0There\u00a0shall\u00a0be\u00a0no\u00a0obligation\u00a0on\u00a0Adaptimmune\u00a0to\u00a0make\u00a0such\u00a0payments\u00a0where\u00a0any\u00a0such\u00a0milestones\u00a0have\u00a0not\u00a0been\u00a0met\u037e\nand\u00a0no\u00a0payments\u00a0of\u00a0Alliance\u00a0Funding\u00a0will\u00a0be\u00a0due\u00a0until\u00a0expiry\u00a0of\u00a0Limited\u00a0Unilateral\u00a0Termination\u00a0Period.\n\u00a0\nAll\u00a0payments\u00a0will\u00a0be\u00a0paid\u00a0by\u00a0Adaptimmune\u00a0within\u00a045\u00a0days\u00a0of\u00a0receipt\u00a0of\u00a0an\u00a0invoice\u00a0from\u00a0MD\u00a0Anderson.\u00a0Such\u00a0invoice\u00a0shall\u00a0be\naddressed\u00a0to\u00a0Adaptimmune\u00a0and\u00a0sent\u00a0by\u00a0electronic\u00a0mail\u00a0to\u00a0 accounts@adaptimmune.com \u00a0with\u00a0copies\u00a0to\u00a0 lini.pandite@adaptimmune.com\nand\u00a0susan\u00a0 cousounis@adaptimmune.com \u00a0for\u00a0Clinical\u00a0Study\u00a0payments\u00a0and\u00a0with\u00a0copies\u00a0to\u00a0 Samik.basu@adaptimmune.com \u00a0in\u00a0relation\u00a0to\nPre-clinical\u00a0Study\u00a0payments.\n\u00a0\nPayments\u00a0will\u00a0be\u00a0made\u00a0by\u00a0Adaptimmune\u00a0to\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0M.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center:\nThe\u00a0University\u00a0of\u00a0Texas\nM.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center\nP.O.\u00a0Box\u00a04390\nHouston,\u00a0Texas\u00a077210-4390\n\u00a0\nOr\u00a0if\u00a0payment\u00a0is\u00a0made\u00a0by\u00a0wire\u00a0transfer,\u00a0wired\u00a0to\u00a0the\u00a0following:\n\u00a0\n***\n***\n***\n***\n***\n***\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n40\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5da1ee0a-23f5-40ad-9121-51f25802dd3b": {"__data__": {"id_": "5da1ee0a-23f5-40ad-9121-51f25802dd3b", "embedding": null, "metadata": {"page_label": "48", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n***\n***\n\u00a0\n***\u00a0Portions\u00a0of\u00a0this\u00a0page\u00a0have\u00a0been\u00a0omitted\u00a0pursuant\u00a0to\u00a0a\u00a0request\u00a0for\u00a0Confidential\u00a0Treatment\u00a0and\u00a0filed\u00a0separately\u00a0with\u00a0the\nCommission.\n\u00a0\n41\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "a601dd17-4f10-42f7-b319-73041a488422": {"__data__": {"id_": "a601dd17-4f10-42f7-b319-73041a488422", "embedding": null, "metadata": {"page_label": "49", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nExhibit\u00a0III\n\u00a0\nSTRATEGIC\u00a0COLLABORATION\u00a0AGREEMENT\u00a0-\u00a0STUDY\u00a0ORDER\n\u00a0\n\u00a0\n\u00a0\nThis\u00a0Study\u00a0Order\u00a0(\u201c Study\u00a0Order \u201d),\u00a0effective\u00a0as\u00a0of\u00a0the\u00a0___\u00a0day\u00a0of\u00a0 ______(\u201c Effective\u00a0Date \u201d\u00a0of\u00a0Study\u00a0Order),\u00a0is\u00a0entered\u00a0into\u00a0by\u00a0and\nbetween\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0M.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center,\u00a0with\u00a0a\u00a0place\u00a0of\u00a0business\u00a0located\u00a0at\u00a01515\u00a0Holcombe\u00a0Blvd.,\nHouston,\u00a0TX\u00a077030,\u00a0USA\u00a0(\u201c MD\u00a0Anderson \u201d),\u00a0a\u00a0member\u00a0institution\u00a0of\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0System\u00a0(\u201c System\u201d)\u037e\u00a0Adaptimmune\nLimited\u00a0with\u00a0a\u00a0place\u00a0of\u00a0business\u00a0at\u00a0101\u00a0Milton\u00a0Park,\u00a0Abingdon,\u00a0Oxfordshire,\u00a0OX14\u00a04RY\u037e\u00a0and\u00a0Adaptimmune\u00a0LLC,\u00a0with\u00a0a\u00a0place\u00a0of\nbusiness\u00a0located\u00a0at\u00a0 2001\u00a0Market\u00a0Street,\u00a0Philadelphia,\u00a0PA\u00a01903,\u00a0USA\u00a0(\u201c Adaptimmune \u201d)\u00a0(MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0each\u00a0a\n\u201cParty\u201d\u00a0and\u00a0collectively\u00a0the\u00a0\u201c Parties\u201d).\u00a0This\u00a0Study\u00a0Order\u00a0is\u00a0a\u00a0part\u00a0of,\u00a0and\u00a0is\u00a0subject\u00a0to,\u00a0the\u00a0terms\u00a0and\u00a0conditions\u00a0of\u00a0the\u00a0Strategic\nCollaboration\u00a0Agreement\u00a0entered\u00a0into\u00a0between\u00a0MD\u00a0Anderson\u00a0and\u00a0Adaptimmune\u00a0dated\u00a0August\u00a0___\u00a02015\u00a0(\u201c Agreement \u201d).\n\u00a0\n1.\u00a0The\u00a0Parties\u00a0enter\u00a0into\u00a0this\u00a0Study\u00a0Order\u00a0in\u00a0connection\u00a0with:\n\u00a0\nthe\u00a0[Pre-Clinical\u00a0or\u00a0Clinical]]\u00a0 Study\u00a0entitled\u00a0__________________,\u00a0to\u00a0be\u00a0conducted\u00a0pursuant\n\u00a0\nfor\u00a0Clinical:\u00a0 to\u00a0Protocol\u00a0No.\u00a0[ Insert\u00a0Protocol\u00a0number ]\u00a0as\u00a0attached\u00a0hereto\u00a0and\u00a0incorporated\u00a0herein.\n\u00a0\nfor\u00a0Preclinical:\u00a0 to\u00a0the\u00a0workscope\u00a0attached\u00a0as\u00a0Appendix\u00a0A\n\u00a0\n2.\u00a0_______\u00a0is\u00a0the\u00a0Principal\u00a0Investigator\u00a0(as\u00a0defined\u00a0in\u00a0the\u00a0Agreement)\u00a0for\u00a0the\u00a0Study\u00a0which\u00a0will\u00a0be\u00a0conducted\u00a0at\u00a0MD\u00a0Anderson.\n\u00a0\n3.\u00a0Study\u00a0Drug\u00a0for\u00a0the\u00a0above\u00a0referenced\u00a0Study\u00a0is\u00a0________________.\n\u00a0\n4.\u00a0The\u00a0parties\u00a0may\u00a0further\u00a0exchange\u00a0the\u00a0following\u00a0Proprietary\u00a0Materials\u00a0(other\u00a0than\u00a0Study\u00a0Drug)\u00a0with\u00a0each\u00a0other\u00a0in\u00a0connection\u00a0with\nthe\u00a0Study:\n_________\u00a0being\u00a0provided\u00a0by\u00a0[Insert\u00a0name\u00a0of\u00a0providing\u00a0party]\n_________\u00a0being\u00a0provided\u00a0by\u00a0[Insert\u00a0name\u00a0of\u00a0providing\u00a0party]\n\u00a0\n5.\u00a0Term:\u00a0This\u00a0Study\u00a0Order\u00a0will\u00a0continue\u00a0until\u00a0the\u00a0Study\u00a0is\u00a0completed,\u00a0which\u00a0is\u00a0expected\u00a0to\u00a0be\u00a0________\u00a0(__)\u00a0months\u00a0after\u00a0the\nEffective\u00a0Date,\u00a0or\u00a0until\u00a0terminated\u00a0early\u00a0as\u00a0provided\u00a0in\u00a0the\u00a0Agreement.\n\u00a0\n\u00a0\n\u00a0\n7.\u00a0Notices.\n\u00a0\nAny\u00a0notice\u00a0or\u00a0other\u00a0formal\u00a0communication\u00a0related\u00a0to\u00a0this\u00a0Agreement\u00a0must\u00a0be\u00a0in\u00a0writing\u00a0and\u00a0will\u00a0be\u00a0deemed\u00a0given\u00a0only\u00a0if:\u00a0(a)\u00a0delivered\nin\u00a0person\u037e\u00a0or\u00a0(b)\u00a0sent\u00a0by\u00a0internationally\u00a0recognized\u00a0overnight\u00a0delivery\u00a0service\u00a0or\u00a0air\u00a0courier\u00a0guaranteeing\u00a0next\u00a0day\u00a0delivery.\u00a0 Until\u00a0a\nchange\u00a0of\u00a0address\u00a0is\u00a0communicated,\u00a0as\u00a0provided\u00a0below,\u00a0all\u00a0notices\u00a0and\u00a0other\u00a0communications\u00a0must\u00a0be\u00a0sent\u00a0to\u00a0the\u00a0Parties\u00a0at\u00a0the\nfollowing\u00a0addresses\u00a0or\u00a0facsimile\u00a0numbers:\n\u00a0\nIf\u00a0to\u00a0MD\u00a0Anderson:\n\u00a0\nThe\u00a0University\u00a0of\u00a0Texas\n\u00a0\n42\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "0f1957de-a818-4c84-9aee-407c905e618b": {"__data__": {"id_": "0f1957de-a818-4c84-9aee-407c905e618b", "embedding": null, "metadata": {"page_label": "50", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nM.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center\nAttn:\u00a0Vice\u00a0President,\u00a0Strategic\u00a0Industry\u00a0Ventures\n1515\u00a0Holcombe\u00a0Boulevard,\u00a0Box\u00a01643\nHouston,\u00a0TX\u00a077030\n\u00a0\nWith\u00a0a\u00a0copy\u00a0to:\n\u00a0\nThe\u00a0University\u00a0of\u00a0Texas\nM.\u00a0D.\u00a0Anderson\u00a0Cancer\u00a0Center\nLegal\u00a0Services\u2014Unit\u00a01674\nPO\u00a0Box\u00a0301407\nHouston,\u00a0Texas\u00a0 77230-1407\nAttn:\u00a0Chief\u00a0Legal\u00a0Officer\n\u00a0\nAnd\u00a0to:\n\u00a0\n\u00a0\n[insert\u00a0investigator\u00a0information]\n\u00a0\nIf\u00a0to\u00a0Adaptimmune:\n\u00a0\n[To\u00a0Be\u00a0Added]\n\u00a0\nWith\u00a0a\u00a0copy\u00a0to:\n\u00a0\n[To\u00a0Be\u00a0Added]\n\u00a0\n12.2\u00a0All\u00a0notices\u00a0will\u00a0be\u00a0effective\u00a0and\u00a0will\u00a0be\u00a0deemed\u00a0delivered:\u00a0(a)\u00a0if\u00a0by\u00a0personal\u00a0delivery,\u00a0delivery\u00a0service\u00a0or\u00a0courier,\u00a0on\u00a0the\u00a0date\u00a0of\ndelivery\u037e\u00a0and\u00a0(b)\u00a0if\u00a0by\u00a0electronic\u00a0facsimile\u00a0communication,\u00a0on\u00a0the\u00a0date\u00a0of\u00a0transmission\u00a0of\u00a0the\u00a0communication.\u00a0Either\u00a0Party\u00a0may\u00a0change\nits\u00a0notice\u00a0address\u00a0by\u00a0sending\u00a0notice\u00a0of\u00a0the\u00a0change\u00a0to\u00a0the\u00a0other\u00a0Party\u00a0in\u00a0the\u00a0manner\u00a0set\u00a0forth\u00a0above.\n\u00a0\n\u00a0\n8.\u00a0Specific\u00a0superseding\u00a0terms:\u00a0N/A.\n\u00a0\nIn\u00a0witness\u00a0whereof ,\u00a0the\u00a0Parties\u00a0hereto\u00a0have\u00a0caused\u00a0this\u00a0Study\u00a0Order\u00a0to\u00a0be\u00a0executed\u00a0by\u00a0their\u00a0duly\u00a0authorized\u00a0representatives\u00a0to\u00a0be\neffective\u00a0as\u00a0of\u00a0the\u00a0Effective\u00a0Date.\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nThe\u00a0University\u00a0of\u00a0Texas\u00a0M.\u00a0D.\u00a0Anderson\u00a0Cancer\nCenter\n\u00a0\u00a0\n\u00a0Adaptimmune\u00a0LLC\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nDate:\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0Date:\n\u00a0\u00a0\n\u00a0\n\u00a0\n43\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "a9929bb3-2849-4e6d-a731-c6d531033a93": {"__data__": {"id_": "a9929bb3-2849-4e6d-a731-c6d531033a93", "embedding": null, "metadata": {"page_label": "51", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nName\n\u00a0\u00a0\n\u00a0Name\n\u00a0\nFunction:\n\u00a0\u00a0\n\u00a0Function:\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nAdaptimmune\u00a0Limited\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nDate:\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nName\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nTitle:\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nREAD\u00a0AND\u00a0UNDERSTOOD:\n\u00a0\nI\u00a0confirm\u00a0that\u00a0I\u00a0have\u00a0received\u00a0a\u00a0copy\u00a0of\u00a0the\u00a0Agreement\u00a0under\u00a0which\u00a0this\u00a0Study\u00a0Order\u00a0is\u00a0issued,\u00a0and\u00a0that\u00a0I\u00a0have\u00a0read\u00a0and\u00a0understand\u00a0the\nAgreement\u00a0and\u00a0this\u00a0Study\u00a0Order.\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nPrincipal\u00a0 Investigator\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nDate:\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "89e415f5-69b1-4737-b9d8-a3f66c4e775c": {"__data__": {"id_": "89e415f5-69b1-4737-b9d8-a3f66c4e775c", "embedding": null, "metadata": {"page_label": "52", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "Name\n\u00a0\u00a0\u00a0\n\u00a0\n44\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "39ac7218-5761-42d7-9266-53122eab889a": {"__data__": {"id_": "39ac7218-5761-42d7-9266-53122eab889a", "embedding": null, "metadata": {"page_label": "53", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nEXHIBIT\u00a0IV\n\u00a0\n45\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "086e843d-fbb4-43e8-9ab1-1d0e2d00bf63": {"__data__": {"id_": "086e843d-fbb4-43e8-9ab1-1d0e2d00bf63", "embedding": null, "metadata": {"page_label": "54", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nDRAFT\u00a0RELEASE\n\u00a0\nMD\u00a0Anderson\u00a0Cancer\u00a0Center\u00a0and\u00a0Adaptimmune\u00a0Form\u00a0Strategic\u00a0Alliance\u00a0to\u00a0Advance\u00a0Development\u00a0of\nImmunotherapies\u00a0Targeting\u00a0Multiple\u00a0Cancers\n\u00a0\nPHILADELPHIA,\u00a0and\u00a0HOUSTON,\u00a0U.S.A.\u00a0and\u00a0OXFORD,\u00a0UK,\u00a0September\u00a0XX,\u00a02016\u00a0\u2014\u00a0Adaptimmune\u00a0Therapeutics\u00a0plc\n(Nasdaq:\u00a0ADAP),\u00a0a\u00a0leader\u00a0in\u00a0T-cell\u00a0therapy\u00a0to\u00a0treat\u00a0cancer,\u00a0and\u00a0The\u00a0University\u00a0of\u00a0Texas\u00a0MD\u00a0Anderson\u00a0Cancer\u00a0Center\nannounced\u00a0today\u00a0that\u00a0they\u00a0have\u00a0entered\u00a0into\u00a0a\u00a0multi-year\u00a0strategic\u00a0alliance\u00a0designed\u00a0to\u00a0expedite\u00a0the\u00a0development\u00a0of\u00a0novel\nadoptive\u00a0T-cell\u00a0therapies\u00a0 for\u00a0multiple\u00a0types\u00a0of\u00a0cancer.\n\u00a0\nThe\u00a0alliance\u00a0pairs\u00a0MD\u00a0Anderson\u2019s\u00a0preclinical\u00a0and\u00a0clinical\u00a0teams\u00a0with\u00a0Adaptimmune\u2019s\u00a0scientists\u00a0and\u00a0proprietary\u00a0SPEAR\u00ae\n(Specific\u00a0Peptide\u00a0Enhanced\u00a0Affinity\u00a0Receptor)\u00a0 T-cell\u00a0technology\u00a0platform,\u00a0which\u00a0enables\u00a0Adaptimmune\u00a0to\u00a0identify\u00a0targets\nexpressed\u00a0on\u00a0solid\u00a0and\u00a0hematologic\u00a0cancers\u00a0and\u00a0to\u00a0develop\u00a0affinity\u00a0enhanced\u00a0T-cell\u00a0receptors\u00a0(TCRs)\u00a0with\u00a0optimal\npotency\u00a0and\u00a0specificity\u00a0against\u00a0them.\n\u00a0\nThe\u00a0teams\u00a0will\u00a0collaborate\u00a0in\u00a0a\u00a0number\u00a0of\u00a0areas\u00a0including\u00a0preclinical\u00a0and\u00a0clinical\u00a0development\u00a0of\u00a0Adaptimmune\u2019s\u00a0SPEAR\nT-cell\u00a0therapies\u00a0targeting\u00a0MAGE-A10\u00a0and\u00a0future\u00a0clinical\u00a0stage\u00a0first\u00a0and\u00a0second\u00a0generation\u00a0SPEAR\u00a0T-cell\u00a0therapies\u00a0such\u00a0as\nMAGE-A4\u00a0across\u00a0a\u00a0number\u00a0of\u00a0cancers,\u00a0including\u00a0bladder,\u00a0lung,\u00a0ovarian,\u00a0head\u00a0and\u00a0neck,\u00a0melanoma,\u00a0esophageal\u00a0and\ngastric\u00a0cancers.\u00a0The\u00a0alliance\u00a0will\u00a0also\u00a0drive\u00a0research\u00a0and\u00a0development\u00a0of\u00a0other\u00a0new\u00a0SPEAR\u00a0TCR\u00a0therapies\u00a0to\u00a0targets\u00a0in\nother\u00a0tumor\u00a0types\u00a0such\u00a0as\u00a0breast\u00a0cancers\u00a0and\u00a0facilitate\u00a0clinical\u00a0study\u00a0participation\u00a0by\u00a0MD\u00a0Anderson\u00a0in\u00a0other\u00a0Adaptimmune\ntrials.\u00a0Access\u00a0to\u00a0MD\u00a0Anderson\u2019s\u00a0tumor\u00a0repository\u00a0will\u00a0guide\u00a0further\u00a0target\u00a0selection\u00a0and\u00a0clinical\u00a0trial\u00a0design,\u00a0while\u00a0its\ncancer\u00a0immunology\u00a0cores\u00a0and\u00a0expertise\u00a0in\u00a0performing\u00a0translational\u00a0medicine\u00a0studies\u00a0may\u00a0help\u00a0optimize\u00a0the\u00a0efficacy\u00a0and\nsafety\u00a0of\u00a0SPEAR\u00a0T-cell\u00a0therapies.\n\u00a0\n\u201cAt\u00a0MD\u00a0Anderson,\u00a0we\u00a0are\u00a0focused\u00a0on\u00a0providing\u00a0the\u00a0best\u00a0possible\u00a0care\u00a0for\u00a0cancer\u00a0patients,\u00a0including\u00a0implementing\nimportant\u00a0new\u00a0technologies\u00a0and\u00a0treatment\u00a0modalities,\u201d\u00a0said\u00a0Elizabeth\u00a0Mittendorf,\u00a0M.D.,\u00a0Ph.D.,\u00a0associate\u00a0professor\u00a0of\nBreast\u00a0Surgical\u00a0Oncology.\n\u00a0\nDavid\u00a0Hong,\u00a0M.D.,\u00a0associate\u00a0professor\u00a0of\u00a0Investigational\u00a0Cancer\u00a0Therapeutics\u00a0at\u00a0MD\u00a0Anderson\u00a0added,\u00a0\u201cIt\u00a0is\u00a0our\u00a0hope\u00a0this\nalliance\u00a0will\u00a0allow\u00a0us\u00a0to\u00a0address\u00a0numerous\u00a0solid\u00a0tumors\u00a0and\u00a0augment\u00a0the\u00a0patient\u2019s\u00a0immune\u00a0system,\u00a0directing\u00a0it\u00a0against\ntumors\u00a0based\u00a0on\u00a0their\u00a0specific\u00a0molecular\u00a0makeup.\u201d\n\u00a0\n\u201cWe\u00a0believe\u00a0that\u00a0this\u00a0strategic\u00a0alliance\u00a0will\u00a0provide\u00a0a\u00a0strong\u00a0partnership\u00a0for\u00a0the\u00a0development\u00a0of\u00a0multiple\u00a0new\u00a0first\u00a0and\nsubsequent\u00a0generation\u00a0SPEAR\u00a0T-cell\u00a0therapies\u00a0against\u00a0many\u00a0intractable\u00a0solid\u00a0tumors\u00a0in\u00a0our\u00a0near-term\u00a0clinical\u00a0programs,\u201d\ncommented\u00a0Rafael\u00a0Amado,\u00a0Adaptimmune\u2019s\u00a0chief\u00a0medical\u00a0officer.\u00a0 \u201cIt\u00a0will\u00a0also\u00a0generate\u00a0invaluable\u00a0data\u00a0from\u00a0patient\nsamples\u00a0that\u00a0will\u00a0help\u00a0us\u00a0understand\u00a0these\u00a0therapies\u00a0and\u00a0design\u00a0the\u00a0next\u00a0generation\u00a0of\u00a0studies.\u00a0We\u00a0are\u00a0very\u00a0proud\u00a0to\nform\u00a0this\u00a0alliance\u00a0with\u00a0the\u00a0outstanding\u00a0team\u00a0of\u00a0cancer\u00a0immunologists\u00a0at\u00a0MD\u00a0Anderson,\u00a0and\u00a0are\u00a0confident\u00a0that\u00a0together\u00a0we\ncan\u00a0move\u00a0these\u00a0novel\u00a0immunotherapeutic\u00a0candidates\u00a0forward\u00a0for\u00a0patients\u00a0who\u00a0are\u00a0fighting\u00a0a\u00a0variety\u00a0of\u00a0cancers.\u201d\n\u00a0\nAbout\u00a0MD\u00a0Anderson\n\u00a0\nThe\u00a0University\u00a0of\u00a0Texas\u00a0MD\u00a0Anderson\u00a0Cancer\u00a0Center \u00a0in\u00a0Houston\u00a0ranks\u00a0as\u00a0one\u00a0of\u00a0the\u00a0world\u2019s\u00a0most\u00a0respected\u00a0centers\nfocused\u00a0on\u00a0cancer\u00a0patient\u00a0care,\u00a0research,\u00a0education\u00a0and\u00a0prevention.\u00a0The\u00a0institution\u2019s\u00a0sole\u00a0mission\u00a0is\u00a0to\u00a0end\u00a0cancer\u00a0for\npatients\u00a0and\u00a0their\u00a0families\u00a0around\u00a0the\u00a0world.\u00a0MD\u00a0Anderson\u00a0is\u00a0one\u00a0of\u00a0only\u00a045\u00a0comprehensive\u00a0cancer\u00a0centers\u00a0designated\u00a0by\nthe\u00a0National\u00a0Cancer\u00a0Institute\u00a0(NCI).\u00a0MD\u00a0Anderson\u00a0is\u00a0ranked\u00a0No.1\u00a0for\u00a0cancer\u00a0care\u00a0in\u00a0U.S.\u00a0News\u00a0&\u00a0World\u00a0Report\u2019s\u00a0\u201cBest\nHospitals\u201d\u00a0survey.\u00a0It\u00a0has\u00a0ranked\u00a0as\u00a0one\u00a0of\u00a0the\u00a0nation\u2019s\u00a0top\u00a0two\u00a0hospitals\u00a0since\u00a0the\u00a0survey\u00a0began\u00a0in\u00a01990,\u00a0and\u00a0has\u00a0ranked\nfirst\u00a0for\u00a0nine\u00a0of\u00a0the\n\u00a0\n46\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5e9f9e7a-0b39-424b-84f0-a64ee5d4532e": {"__data__": {"id_": "5e9f9e7a-0b39-424b-84f0-a64ee5d4532e", "embedding": null, "metadata": {"page_label": "55", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\npast\u00a010\u00a0years.\u00a0MD\u00a0Anderson\u00a0receives\u00a0a\u00a0cancer\u00a0center\u00a0support\u00a0grant\u00a0from\u00a0the\u00a0NCI\u00a0of\u00a0the\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(P30\nCA016672).\n\u00a0\nAbout\u00a0Adaptimmune\n\u00a0\nAdaptimmune\u00a0is\u00a0a\u00a0clinical\u00a0stage\u00a0biopharmaceutical\u00a0company\u00a0focused\u00a0on\u00a0novel\u00a0cancer\u00a0immunotherapy\u00a0products\u00a0based\u00a0on\u00a0its\u00a0SPEAR\u00ae\n(Specific\u00a0Peptide\u00a0Enhanced\u00a0Affinity\u00a0Receptor)\u00a0T-cell\u00a0platform.\u00a0Established\u00a0in\u00a02008,\u00a0the\u00a0company\u00a0aims\u00a0to\u00a0utilize\u00a0the\u00a0body\u2019s\u00a0own\nmachinery\u00a0-\u00a0the\u00a0T-cell\u00a0-\u00a0to\u00a0target\u00a0and\u00a0destroy\u00a0cancer\u00a0cells\u00a0by\u00a0using\u00a0engineered,\u00a0increased\u00a0affinity\u00a0TCRs\u00a0as\u00a0a\u00a0means\u00a0of\u00a0strengthening\nnatural\u00a0patient\u00a0T-cell\u00a0responses.\u00a0Adaptimmune\u2019s\u00a0lead\u00a0program\u00a0is\u00a0a\u00a0SPEAR\u00a0T-cell\u00a0therapy\u00a0targeting\u00a0the\u00a0NY-ESO\u00a0cancer\u00a0antigen.\u00a0Its\nNY-ESO\u00a0SPEAR\u00a0T-cell\u00a0therapy\u00a0has\u00a0demonstrated\u00a0signs\u00a0of\u00a0efficacy\u00a0and\u00a0tolerability\u00a0in\u00a0Phase\u00a01/2\u00a0trials\u00a0in\u00a0solid\u00a0tumors\u00a0and\u00a0in\nhematologic\u00a0cancer\u00a0types,\u00a0including\u00a0synovial\u00a0sarcoma\u00a0and\u00a0multiple\u00a0myeloma.\u00a0Adaptimmune\u00a0has\u00a0a\u00a0strategic\u00a0collaboration\u00a0and\u00a0licensing\nagreement\u00a0with\u00a0GlaxoSmithKline\u00a0for\u00a0the\u00a0development\u00a0and\u00a0commercialization\u00a0of\u00a0the\u00a0NY-ESO\u00a0TCR\u00a0program.\u00a0In\u00a0addition,\nAdaptimmune\u00a0has\u00a0a\u00a0number\u00a0of\u00a0proprietary\u00a0programs.\u00a0 These\u00a0include\u00a0SPEAR\u00a0T-cell\u00a0therapies\u00a0targeting\u00a0the\u00a0MAGE-A10\u00a0and\u00a0AFP\ncancer\u00a0antigens,\u00a0which\u00a0both\u00a0have\u00a0open\u00a0INDs,\u00a0and\u00a0a\u00a0further\u00a0SPEAR\u00a0T-cell\u00a0therapy\u00a0targeting\u00a0the\u00a0MAGE-A4\u00a0cancer\u00a0antigen\u00a0that\u00a0is\u00a0in\npre-clinical\u00a0phase\u00a0with\u00a0IND\u00a0acceptance\u00a0targeted\u00a0for\u00a02017.\u00a0 The\u00a0company\u00a0has\u00a0identified\u00a0over\u00a030\u00a0intracellular\u00a0target\u00a0peptides\npreferentially\u00a0expressed\u00a0in\u00a0cancer\u00a0cells\u00a0and\u00a0is\u00a0currently\u00a0progressing\u00a012\u00a0through\u00a0unpartnered\u00a0research\u00a0programs.\u00a0Adaptimmune\u00a0has\nover\u00a0250\u00a0employees\u00a0and\u00a0is\u00a0located\u00a0in\u00a0Oxfordshire,\u00a0U.K.\u00a0and\u00a0Philadelphia,\u00a0USA.\u00a0For\u00a0more\u00a0information:\u00a0 http://www.adaptimmune.com\n\u00a0\nForward-Looking\u00a0Statements\n\u00a0\nThis\u00a0release\u00a0contains\u00a0\u201cforward-looking\u00a0statements\u201d\u00a0within\u00a0the\u00a0meaning\u00a0of\u00a0the\u00a0Private\u00a0Securities\u00a0Litigation\u00a0Reform\u00a0Act\u00a0of\u00a01995\n(PSLRA).\u00a0 These\u00a0forward-looking\u00a0statements\u00a0involve\u00a0certain\u00a0risks\u00a0and\u00a0uncertainties.\u00a0Such\u00a0risks\u00a0and\u00a0uncertainties\u00a0could\u00a0cause\u00a0our\nactual\u00a0results\u00a0to\u00a0differ\u00a0materially\u00a0from\u00a0those\u00a0indicated\u00a0by\u00a0such\u00a0forward-looking\u00a0statements,\u00a0and\u00a0include,\u00a0without\u00a0limitation:\u00a0the\u00a0success,\ncost\u00a0and\u00a0timing\u00a0of\u00a0our\u00a0product\u00a0development\u00a0activities\u00a0and\u00a0clinical\u00a0trials\u00a0and\u00a0our\u00a0ability\u00a0to\u00a0successfully\u00a0advance\u00a0our\u00a0TCR\u00a0therapeutic\ncandidates\u00a0through\u00a0the\u00a0regulatory\u00a0and\u00a0commercialization\u00a0processes.\u00a0For\u00a0a\u00a0further\u00a0description\u00a0of\u00a0the\u00a0risks\u00a0and\u00a0uncertainties\u00a0that\u00a0could\ncause\u00a0our\u00a0actual\u00a0results\u00a0to\u00a0differ\u00a0materially\u00a0from\u00a0those\u00a0expressed\u00a0in\u00a0these\u00a0forward-looking\u00a0statements,\u00a0as\u00a0well\u00a0as\u00a0risks\u00a0relating\u00a0to\u00a0our\nbusiness\u00a0in\u00a0general,\u00a0we\u00a0refer\u00a0you\u00a0to\u00a0our\u00a0Quarterly\u00a0Report\u00a0on\u00a0Form\u00a010-Q\u00a0filed\u00a0with\u00a0the\u00a0Securities\u00a0and\u00a0Exchange\u00a0Commission\u00a0(SEC)\u00a0on\nAugust\u00a08,\u00a02016,\u00a0and\u00a0our\u00a0other\u00a0SEC\u00a0filings.\u00a0The\u00a0forward-looking\u00a0statements\u00a0contained\u00a0in\u00a0this\u00a0press\u00a0release\u00a0speak\u00a0only\u00a0as\u00a0of\u00a0the\u00a0date\nthe\u00a0statements\u00a0were\u00a0made\u00a0and\u00a0we\u00a0do\u00a0not\u00a0undertake\u00a0any\u00a0obligation\u00a0to\u00a0update\u00a0such\u00a0forward-looking\u00a0statements\u00a0to\u00a0reflect\u00a0subsequent\nevents\u00a0or\u00a0circumstances.\n\u00a0\nAdaptimmune\u00a0Contacts\n\u00a0\nWill\u00a0Roberts\nVice\u00a0President,\u00a0Investor\u00a0Relations\nT:\u00a0(215)\u00a0825-9306\nE:\u00a0will.roberts@adaptimmune.com\n\u00a0\nMargaret\u00a0Henry\nHead\u00a0of\u00a0PR\nT:\u00a0+44\u00a0(0)1235\u00a0430036\nMobile:\u00a0+44\u00a0(0)7710\u00a0304249\n\u00a0\n47\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}, "5cc0f876-aacf-4840-95e3-646ff525999c": {"__data__": {"id_": "5cc0f876-aacf-4840-95e3-646ff525999c", "embedding": null, "metadata": {"page_label": "56", "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Strategic Alliance\\ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.PDF", "file_type": "application/pdf", "file_size": 376266, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "text": "\u00a0\nE:\u00a0margaret.henry@adaptimmune.com\n\u00a0\nMD\u00a0Anderson\u00a0Contact:\n\u00a0\nRon\u00a0Gilmore\nRlgilmore1@mdanderson.org\nPhone:\u00a0713-745-1898\n\u00a0\n48\n", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "Document"}, "__type__": "4"}}, "docstore/metadata": {"3c34daa5-c03c-47a0-a9b3-155c75c619b2": {"doc_hash": "e6ddd0eef464c362299abfe1773adfe7083b8b8fe1adc418b41fab99b5fd6009"}, "f80b64e2-d6a1-4315-b037-2e79ed9010d0": {"doc_hash": "6290b542a7c1c6ee5d8a488b69af32d779c9782611e051e90210db0c91fa55b9"}, "3b7cbd0d-b700-43a9-ab09-6ee3a844d9f2": {"doc_hash": "1a809d6a0ecfef7abec0496fbcb9f5beb9e408b7ce11fe392b21fc1a92d82444"}, "ca173bb5-83b4-4a03-a2fe-33b195909863": {"doc_hash": "15b36d0a1fc0c730f3d588e575ae600f047933cb5b3da34a7330bb538b8826d9"}, "c389685b-6ecf-4e20-83a8-c8297388daae": {"doc_hash": "1b6e64223fb7342a3e8040b67fd993a072ac7fef3408dfcb305e016040e03c86"}, "7a831371-f5d0-43fd-83e5-5b43f4440ba5": {"doc_hash": "90948a30c478a16ce53136492308f56f1683be0bb69c01d0cdd8be52b302f861"}, "91df6256-aa31-469c-9eeb-d0d32509bcd7": {"doc_hash": "63bf72bf347c9bd773e0c974093fb846a8bdc78603ef54532fa69799993c9eca"}, "b8dec37e-54ea-4f03-9ebf-1cbc64a1ab7a": {"doc_hash": "fca3b03487b1d745eafd3ed16a6469a275736dff61d7e82b4d97e17987ebd4ba"}, "9c7f7fcc-62f3-4893-9621-2e66adda29e5": {"doc_hash": "3c24255f485e1c8b48a44cc11aae1d0e51fb2c07e11d422e8cc2dd8c57a5f017"}, "ca6ab39c-d41a-4a25-9215-9101fd3bdad8": {"doc_hash": "87da42720aa21841387c7fa3217741e422dc4875fb273cd0b8d956cc1904f591"}, "8699ea14-6024-4097-a3a8-b266941a651e": {"doc_hash": "fa5c726a27668de90d78c8c161a2abb1d85c479a346d862cbaa175a3f610301c"}, "0279ccce-e4ff-4e1b-a6c3-bef6f57f7358": {"doc_hash": "587f9f5f8702af4f6a0bf0144ee1b2498dbe9460b92ace256f7352578b5a5dc4"}, "67e8ffaf-0c1d-4296-b33e-a446c4bb1b56": {"doc_hash": "28b9d778a2a13530308a7f692c7fc4754f335f6b15f585c9f5a3e83a26077ecf"}, "546a8002-122d-4970-871e-02af3235128c": {"doc_hash": "8475e5ead74c10231127e9404142797aae613fe99b4bc1ec86b30bf24cb2b2e1"}, "b5f68e89-4f15-4bd9-8bbc-3ba3bdb12f00": {"doc_hash": "8e9bc1fe5fb2e1c92053082b1ca13ae2ae25b382b6784c97d8931248bea30d42"}, "0a6d4cba-a916-46ec-be92-ba675ef69b3a": {"doc_hash": "6c7fb421845a9b86a81e64c06a15e57710f8a4db048bdb50fd60792d11aeabec"}, "92aee01a-9370-4c77-bb24-4150711972cd": {"doc_hash": "5d56684761d4bbb509296768729c04a309fff1fb0b6abddeb42af1ac378acab3"}, "e80d898f-3614-4109-b8d8-6567ba868d2a": {"doc_hash": "1e63b048ae0977f73119bb82a924b3fee22394fd648ebdfdb9abe018340f2c92"}, "75dd04ae-8144-4945-ab81-7a10648599d2": {"doc_hash": "04dd2a57e1c41b4aeac3c7bf2677995fe65cafea34c12a82179de98024ea15e3"}, "25575e38-1a2a-4fe2-a406-18d163da8cbf": {"doc_hash": "58f6ba7daf96ca698ef1b7557096ba77c77c47a329604ea165ed18ee25caaac5"}, "ac0e77dd-aecb-4623-ada7-46329e33d098": {"doc_hash": "71007cfb1efde09949f8586048da60aa6ba3fd3f83483ca21b4e961cff9b5b96"}, "5548556f-24b4-4ad1-8fc3-e373f3a36ed0": {"doc_hash": "7a474f1efb690ebc0255dbbdb8a33926776cbb893d3bd70e76773729b27d6d28"}, "e5c819ac-f551-485a-b7b3-582d8d2bb2e1": {"doc_hash": "bfde088da86e2caf3f76645ec25156c5a148fcfa9a399816f79d936c08eae7f2"}, "44b70046-78b9-4dbb-9a5d-84485ff02c5a": {"doc_hash": "decf9e44a05f2d41328e9dc12d0f2143f2483b17989a8e9cca7dc0bde1976413"}, "5766bedc-6c38-4888-b641-06eb3524fe7e": {"doc_hash": "1b11a32da8b8c971d8467348975c8a355eb6417f72cf07723728bfe0373f28d0"}, "5aa048f3-a174-4b6d-a46e-da4745e805b7": {"doc_hash": "304cc62c3cf56be17d69142277f2385e20ec324c4a2a3bb295a24571aaea73ba"}, "1d0896bd-c3ab-4449-a787-2d76f0004005": {"doc_hash": "970120b85662d51e2640909b9bfa4d02be0560f53fd4a329cda525cef689ffa3"}, "adeb6c37-5bf6-472b-85ce-c9b45c7265b1": {"doc_hash": "be5bb9adb73f44cfeef826b9c14e567aad739506203b3c2d7abb199ff72f530a"}, "a06e998f-a370-422e-8152-be9ff6c637df": {"doc_hash": "17e283550c8c65762419a396f37987f02c33ba2f2ceea44a98c0f76741e4d666"}, "53fc1254-e5a2-4d2f-a45a-063280e62dab": {"doc_hash": "846d005e809b11a450b6547366a54314dd4579929718a9cb7228004861a90275"}, "8e482821-d11b-4ca9-b518-7ea18703ccab": {"doc_hash": "afb31a28a642704429bec7ea2389e41d0a30523d0bde2e8354f0430ad397d5f0"}, "0a468ee2-0123-4a56-ad03-3d1ce6cfa897": {"doc_hash": "d2db7eb2781dbf16157862c0b1525b291fa0db37608e6b80b6bde988d99aeb41"}, "a5bae146-bacc-4ad8-af15-05bcd0f5d996": {"doc_hash": "1079a498afe259029193f6a3756c1aa4c6afbc424dbb00fc455cf24c942fc38c"}, "5b5af5f4-b103-4b9e-b3b2-de8c71504cb8": {"doc_hash": "0ecc247d67a2a6ae65a40774a73d50b53421975ce3de070a391b3bdd83c90b42"}, "e93b6a64-04e0-4ee7-b4e2-219b8ee8a5e0": {"doc_hash": "22c93f25b1c08fc0bbff93da0af4f47d30c2cf7af6c6d4e933f42655e49c9c8b"}, "23abea33-5ed6-4f8a-9894-0132e70614c1": {"doc_hash": "01ef403b205a9cfa790561838e63c900125cd5567fcd2f2376ca4ab561dfe9ad"}, "0ea005fe-b510-4a38-bdbb-383b6a8f63ce": {"doc_hash": "90483a71d933db38f01b4f72cba23aaf0cc01a9c863ac5d866dd160a471bd01e"}, "51e8e912-e942-471f-b12c-fd1acf520ee0": {"doc_hash": "737bf336e25e09f3e30c1cef4ef9b53f1040b4959bef51cb5b5ccb98f18110db"}, "629aa127-89d5-477e-b880-d272f3b0f0f2": {"doc_hash": "e4110275c7ec4efe962ec77ff9cc8203f33d8093ddba818d6c6321708ef2d250"}, "15ce442f-424e-4600-aa79-50e802f1143d": {"doc_hash": "ca76c0cd3993938a0ab95c2ef7cf98c265d14d8cf1fc8a3d9ec6baceddb6fb8f"}, "25d95052-14f3-4a0c-a1fe-36ea2a4d4ed9": {"doc_hash": "5db96c76ee0b0856b2e4b3927fd8eea6ce07899494a1207bd4e29e8634635eed"}, "1503df9a-def1-47ed-a73a-b822ce5d9da9": {"doc_hash": "73f51743a64a6e10b5948087f6b86a619913f7c9ac2866516443a95ce91e2da0"}, "90907468-c076-4b53-a4f4-8e3ff2995110": {"doc_hash": "80cd2110329c45bc184afe8066cd8a103616a394518108fc27fa7be4d9119ec0"}, "430d2a28-c503-4bb9-99e0-f629831c5b8b": {"doc_hash": "08ff2df6072e115c5cffb56debbc0f4e5284e36d3a02f8220be7c210c32f6e58"}, "b30adf3c-c379-420a-9c2a-588f17312fed": {"doc_hash": "912459a40c38ffc58aa945adbaa2c9ee3990a9ec12bfe2946b5090b9a00b1120"}, "06969e7e-7591-4294-a303-853b528c1440": {"doc_hash": "ce8b1531750e3d9978a8d7bf2f3ea9befed95e4c8d97332a79fc54d59c33ca62"}, "b0f27985-8e4e-46b1-882f-e377ed2128d0": {"doc_hash": "822acbbd3653da28815e7ea7b79ecbe2a1a53269ce25ae23a55c880b377fd66b"}, "5da1ee0a-23f5-40ad-9121-51f25802dd3b": {"doc_hash": "f448389ca096383d391db15ecfd31bafd5401725a34077162b0572d2ab0158c4"}, "a601dd17-4f10-42f7-b319-73041a488422": {"doc_hash": "7df9b499be77277d647f999056082a8a13f9dc0bb54ea9b50d97f24b2bbae518"}, "0f1957de-a818-4c84-9aee-407c905e618b": {"doc_hash": "61bad0f0d37e127a7b6ceaef03d5d063ec5a2b879c5b4d692107d520d7e49510"}, "a9929bb3-2849-4e6d-a731-c6d531033a93": {"doc_hash": "c4a5845e3df45f90408b9981566ad8eedee8fc3793e97c50650d08d4a75f1de7"}, "89e415f5-69b1-4737-b9d8-a3f66c4e775c": {"doc_hash": "562a3749bc0ba0f988e84b63c485258671c6b92c98e3b44c4b56e803399aebd9"}, "39ac7218-5761-42d7-9266-53122eab889a": {"doc_hash": "453aa31c01bab4e39b4c563b36835807b589bdd436c6156d9d32fce6c2a45141"}, "086e843d-fbb4-43e8-9ab1-1d0e2d00bf63": {"doc_hash": "c5714b9843fbfca6be7c5b0f2e4a0812460cd90cbd208af64dea132d6d4f8ea5"}, "5e9f9e7a-0b39-424b-84f0-a64ee5d4532e": {"doc_hash": "e05b566a5ebfad1a10a54d43a0bcfa1557e413acf09decaac5acc19e7444e6f8"}, "5cc0f876-aacf-4840-95e3-646ff525999c": {"doc_hash": "00eea10bf5df700e7e2fb0c50be88bae96b53067bb0a9faa162f55ce30b3c560"}}}